



# RESEARCH ACTIVITY

at the Division of  
Ear, Nose and Throat Diseases

2022





# CONTENT

Management at CLINTEC.....	4.
Member of the FoU Council .....	5.
Professors.....	6.
Dissertations/halftime seminar 2020.....	7.
Participation halftime seminars 2010-2020 .....	8.
Senior researchers .....	9.
Summary, senior researcher .....	11.
PhD-students.....	85.
Summary, PhD-students.....	86.
Appendix 1-3 (in Swedish).....	121.
1. Checklist, starting project.....	122.
2. Admission process, doctoral education.....	131.
3. Add a new email account to Outlook .....	135.

# Management

## Management at CLINTEC



Head of Department  
Lars Henningsohn

[lars.henningsohn@ki.se](mailto:lars.henningsohn@ki.se)



Director of postgraduate studies  
Li Felländer Tsai

[li.fellander-tsai@ki.se](mailto:li.fellander-tsai@ki.se)



Administrator at the Division/  
LADOK-administrator  
Agneta Wittlock  
[agneta.wittlock@ki.se](mailto:agneta.wittlock@ki.se)  
+46 8 123 87353

# Management

## Members of the FoUU Council



Head of the Division, Professor

Lars Olaf Cardell  
lars-olaf.cardell@ki.se



Head of ME ÖNHHB

Alexander Ahlberg  
alexander.ahlberg@regionsstockholm.se



Maoli Duan  
maoli.duan@regionstockholm.se



Caroline Gahm  
caroline.gahm@regionstockholm.se



Anna Granath  
anna.granath@regionstockholm.se



Sten Hellström  
sten.hellstrom@ki.se



Laila Hellkvist  
laila.hellkvist@regionstockholm.se




Stellan Hertegård  
stellan.hertegard@regionstockholm.se



Linda Marklund  
linda.marklund@regionstockholm.se



Eva Munck af Rosenschöld Wikland  
eva.munck-afrosenschold-wikland@regionstockholm.se



Anna Persson  
anna.persson.3@ki.se



Krzysztof Piersiala  
krzysztof.piessiala@regionstockholm.se



Pär Stjärne  
par.stjarne@regionstockholm.se

# **Professors**

## **Professor and Senior Professors**

Lars Olaf Cardell, Professor  
Stellan Hertegård, Adjunct Professor  
Eva Munck Wikland, Adjunct Professor  
Pär Stjärne, Adjunct Professor  
Claus Bachert, Affiliated Professor  
Antti Mäkitie, Affiliated Professor  
Sten Hellström, Senior Professor  
Dan Bagger-Sjöbäck, Professor Emeritus  
Ulf Rosenhall, Professor Emeritus  
Bengt Carlsöö, Professor Emeritus

## **Assoc. Professors**


Erik Berninger  
Maoli Duan  
Lalle Hammarstedt Nordenvall  
Linda Marklund  
Riitta Möller  
Inger Uhlén

## Dissertations / Half time seminars 2022



Date		Name	Title
2022-06-02	Half time	Fatima Moumén Denanto	
2022-06-03	Dissertation	David Landin	Clinical use of prognostic markers in head- and neck cancer
2022-06-14	Dissertation	Malin Sellberg	Students' and supervisors' experiences of supervision and training in clinical learning environment
2022-06-16	Half time	Krzysztof Piersiala	
2022-09-02	Half time	Hanna Josefsson Dahlgren	
2022-10-07	Dissertation	Eric Hjalmarsson	Allergic rhinitis and intralymphatic vaccination: immune response and tolerance
2022-10-14	Dissertation	Allison Mackey	Perspectives on screening strategies for early detection of childhood hearing impairment
2022-12-02	Half time	Sigurdur Arnason	
2022-12-09	Half time	Björn Eriksson	

## Participation at halftime seminars during 2010-10 to 2022-12-31



# Senior Researchers

Alinasab, Babak .....	11.
Arebro, Julia.....	12.
Asp, Filip .....	13.
Bachert, Claus.....	15.
Bark, Rusana.....	23.
Benson, Mikael .....	24.
Berninger, Erik .....	25.
Bonnard, Åsa .....	26
Borgström, Anna.....	27.
Browaldh, Nanna .....	28.
Cardell, Lars Olaf.....	29.
Duan, Maoli .....	31.
Ehnitage, Anders.....	33.
Eklöf, Martin .....	34.
Ekstedt, Sandra .....	35.
Elliot, Alexandra.....	36.
Engmér Berglin, Cecilia .....	37.
Fehrm, Johan .....	38.
Forshell Hederstierna, Christina .....	39.
Froissart Nerfeldt, Pia .....	40.
Gahm, Caroline .....	42.
Granath, Anna .....	43.
Hammarstedt Nordenvall, Lalle .....	44.
Hedin Skogman, Barbro .....	46.
Hellkvist, Laila .....	48.
Hellström, Sten .....	49.
Henriksson, Gert .....	50.
Hertegård, Stellan .....	51.
Hjalmarsson, Eric .....	52.
Holmström, Mats.....	53.
Hultman Dennison, Sofia .....	54.
Idrizbegovic, Esma .....	55.
Jonstam, Karin .....	56.
Kumlien Georén, Susanna.....	57.
Kågedal, Åsa.....	59.
Landin, David .....	60.
Li, Xinxiu.....	61.
Löfkvist, Ulrika .....	62.
Marklund, Linda.....	63.
Marsk, Elin .....	65.
Munck af Rosenschöld Wikland, Eva .....	66.
Mäkitie, Antti .....	67.
Möller, Riitta .....	68.
Nygren, Lina.....	69.
Olsson, Petter .....	70.
Palmgren, Björn .....	71.
Smeds, Henrik.....	72.
Stjärne, Pär .....	73.
Sundman, Joar .....	75.
Tideholm, Bo.....	76.
Toll, Karin .....	77.
Uhlén, Inger .....	78.
Verrecchia, Luca.....	80.
von Becherath, Mathias.....	81.
Wales, Jeremy .....	83.
Wendt, Malin.....	84.

Affiliated not presented in this book:  
Karlton, Eva, Tomanovic, Tatjana



Babak Alinasab

MD, PhD.

+46 70 7630065

[babak.alinasab@regionstockholm.se](mailto:babak.alinasab@regionstockholm.se)



### I. Mapping of Sinonasal cancer in Sweden.

Treatment for sinonasal malignancies, like other malignancies includes surgery, radiotherapy and chemotherapy of which surgery is the most central. What combination treatment that is most effective, however, is disputed.

Recent publications of treatment combinations has found that multimodal treatment was superior, as measured by survival. Herein there is a knowledge gap that this project will attempt to address.

The aim of this ongoing project is to both map the incidence, prevalence and relative survival of patients with sinonasal cancer. Different treatment modalities will be compared and evaluated in relation to long term survival and recurrence.

### II. Isolated Orbital Floor Fractures – To operate or not to operate.

A significant BOF needs surgical treatment otherwise it may lead to double vision and aesthetic deformities such as sunken eye. It is highly important to differentiate which patients need to be operated on or which do not.

In the on going projects below, we aim to identify which patients with BOF need an operation and which do not require an operation to prevent functional and aesthetic disorders.

1. Controlled randomized studies on patients with BOF with inferior BOF with a herniation > 1mL.

2. Prospective cohort study on isolated medial BOF.

### III. Zygomaticomaxillary Complex Fractures: aspects of diagnostic methods, treatment and sequelae

In zygomaticomaxillary Complex fractures, the surgeons' individual training, experience and preference influences the treatment and not systematic evidence, even though earlier studies on surgical treatment have shown that the choice of treatment have an impact on surgical outcome. As the degree and success of the reconstruction of a fractured zygoma is assessed by evaluating the contralateral, non-fractured side, the unfractured zygoma is used as a reference when planning for surgery.

In this ongoing project we aim to:

-Evaluate the long-term results of patients with ZMC fractures.

-Detect correlations between complications and to evaluate the overall management of ZMC fractures.

-To introduce a reliable treatment algorithm based on evidence based medicine.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Samin Rahbin	

Ethical permit No.

2009/331-31	2018/302-31	2019-04287-1	
-------------	-------------	--------------	--

### Publications 2020, 2021, 2022

1. The Volume Difference Along the External Surface of the Zygomatic Bone: A Novel Method of Measuring Zygomatic Bone Asymmetry. The Journal of Craniofacial Surgery Volume 00, Number 00, Month 2021
2. Loss of Malar Bags in Lower Eyelid In Orbital Blow Out Fracture Reconstruction Following Pre- or Retro-septal Transconjunctival Incision. Craniomaxillofacial Trauma Reconstruction. The Journal of Craniofacial Surgery Volume 31, Number 3, May/ June 2020
3. New Algorithm for Management of Orbital Blow Out Fracture Based on Prospective Study. Babak Alinasab, Karl-Johan Borstedt, Rebecka Rudström, Michael Ryott, Abdul Rashid Qureshi, Mats O. Beckman, Pär Stjärne. Craniomaxillofac Trauma Reconstr. 2018 Dec;11(4):285-295. doi: 10.1055/s-0038-1641714. Epub 2018 May 1.
4. Prospective Randomized Controlled Pilot Study on Orbital Blow out Fracture. Babak Alinasab, Karl-Johan Borstedt, Rebecka Rudström, Michael Ryott, Abdul Rashid Qureshi, Pär Stjärne. Craniomaxillofac Trauma Reconstr. 2018 Sep;11(3):165-171.
5. Supra Blepharoplasty Approach for Correcting Fractures of Frontal Bone Fracture. Babak Alinasab, Ola Fridman Bengtsson, Pär Stjärne. J Craniofac Surg. 2018 Oct;29(7):1906-1909.
6. Prospective study on ocular motility limitation due to orbital muscle entrapment or impingement associated with orbital wall fracture. Alinasab B, Qureshi AR, Stjärne P. Injury. 2017 Jul;48(7):1408-1416.



**Julia Arebro**  
MD, PhD.  
+46 73 9165066  
julia.arebro@regionstockholm.se

## Local mapping of middle ear disease

The underlying causes of middle ear disease like chronic otitis including chronic perforations of the tympanic membrane and cholesteatoma/retraction of the tympanic membrane as well as otosclerosis is highly unknown. We aim to search for underlying causes (studying RNA, proteins an immunological aspect as well as microbiological factors) through a patient based pre-clinical mapping project on .

Oral squamous cell carcinoma (OSCC) remains an under-studied and significant global cancer killer; dismal survival rates have not changed in decades. A better understanding of the molecular basis of OSCC progression and metastasis is needed to provide new treatment/disease management options. We aim to find new strategies in diagnosing and treating this disease through studying fibroblasts in the tumor microenvironment and signalling of miRNA in extracellular vesicles.

WHO have stated COPD to be the third most common cause of death worldwide. In Sweden, up to 700,000 people suffer from COPD generating a yearly cost of 15 billion SEK. Today's methods for diagnosing, treating and monitoring COPD and chronic bronchitis are insufficient. It is well known that smokers with COPD and/or chronic bronchitis suffer from repeated airway infections but the underlying mechanisms are unknown. We aim to investigate IL-26, IL-17 and other markers from Th17 helper cells in the upper airway in an attempt to see if COPD and chronic bronchitis can be monitored through markers in the upper airways.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

H15-02913	2022-06851-01			
-----------	---------------	--	--	--

### Publications 2020, 2021, 2022

1. Arebro J, Towle R, Li CM, Garnis C. CAFs activated through oral cancer derived EVs display unique pro-inflammatory properties. Manuscript
2. Khan A, et al. Identification and Characterization of a Severe Burden Subgroup of Chronic Rhinosinusitis With Nasal Polypsis Patients using Cluster Analysis. Manuscript
3. Arebro J, Palmgren B. Post-surgical pyoderma gangrenosum and flap necrosis in a head and neck cancer patient following neck dissection. Clin Case Rep. 2020;00:1–5



## Bilateral benefits and long-term outcomes of auditory implants and hearing aids in children

Hearing with two ears (binaural hearing) improves spatial hearing, which facilitates recognition of speech in conditions with multiple talkers, and sound localization. Horizontal sound localization is an ideal ability for the study of deficits in binaural hearing, since high accuracy is dependent on precise temporal processing and interaural comparison of acoustic signals. Hearing loss has a negative impact on sound localization, also in mild cases, for example unilateral hearing loss. We study the effects of congenital and acquired hearing loss and various interventions (e.g. auditory implants and hearing aids) on sound localization from as early as 6 months of age, using a rapid and objective technique. Our innovative method measures latency and accuracy of eye-movements towards auditory events, as an index of localization ability.

We also study the long-term hearing outcomes of cochlear implantation in individuals who received cochlear implants by 2.5 years of age, and now are young adults. We are interested in the interplay between age at implantation, hearing sensitivity, technical settings of the cochlear implant system, and intra-cochlear electrode placement and the combined effect of these variables on functional hearing.

The ultimate goal with these projects is to alleviate the negative impact of hearing impairment, and increase our understanding of how impaired spatial hearing affects humans, specifically during critical periods of development.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Fatima Moumèn Denanto	Marlin Johansson
	Malin Siegbahn
	Hanna Josefsson

### Ethical permit No.

2016/414-16 (Gothenburg)	2019-04696	2022-00863-02		
-----------------------------	------------	---------------	--	--

### Publications 2020, 2021, 2022

1. Asp, F., & Reinfeldt, S. (2020). Effects of Simulated and Profound Unilateral Sensorineural Hearing Loss on Recognition of Speech in Competing Speech. *Ear Hear*, 41(2), 411-419. <https://doi.org/10.1097/AUD.0000000000000764>
2. Johansson, M., Asp, F., & Berninger, E. (2020). Children With Congenital Unilateral Sensorineural Hearing Loss: Effects of Late Hearing Aid Amplification-A Pilot Study. *Ear Hear*, 41(1), 55-66. <https://doi.org/10.1097/AUD.0000000000000730>
3. Karlsson, E., Eklof, M., Ostlund, E., Asp, F., Tideholm, B., & Lofkvist, U. (2020). Cochlear implants before 9 months of age led to more natural spoken language
4. development without increased surgical risks. *Acta Paediatr*, 109(2), 332-341. <https://doi.org/10.1111/apa.14954>
5. Rigato, C., Reinfeldt, S., & Asp, F. (2020). The effect of an active transcutaneous bone conduction device on spatial release from masking. *Int J Audiol*, 59(5), 348-359. <https://doi.org/10.1080/14992027.2019.1705406>
6. Eklof, M., Asp, F., & Berninger, E. (2020). Sound localization latency in normal hearing and simulated unilateral hearing loss. *Hear Res*, 395, 108011. <https://doi.org/10.1016/j.heares.2020.108011>
7. Asp, F., Stokroos, R. J., & Agterberg, M. J. H. (2021). Toward Optimal Care for Children With Congenital Unilateral Aural Atresia. *Front Neurol*, 12, 687070. <https://doi.org/10.3389/fneur.2021.687070>

8. Siegbahn, M., Engmer Berglin, C., Hultcrantz, M., & Asp, F. (2021). Adults with unilateral congenital ear canal atresia - sound localization ability and recognition of speech in competing speech in unaided condition. *Acta Otolaryngol*, 141(7), 689-694. <https://doi.org/10.1080/00016489.2021.1921843>
9. Smeds, H., Wales, J., Karlsson, E., Anderlid, B. M., Henricson, C., Asp, F., Anmyr, L., Lagerstedt-Robinson, K., & Lofkvist, U. (2021). X-linked Malformation Deafness: Neurodevelopmental Symptoms Are Common in Children With IP3 Malformation and Mutation in POU3F4. *Ear Hear*. <https://doi.org/10.1097/AUD.0000000000001073>
10. Moumèn-Denanto, F., Tideholm, B., Hellström S., Asp, F., (2022). Differing bilateral benefits for spatial release from masking and sound localization accuracy using bone conduction devices. *Ear Hear*. 2022 May 19. doi: 10.1097/AUD.0000000000001234
11. Eklöf, M., Asp, F., Berninger, E., (2022). The development of sound localization latency in infants and young children with normal hearing. *Trends in hearing*. Accepted and in press.
12. Asp, F.; Karlsson, E.; Berninger, E. Development of Sound Localization in Infants and Young Children with Cochlear Implants. *J. Clin. Med.* 2022, 11(22), 6758; <https://doi.org/10.3390/jcm11226758>. <https://www.mdpi.com/2077-0383/11/22/6758>
13. Johansson, M., Karlsson, E., Asp, F., Berninger, E. A Prospective Study of Genetic Variants in Infants with Congenital Unilateral Sensorineural Hearing Loss. *J. Clin. Med.* 2023, 12, 495. <https://doi.org/10.3390/jcm12020495>.
14. Eklof, M., Asp, F., & Berninger, E. (2020). Sound localization latency in normal hearing and simulated unilateral hearing loss. *Hear Res*, 395, 108011. <https://doi.org/10.1016/j.heares.2020.108011>
15. Asp, F., Stokroos, R. J., & Agterberg, M. J. H. (2021). Toward Optimal Care for Children With Congenital Unilateral Aural Atresia. *Front Neurol*, 12, 687070. <https://doi.org/10.3389/fneur.2021.687070>
16. Siegbahn, M., Engmer Berglin, C., Hultcrantz, M., & Asp, F. (2021). Adults with unilateral congenital ear canal atresia - sound localization ability and recognition of speech in competing speech in unaided condition. *Acta Otolaryngol*, 141(7), 689-694. <https://doi.org/10.1080/00016489.2021.1921843>
17. Smeds, H., Wales, J., Karlsson, E., Anderlid, B. M., Henricson, C., Asp, F., Anmyr, L., Lagerstedt-Robinson, K., & Lofkvist, U. (2021). X-linked Malformation Deafness: Neurodevelopmental Symptoms Are Common in Children With IP3 Malformation and Mutation in POU3F4. *Ear Hear*. <https://doi.org/10.1097/AUD.0000000000001073>

**Claus Bachert**  
 Affiliated Professor from Ghent  
 +32 473310902  
 claus.bachert@ki.se



## Inflammation in the Upper Airways

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

--	--	--	--

### Publications 2020, 2021, 2022

1. IF 12.339 Bachert C, Humbert M, Hanania NA, Zhang N, Holgate S, Buhl R, Bröker BM. Staphylococcus aureus and its IgE-inducing Enterotoxins in Asthma: Current Knowledge. *Eur Respir J.* 2020 Apr 3;55(4):1901592
2. IF 10.228 Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. *J Allergy Clin Immunol.* 2020 Mar;145(3):725-739.
3. IF 6.780Xepapadaki P, Korovessi P, Bachert C, Finotto S, Jartti T, Lakoumentas J, Kowalski ML, Lewandowska-Polak A, Lukkarinen H, Zhang N, Zimmermann T, Papadopoulos NG. Evolution of Airway Inflammation in Preschoolers with Asthma-Results of a Two-Year Longitudinal Study. *J Clin Med.* 2020 Jan 9;9
4. IF 5.329 Ascari G, Peelman F, Farinelli P, Rosseel T, Lambrechts N, Wunderlich KA, Wagner M, Nikopoulos K, Martens P, Balikova I, Derycke L, Holtappels G, Krysko O, Van Laethem T, De Jaegere S, Guillemin B, De Rycke R, De Bleeker J, Creytens D, Van Dorpe J, Gerris J, Bachert C, Neuhofer C, Walraedt S, Bischoff A, Pedersen LB, Klopstock T, Rivolta C, Leroy BP, De Baere E, Coppieters F. Functional characterization of the first missense variant in CEP78, a founder allele associated with cone-rod dystrophy, hearing loss and reduced male fertility. *Hum Mutat.* 2020 Jan 30.
5. IF 8.71 Bédard A, Antó JM, Fonseca JA, Arnavielhe S, Bachert C, Bedbrook A, Bindslev-Jensen C, Bosnic-Anticevich S, Cardona V, Cruz AA, Fokkens WJ, Garcia-Aymerich J, Hellings PW, Ivancevich JC, Klimek L, Kuna P, Kvedariene V, Larenas-Linnemann D, Melén E, Monti R, Mösges R, Mullol J, Papadopoulos NG, Pham-Thi N, Samolinski B, V Tomazic P, Toppila-Salmi S, Ventura MT, Yorgancioglu A, Bousquet J, Pfaar O, Basagaña X; MASK study group. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App. *Allergy.* 2020 Jan 29
6. IF 10.228 Cardell LO, Stjärne P, Jonstam K, Bachert C. Endotypes of chronic rhinosinusitis: impact on management. *J Allergy Clin Immunol.* 2020 Jan 27 Rostrum
7. IF 10.228 Howarth P, Chupp G, Nelsen LM, Bradford ES, Bratton DJ, Smith SG, Albers FC, Brusselle G, Bachert C. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved outcomes with mepolizumab therapy. *J Allergy Clin Immunol.* 2020 Feb 18 LtE
8. IF 3.35 European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Matricardi PM, Meco C, O Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia T, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, Devyani L, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kjeldsen A, Klimek L, Kim SW, Letort JJ, Lopatin A, Mahdjoubi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepagaran N, Psaltis A, Pugin B, Raftopoulos M, Rombaux P, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Snidvongs K, Soklic Kosak T, Stjarne P. *Rhinology.* 2020 Feb 20;58(Suppl S29):1-464.
9. IF 8.71 Lan F, Zhang N, Bachert C, Zhang L. Stability of regulatory T cells in T helper 2-biased allergic airway diseases. *Allergy.* 2020 Mar 3.
10. IF 7.574 Naclerio R, Baroody F, Bachert C, Bleier B, Borish L, Brittain E, Chupp G, Fisher A, Fokkens W, Gevaert P, Kennedy D, Kim J, Laidlaw TM, Lee JJ, Piccirillo JF, Pinto JM, Roland LT, Schleimer RP, Schlosser RJ, Schwaninger JM, Smith TL, Tan BK, Tan M, Toskala E, Wenzel S, Togias A. Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics. A National Institute of Allergy and Infectious Diseases Workshop. *JACI IP.* 2020 Mar 3
11. IF 3.895 Abdurrahman G, Schmiedeke F, Bachert C, Bröker B, Holtfreter S. Allergy – a new role for T cell superantigens of Staphylococcus aureus? *Toxins.* 2020 Mar 12;12(3).
12. IF 7.574 Bachert C, Marple B, Hosemann W, Cavaliere C, Wen W, Zhang Nan. Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and Possible Therapeutic Implications. *J Allergy Clin Immunol Pract.* 2020 May;8(5):1514-1519

13. Klimek L, Bachert C, Pfaar O, Becker S, Bieber T, Brehler R, Buhl R, Casper I, Chaker A, Czech W, Fischer J, Fuchs T, Gerstlauer M, Hörmann K, Jakob T, Jung K, Kopp MV, Mahler V, Merk H, Mülleneisen N, Nemat K, Rabe U, Ring J, Saloga J, Schlenter W, Schmidt-Weber C, Seyfarth H, Sperl A, Spindler T, Staubach P, Strieth S, Treudler R, Vogelberg C, Wallrafen A, Wehrmann W, Wrede H, Zuberbier T, Bedbrook A, Canonica GW, Cardona V, Casale TB, Czarlewski W, Fokkens WJ, Hamelmann E, Jutel M, Larenas-Linnemann D, Mullol J, Papadopoulos NG, Toppila-Salmi S, Werfel T, Bousquet J. ARIA guideline 2019: treatment of allergic rhinitis in the German health system. *Allergol Select*. 2019 Dec 30;3(1):22-50.
14. IF 8.71 Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I, Ansotegui IJ, Bedbrook A, Bosnic-Anticevich S, Canonica GW, Chivato T, Cruz AA, Czarlewski W, Del Giacco S, Du H, Fonseca JA, Gao Y, Haahtela T, Hoffmann-Sommergruber K, Ivancevich JC, Khaltaev N, Knol EF, Kuna P, Larenas-Linnemann D, Mullol J, Naclerio R, Ohta K, Okamoto Y, O'Mahony L, Onorato GL, Papadopoulos NG, Pfaar O, Samolinski B, Schwarze J, Toppila-Salmi S, Teresa Ventura M, Valiulis A, Yorgancioglu A, Zuberbier T; ARIA-MASK study group. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. *Allergy* 2020 Mar 31
15. Klimek L, Förster-Ruhrmann U, Becker S, Chaker A, Huppertz T, Deitmer T, Olze H, Strieth S, Wrede H, Schlenter W, Löbler J, Wollenberg B, Beule AG, Rudack C, Bachert C, Dietz A Stellungnahme zur Anwendung von Glukokortikoiden bei entzündlichen Erkrankungen der oberen Atemwege (u. a. allergische Rhinitis/chronische Rhinosinusitis) während der aktuellen COVID-19 Pandemie. *Laryngorhinologie* 2020 Mar 31
16. IF 8.71 Klimek L, Jutel M, Akdis C, Bousquet J, Akdis M, Bachert C, Agache I, Ansotegui I, Bedbrook A, Bosnic-Anticevich S, Canonica GW, Chivato T, Cruz AA, Czarlewski W, Giacco SD, Du H, Fonseca JA, Gao Y, Haahtela T, Hoffmann-Sommergruber K, Ivancevich JC, Khaltaev N, Knol EF, Kuna P, Larenas-Linnemann D, Melen E, Mullol J, Naclerio R, Ohta K, Okamoto Y, O'Mahony L, Onorato GL, Papadopoulos NG, Pawankar R, Pfaar O, Samolinski B, Schwarze J, Toppila-Salmi S, Shamji MH, Ventura MT, Valiulis A, Yorgancioglu A, Matricardi P, Zuberbier T; ARIA-MASK study group. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. *Allergy*. 2020 Apr 24. doi: 10.1111/all.14336
17. IF 3.35 Prokopakis E, Vardouniotis A, Bachert C, Bousquet J, Carrie S, Castelnuevo P, Constantinidis J, Fokkens W, Hopkins C, Leunig A, Molteni G, Mullol J, Scadding G, Marien G, Doulaptsi M, Hellings P. Rhinology Future Debates 2018, a EUFOREA Report. *Rhinology*. 2020 Apr 25. doi: 10.4193/Rhin19.455.
18. Bogaert S, Bachert C. Chronic rhinosinusitis: assessment of changes in nociceptive neurons in chronic rhinosinusitis. International Forum of Allergy & Rhinology 2020
19. IF 40.689 Bousquet J, Josep M Anto, Claus Bachert, Ilaria Baiardini, Sinthia Bosnic-Anticevich, G Walter Canonica, Erik Melén, Oscar Palomares, Glenis K. Scadding, Alkis Togias, Sanna Toppila-Salmi. Allergic rhinitis. *Nature Reviews Disease Primer* 2020 Dec 3;6(1):95
20. 606 IF 40.689 IF 52.3 Bachert C, Marple B, Schlosser RJ, Hopkins C, Schleimer RP, Lambrecht BN, Bröker BM, Laidlaw T, Song WJ. Adult chronic rhinosinusitis. *Nature Reviews Disease Primer* 2020, 29:6:86
21. IF 10.228 Delemarre T, Holtappels G, De Ruyck N, Zhang N, Nauwynck H, Bachert C, Gevaert E. Type 2 Inflammation in Chronic Rhinosinusitis without Nasal Polyps: Another Relevant Endotype. *JACI* 2020;146:337-343
22. IF 10.228 Förster-Ruhrmann U, Szczepek AJ, Bachert C, Olze H. COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab. *J Allergy Clin Immunol*. 2020 Jul;146(1):218-220
23. IF 10.228 Jian Li, Yi Wei, Nan Zhang, Weiping Wen, Krysko O, Song WJ, Bachert C. Perspective: COVID-19, Implications of nasal diseases and consequences for their management. *J Allergy Clin Immunol*. 2020 Apr 30. pii: S0091-6749(20)30625-4. doi: 10.1016/j.jaci.2020.04.030.
24. IF 10.228 Gevaert P, Omachi T, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. *JACI* 2020;146:595-605
25. Meltzer EO, Bachert C, Mayer MJ, Kopietz F, Koltun A, Maus J, D'Addio AD. Deposition characteristics of a Novel Intranasal Formulation of Azelastine Hydrochloride plus Fluticasone Propionate in an anatomic model of the human nasal cavity. *Allergy Asthma Proc*. 2020 May 11.
26. IF 8.71 Seys SF, De Bont S, Bachert C, Alobid I, Bernal-Sprekelsen M, Bjermer L, Callebaut I, Cardell LO, Carrie S, Castelnovo P, Cathcart R, Constantinidis J, Cools L, Cornet M, Clement G, Cox T, Delsupehe L, Correia-de-Sousa J, Deneyer L, De Vos G, Diamant Z, Doulaptsi M, Gane S, Gevaert P, Hopkins C, Hox V, Hummel T, Hosemann W, Jacobs R, Jorissen M, Kjeldsen A, Landis BN, Lemmens W, Leunig A, Lund V, Mariën G, Mullol J, Onerci M, Palkonen S, Proano I, Prokopakis E, Ryan D, Riechelmann H, Sahlstrand-Johnson P, Salmi-Toppila S, Segboer C, Speleman K, Steinsvik A, Surda P, Tomazic PV, Vanderveken O, Van Gerven L, Van Zele T, Verfaillie J, Verhaeghe B, Vierstraete K, Vlaminck S, Wagenmann M, Pugin B, Hellings PW. Real-life assessment of chronic rhinosinusitis patients using mobile technology: the mySinusitisCoach project by EUFOREA. *Allergy*. 2020 May 18. doi: 10.1111
27. Lourenço O, Bosnic-Anticevich S, Costa E, Fonseca JA, Menditto E, Cvetkovski B, Kritikos V, Tan R, Bedbrook A, Scheire S, Bachert C, Blaétek S, Briedis V, Boussery K, Canonica GW, Haahtela T, Kuna P, Novellino E, Samolinski B, Schünemann HJ, Wallace D, Bousquet J. Managing Allergic Rhinitis in the Pharmacy: An ARIA Guide for Implementation in Practice. *Pharmacy (Basel)*. 2020 May 16;8(2):E85.
28. IF 5.670 Van Hoecke L, Verbeke R, De Vlieger D, Dewitte H, Roose K, Van Nevel S, Krysko O, Bachert C, Schepens B, Lentacker I, Saelens X. Van Hoecke L, et al. mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice. *Mol Ther Nucleic Acids*. 2020 May 1;20:777-787.
29. IF 4.340 Werner U, A Künstner, M Drenckhan, R Pries, KL Bruchhage, H Busch, C Bachert, B Wollenberg: Linking complement C3 and B cells in nasal polyposis. *J Immunol Research* 2020
30. IF 8.71 Jartti T, Liimatainen U, Xepapadaki P, Vahlberg T, Bachert C, Finotto S, Kowalski ML, Sobanska A, Lukkarinen H, Pasitoli M, Vuorinen T, Zhang N, Zimmermann T, Papadopoulos NG. Clinical correlates of rhinovirus infection in preschool asthma. *Allergy*. 2020 Jul 3. doi: 10.1111/all.14479. PMID: 32621330
31. Eckrich J, Hinkel J, Fischl A, Herrmann E, Holtappels G, Bachert C, Zielen S. Nasal IgE in subjects with allergic and non-allergic rhinitis. *World Allergy Organ J*. 2020 Jun 23;13(6):100129
32. Berger WE, Bachert C, Allara R, Koltun A, Kopietz F, Maus JG, D'Addio AD. Evaluation of in vitro Penetration of Fluticasone Propionate from MP-AzeFlu and Fluticasone Propionate Nasal Spray Through EpiAirway™606 Tissues Using Vertical Diffusion Cells. *J Asthma Allergy*. 2020 May 28;13:187-192. PMID: 32547111
33. IF 8.71 Pfaar O, Klimek L, Jutel M, Akdis CA, Bousquet J, Breiteneder H, Chinthurajah S, Diamant Z, Eiwegger T, Fokkens WJ, Fritsch HW, Na-

- deau KC, O'Hehir RE, O'Mahony L, Rief W, Sampath V, Schedlowski M, Torres M, Traidl-Hoffmann C, Wang DY, Zhang L, Bonini M, Brehler R, Brough HA, Chivato T, Del Giacco S, Dramburg S, Gawlik R, Gelincik A, Hoffmann-Sommergruber K, Hox V, Knol E, Lauferma A, Matriardi PM, Mortz CG, Ollert M, Palomares O, Riggioni C, Schwarze J, Skypala I, Untersmayr S, Walusiak-Skorupa J, Ansotegui I, Bachert C, Bedbrook A, Bosnic-Anticevich S, Brussino L, Canonica GW, Cardona V, Carreiro-Martins P, Cruz AA, Czarlewski W, Fonseca JA, Gotua M, Haatela T, Ivancevich JC, Kuna P, Kvedariene V, Larenas-Linnemann D, Latiff A, Morais-Almeida M, Mullol J, Naclerio R, Ohta K, Okamoto Y, Onorato GL, Papadopoulos NG, Patella V, Regateiro FS, Samolinski B, Suppli Ulrik C, Toppila-Salmi S, Valiulis A, Ventura MT, Yorgancioglu A, Zuberbier T, Agache I. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper. *Allergy*. 2020 Jun 12;10.1111/all.14453. PMID: 3253110
34. Kim C, Han J, Wu T, Bachert C, Fokkens W, Hellings P, Hopkins C, Lee S, Mullol J, Lee JT. Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review. *Otolaryngol Head Neck Surg*. 2020 Aug 4;194599820939964
  35. IF 10.228 IF 11.8 Howarth P, Bachert C, Sousa A, Chan R. Reply. *J Allergy Clin Immunol*. 2020 Sep;146(3): 683-684
  36. IF 60.392 Bachert C, Mannent LP. Dupilumab for nasal polyposis - Authors' reply. *Lancet*. 2020 Jul 25;396(10246):233-234
  37. Allais L, S Verschueren, T Maes, R De Smet, S Devries, GB Gonzales, H Peeters, K Van Crombruggen, C Bachert, M De Vos, GG. Brusselle, KR. Bracke, CA. Cuvelier, D Laukens. Translational research into the effects of cigarette smoke on inflammatory mediators and epithelial TRPV1 in Crohn's disease. *PLoS One*. 2020 Aug 6;15(8):e0236657.
  38. IF 8.71 Bousquet J, Anto JM, Czarlewski W, Haahetla T, Fonseca SC, Iaccarino G, Blain H, Vidal A, Sheikh A, Akdis CA, Zuberbier T; ARIA group. Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. *Allergy*. 2020 Aug 6. doi: 10.1111/all.14549
  39. IF 4.534 Teufelberger A, Sharon Van Nevel, Paco Hulpiau, Maria Nordengrün, Savvas N Savvides, Sarah De Graeve, Srinivas Akula, Gabriele Holtappels, Natalie De Ruyck, Wim Declercq, Peter Vandebaelee, Lars Hellman, Barbara M. Bröker, Dmitri V. Krysko, Claus Bachert, Olga Krysko. Mouse strain-dependent difference towards the *Staphylococcus aureus* allergen Serine protease-like protein D reveals a novel regulator of IL-33. *Front Immunol*. 2020 Sep 25;11:582044
  40. IF 10.228 Delemarre T, G Holtappels, N De Ruyck, N Zhang, H Nauwynck, C Bachert, E Gevaert. A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps. *JACI* 2020 Sep 16:S0091-6749(20)31275-6.
  41. IF 8.71 Incorvaia C, Al-Ahmad M, Ansotegui I, Arasi S, Bachert C, Bos C, Bousquet J, Bozek A, Caimmi D, Calderón M, Casale T, Custovic A, De Blay F, Demoly P, Devillier P, Didier A, Fiocchi A, Fox A, Gevaert P, Gomez M, Heffler E, Ilina N, Irani C, Jutel M, Karagiannis E, Klimek L, Kuna P, O'Hehir R, Kurbacheva O, Matricardi PM, Morais de Almeida M, Mosges R, Novak N, Okamoto Y, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Pfaar O, Schmid-Grendelmeier P, Scurati S, Tortajada-Girbés M, Vidal C, Virchow C, Wahn U, Worm M, Zieglmayer P, Canonica GW. Personalized Medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model. *Allergy*. 2020 Sep 1. doi: 10.1111/all.14575.
  42. Klimek L, Beule AG, Förster-Ruhrmann U, Becker S, Chaker A, Huppertz T, Hagemann J, Hoffmann TK, Dazert S, Deitmer T, Wrede H, Schlenter W, Welkoborsky HJ, Wollenberg B, Olze H, Rudack C, Sperl A, Casper I, Dietz A, Wagenmann M, Zuberbier T, Bergmann KC, Bedbrook A, Bousquet J, Bachert C. Positions paper: Hinweise zur Patienteninformation und -aufklärung vor Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP). *Laryngorhinootologie*. 2020 Aug 28.
  43. Jonstam K, Delemarre T, Holtappels G, Cardell LO, Westman M, Bachert C. Type 2 inflammatory shift in chronic rhinosinusitis during 2007-2018 in Belgium. *The Laryngoscope* 2020
  44. IF 4.217 Du, Kun; Zheng, Ming; Zhao, Yan; Xu, Wenbin; Hao, Yun; Wang, Yue; Zhao, Jinming; Zhang, Nan; WANG, Xiangdong; Zhang, Luo; Bachert, Claus. Impaired small airway function in non-asthmatic chronic rhinosinusitis with nasal polyps. *CEA-2020-0313.R1*
  45. IF 4.217 Delemarre T; Holtappels G; Bachert C; Gevaert E. Unravelling the expression of interleukin-9 in chronic rhinosinusitis: A possible role for *Staphylococcus aureus*. *Clin Translat Allergy* 2020 Oct 29;10(1):41
  46. IF 3.35 Hellings PW, Scadding G, Bachert C, Bjermer L, Canonica GW, Cardell LO, Carney AS, Constantinidis J, Deneyer L, Diamant Z, Durham S, Gevaert P, Harvey R, Hopkins C, Kjeldsen A, Klimek L, Lund VJ, Price D, Rimmer J, Ryan D, Roberts G, Sahlstrand-Johnson P, Salmi S, Samji M, Scadding G, Smith P, Steinsvik A, Wagenmann M, Seys S, Wahn U, Fokkens. EUFOREA treatment algorithm for allergic rhinitis. *Rhinology* 2020 Sep 29. doi: 10.4193/Rhin20.246.
  47. Vlaminck S, Acke F, Prokopakis E, Speleman K, Kawauchi H, van Cutsem JC, Hellings PW, Jorissen M, Seys S, Bachert C, Zele TV, Lambrecht BN, Gevaert P. Surgery in Nasal Polyp Patients: Outcome After a Minimum Observation of 10 Years. *Am J Rhinol Allergy* 2020 Oct 5:1945892420961964.
  48. IF 9.9 Efimova I, Catanzaro E, Van der Meeren L, Turubanova VD, Hammad H, Mishchenko TA, Vedunova MV, Fimognari C, Bachert C, Coppieters F, Lefever S, Skirtach AG, Krysko O, Krysko DV. Efimova I, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. *J Immunother Cancer*. 2020 Nov;8(2):e001369. Journal for ImmunoTherapy of Cancer (JITC): Best Basic Tumor Immunology Paper Award
  49. IF 8.71 Klimek L, Jutel M, Bousquet J, Agache I, Akdis C, Hox V, Gevaert P, Tomazic PV, Rondon C, Cingi C, Toppila-Salmi S, Karavelia A, Bozkurt B, Förster-Ruhrmann U, Becker S, Chaker AM, Wollenberg B, Mösges R, Huppertz T, Hagemann J, Bachert C, Fokkens W. Klimek L, et al. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic - An EAACI Position Paper. *Allergy*. 2020 Oct 19.
  50. Price D et al. Evaluating the Real-life Effect of MP-AzeFlu On Asthma Outcomes In Patients With Allergic Rhinitis and Asthma In UK Primary Care. *WAO Journal* 2020
  51. IF 10.228 Gevaert P, Corren J, Mullol J, Han J, Lee SE, Ligueros-Saylan M, Wong K, Omachi TA, Bachert C. Reply *J Allergy Clin Immunol*. 2020 Nov 4:S0091-6749(20)31391-9.
  52. Bousquet J, Cristol JP, Czarlewski W, Anto JM, Martineau A, Haahetla T, Fonseca SC, Iaccarino G, Blain H, Fiocchi A, Canonica GW, Fonseca JA, Vidal A, Choi HJ, Kim HJ, Le Moing V, Reynes J, Sheikh A, Akdis CA, Zuberbier T; ARIA group. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. *Clin Transl Allergy*. 2020 Dec 3;10(1):58.
  53. Fonseca J, Taveira-Gomes T, Pereira AM, Branco-Ferreira M, Carreiro-Martins P, Alves-Correia M, Correia de Sousa J, Costa E, Lourenço O, Morais-Almeida M, Morête A, Regateiro F, Todo Bom A, Bachert C, Pfaar O, Wallace D, Bedbrook A, Czarlewski W, Bousquet J. Fonseca J, et al. ARIA 2019: An Integrated Care Pathway for Allergic Rhinitis in Portugal. *Acta Med Port*. 2020 Dec 4.

54. Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong A, Poetker DM, Soler Z, Welch KC, Wise SK, Adappa N, Alt JA, Anselmo-Lima WT, Bachert C, Baroody FM, Batra PS, Bernal-Sprekelsen M, Beswick D, Bhattacharyya N, Chandra RK, Chang E, Chiu A, Chowdhury N, Citardi MJ, Cohen NA, Conley DB, DelGaudio J, Desrosiers M, Douglas R, Eloy JA, Fokkens WJ, Gray ST, Gudis DA, Hamilos DL, Han JK, Harvey R, Hellings P, Holbrook EH, Hopkins C, Hwang P, Javer AR, Jiang RS, Kennedy D, Kern R, Laidlaw T, Lal D, Lane A, Lee HM, Lee JT, Levy JM, Lin SY, Lund V, McMains KC, Metson R, Mullol J, Naclerio R, Oakley G, Otori N, Palmer JN, Parikh SR, Passali D, Patel Z, Peters A, Philpott C, Psaltis AJ, Ramakrishnan VR, Ramanathan M Jr, Roh HJ, Rudmik L, Sacks R, Schlosser RJ, Sedaghat AR, Senior BA, Sindwani R, Smith K, Snidvongs K, Stewart M, Suh J, Tan BK, Turner JH, van Drunen CM, Voegels R, Wang Y, Woodworth BA, Wormald PJ, Wright ED, Yan C, Zhang L, Zhou B. Orlandi RR, et al. International Consensus Statement on Rhinology and Allergy: Rhinosinusitis. *Int Forum Allergy Rhinol.* 2020 Nov 24.
55. Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S, Bedbrook A, Onorato GL, Czarlewski W, Murray R, Almeida R, Fonseca JA, Correia da Sousa J, Costa E, Morais-Almeida M, Todo-Bom A, Cecchi L, De Feo G, Illario M, Menditto E, Monti R, Stellato C, Ventura MT, Annesi-Maesano I, Bosse I, Fontaine JF, Pham-Thi N, Thibaudon M, Schmid-Grendelmeier P, Spertini F, Chavannes NH, Fokkens WJ, Reitsma S, Dubakiene R, Emuzyte R, Kvedariene V, Valiulis A, Kuna P, Samolinski B, Klimek L, Mösges R, Pfaar O, Shamai S, Roller-Wirnsberger RE, Tomazic PV, Ryan D, Sheikh A, Haahtela T, Toppila-Salmi S, Valovirta E, Cardona V, Mullol J, Valero A, Makris M, Papadopoulos NG, Prokopakis EP, Psarros F, Bachert C, Hellings PW, Pugin B, Bindslev-Jensen C, Eller E, Kull I, Melén E, Wickman M, De Vries G, van Eerd M, Agache I, Ansotegui IJ, Bosnic-Anticevich S, Cruz AA, Casale T, Ivancevich JC, Larenas-Linnemann DE, Sofiev M, Wallace D, Waserman S, Yorgancioglu A, Laune D, Bousquet J; MASK study group. Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. *Clin Transl Allergy.* 2020 Dec 9;10(1):62.
56. Liu X, Wang Y, Charn TC, Koh LT, Teo NW, Ong YK, Thong MK, Bachert C, Pfaar O, Schünemann HJ, Bedbrook A, Czarlewski W, Bousquet J. Generation Allergic Rhinitis Care in Singapore: 2019 ARIA Care Pathways. *Ann Acad Med Singap.* 2020 Nov;49(11):885-896.
57. Horn A, Bachert C, Brehmer D. Clinical post-approval studies as part of the Therapy Allergen Regulation (TAV): A systematic review. *Z Evid Fortbild Qual Gesundhwes.* 2021 Jan 14:S1865-9217(20)30199-9.
58. De Jong HJI, Voorham J, Scadding GK, Bachert C, Canonica GW, Smith P, Wahn U, Ryan D, Castillo JA, Carter VA, Murray RB, Price DB. Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care. *World Allergy Organ J.* 2020 Dec 19;13(12):1004
59. IF 8.71 Jonstam K, Alsharif S, Bogaert S, Suchonos N, Holtappels G, Jae-Hyun Park J, Bachert C. Extent of inflammation in severe nasal polyposis and effect of sinus surgery on inflammation. *Allergy* 2021;76(3):933-936
60. IF 10.793 Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, Mullol J, Gevaert P, Klimek L, Prokopakis E, Knill A, Cavaliere C, Hopkins C, Hellings P. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. *J Allergy Clin Immunol.* 2021 Jan;147(1):29-36.
61. Laidlaw TM, Bachert C, Amin N, Desrosiers M, Hellings PW, Mullol J, Maspero JF, Gevaert P, Zhang M, Mao X, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP. Dupilumab improves upper- and lower-airway disease control in chronic rhinosinusitis with nasal polyps and asthma. *Ann Allergy Asthma Immunol.* 2021 Jan 16:S1081-1206(21)00020-X.
62. IF 8 Peters AT, Han JK, Hellings P, Heffler E, Gevaert P, Bachert C, Xu Y, Chuang CC, Neupane B, Msihid J, Mannent LP, Guyot P, Kamat S. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. *J Allergy Clin Immunol Pract.* 2021 Feb 3:S2213-2198(21)00159-8
63. IF 30.70 Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Mepo-lizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med.* 2021 Apr 16:S2213-2600(21)00097-7.
64. Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps. *J Asthma Allergy.* 2021 Feb 11;14:127-134
65. Renz H, C Bachert, C Berek, E Hamelmann, F Levi-Schaffer, U Raap, HU Simon, S Ploetz, C Taube, P Valent, D Voehringer, T Werfel, N Zhang, J Ring. Physiology and Pathology of Eosinophils: Recent Developments. *Scand J Immunol* 2021 Feb 23;e13032.
66. IF 11 Bousquet J, Jutel M, Pfaar O, Fonseca JA, Agache I, Czarlewski W, Bachert C, Bergmann KC, Cruz AA, Klimek L, Kvedariene V, Larenas-Linnemann DE, Papadopoulos NG, Patella V, Regateiro FS, Scichilone N, Shamji MH, Sheikh A, Valovirta E, Ventura MT, Zuberbier T. The role of mobile health technologies in stratifying patients for AIT and its cessation. The ARIA-EAACI perspective. *J Allergy Clin Immunol Pract.* 2021 Mar 1:S2213-2198(21)00240-3.
67. IF 10.793 Bachert C, Maurer M, Palomares O, Busse WW. What is the contribution of IgE to nasal polyposis? *J Allergy Clin Immunol* 2021 Mar 20:S0091-6749(21)00472-3
68. IF 8.71 Hagemann J, Onorato GL, Jutel M, Akdis CA, Agache I, Zuberbier T, Czarlewski W, Mullol J, Bedbrook A, Bachert C, Bennoor KS, Bergmann KC, Braido F, Camargos P, Caraballo L, Cardona V, Casale T, Cecchi I, Chivato T, Chu DK, Cingi C, Correia-de-Sousa J, Del Giacco S, Dokic D, Dykewicz M, Ebisawa M, El-Gamal Y, Emuzyte R, Fauquert JL, Fiocchi A, Fokkens WJ, Fonseca JA, Gemicioglu B, Gomez M, Maia G, Haahtela T, Hamelmann E, Inuma T, Ivancevich JC, Jassem E, Kalayci O, Kardas P, Khatov M, Kuna P, Kvedariene V, Larenas-Linnemann DE, Lipworth B, Makris M, Maspero JF, Miculinic N, Mihaltan F, Mohammad Y, Montefort S, Morais-Almeida M, Mösges R, Naclerio R, Neffen H, Niedoszytko M, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Panzner P, Papadopoulos NG, Passalacqua G, Patella V, Pereira A, Pfaar O, Plavec D, Popov TA, Prokopakis EP, Puggioni F, Raciborski F, Reijula J, Regateiro FS, Reitsma S, Romano A, Rosario N, Rottem M, Ryan D, Samolinski B, Sastre J, Solé D, Sova M, Stellato C, Suppli-Ulrik C, Tsiliogianni I, Valero A, Valiulis A, Valovirta E, Vasankari T, Ventura MT, Wallace D, Wang Y, Williams I, Yorgancioglu A, Yusuf OM, Zernotti M, Bousquet J, Klimek L. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold- An ARIA-EAACI-GA2LEN consensus. *Allergy.* 2021 Mar 17. doi: 10.1111/all.14815
69. IF 10.793 Delemarre T, Bochner BS, Simon HU, Bachert C. Rethinking Neutrophils and Eosinophils in Chronic Rhinosinusitis. *JACI* 2021 Apr 21:S0091-6749(21)00545-5
70. Turubanova VD, Mishchenko TA, Balalaeva IV, Efimova I, Peskova NN, Klapshina LG, Lermontova SA, Bachert C, Krysko O, Vedunova MV, Krysko DV. Novel porphyrazine-based photodynamic anti-cancer therapy induces immunogenic cell death. *Sci Rep.* 2021 Mar 30;11(1):7205.
71. Klimek L, Chaker A, Deitmer T, Plontke SK, Wollenberg B, Bousquet J, Bachert C. Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps. *HNO* 2021 Mar 18:1-10.

72. IF 13.146 Bousquet J, Agache I, Blain H, Jutel M, Ventura MT, Worm M, Del Giacco S, Benetos A, Bilo MB, Czarlewski W, Abdul Latiff AH, Al-Ahmad M, Angier E, Annesi-Maesano I, Atanaskovic-Markovic M, Bachert C, Barbaud A, Bedbrook A, Bennoor KS, Berghea EC, Bindslev-Jensen C, Bonini S, Bosnic-Anticevich S, Brockow K, Brussino L, Camargos P, Canonica GW, Cardona V, Carreiro-Martins P, Carrizo A, Casale T, Caubet JC, Cecchi L, Cherubini A, Christoff G, Chu DK, Cruz AA, Dokic D, El-Gamal Y, Ebisawa M, Eberlein B, Farrell J, Fernandez-Rivas M, Fokkens WJ, Fonseca JA, Gao Y, Gavazzi G, Gawlik R, Gelincik A, Gemicioglu B, Gotua M, Guérin O, Haahtela T, Hoffmann-Sommergruber K, Hoffmann HJ, Hofmann M, Hrubisko M, Ienallario M, Irani C, Ispayeva Z, Ivancevich JC, Julge K, Kaidashev I, Khaitov M, Knol E, Kraxner H, Kuna P, Kvedariene V, Lauferma A, Le LT, Le Moing V, Levin M, Louis R, Lourenco O, Mahler V, Martin FC, Matucci A, Milenkovic B, Miot S, Montella E, Morais-Almeida M, Mortz CG, Mullol J, Namazova-Baranova L, Neffen H, Nekam K, Niedoszytko M, Odemir M, O'Hehir RE, Okamoto Y, Ollert M, Palomares O, Papadopoulos NG, Panzner P, Passalacqua G, Patella V, Petrovic M, Pfaar O, Pham-Thi N, Plavec D, Popov TA, Recto MT, Regateiro FS, Reynes J, Roller-Winsberger RE, Rolland Y, Romano A, Rondon C, Rottem M, Rouadi PW, Salles N, Samolinski B, Santos AF, Serpa FS, Sastre J, Schols JMGA, Scichilone N, Sediva A, Shamji MH, Sheikh A, Skypala I, Smolinska S, Sokolowska M, Sousa-Pinto B, Sova M, Stelmach R, Sturm G, Suppli Ulrik C, Todo-Bom AM, Toppila-Salmi S, Tsiligianni I, Torres M, Untersmayr E, Urrutia Pereira M, Valiulis A, Vitte J, Vultaggio A, Wallace D, Walusiak-Skorupa J, Wang DY, Waserman S, Yorgancioglu A, Yusuf OM, Zernotti M, Zidarn M, Chivato T, Akdis CA, Zuberbier T, Klimek L. Management of anaphylaxis due to COVID-19 vaccines in the elderly. *Allergy*. 2021 Apr 2. doi: 10.1111/all.14838.
73. Duan S, Zhao L, Zhang Y, Zhang N, Zheng M, Wang Q, Zhang X, Wang X, Ying S, Bachert C, Zhang L, Lan F. Tropomyosin in mugwort cross-reacts to house dust mite, eliciting non-Th2 response in allergic rhinitis patients sensitized to house dust mite. *Clin Mol Allergy*. 2021 Apr 2;19(1):2.
74. Bousquet, Jean; Schroeder-Bernhardi, Detlef; Bachert, Claus; Canonica, Giorgio Walter; Cardona, Victoria; Costa, Elisio; Czarlewski, Wienia; Devillier, Philippe; Fonseca, João; Klimek, Ludger; Kuna, Piotr; Lourenco, Olga; Mullol, Joaquim; Pfaar, Oliver; Pham Thi, Nhân; Samoliński, Bolesław; Saueressig, Julia; Scadding, Glenis; Stroh, Ann-Kathrin; Scheire, Sophie; Van Ganse, Eric; Zuberbier, Torsten. Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. *CEA* 2021 Apr 20.
75. Desrosiers M, Mannent LP, Amin N, Canonica GW, Hellings PW, Gevaert P, Mullol J, Lee SE, Fujieda S, Han JK, Hopkins C, Fokkens W, Janowski R, Cho SH, Mao X, Zhang M, Rice MS, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Bachert C. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. *Rhinology*. 2021 Apr 13. doi: 10.4193/Rhin20.415.
76. Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Reducing Fungal Exposure Critical for Treating Rhinosinusitis with or without Polyps [Response to Letter]. *J Asthma Allergy*. 2021 Apr 19;14:393-395.
77. IF 13.146 Fujieda S, Matsune S, Takeno S, Ohta N, Asako M, Bachert C, Inoue T, Takahashi Y, Fujita H, Deniz Y, Rowe P, Ortiz B, Li Y, Mannent LP. Dupilumab efficacy in chronic rhino-sinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. *Allergy* 2021 May 16. doi: 10.1111/all.14906.
78. IF 13.44 Ma Junjie, Christopher A. Tibbitt, Susanna Kumlien Georén, Murray Christian, Ben Murrell, Lars-Olaf Cardell, Claus Bachert, Jonathan M. Coquet. Single cell analysis pinpoints distinct populations of cytotoxic CD4 T cells and an IL-10+CD109+ Th2 cell population in nasal polyps. *Science Immunology* 13 Aug 2021: Vol. 6, Issue 62, eabg6356
79. Larsson O, Sunnergren O, Bachert C, Kumlien Georén S, Cardell LO. The SP-TLR axis, which locally primes the nasal mucosa, is impeded in patients with allergic rhinitis. *Clin Transl Allergy*. 2021 Mar;11(1):e12009.
80. Bousquet J, Bedbrook A, Czarlewski W, De Carlo G, Fonseca JA, González Ballester MA, Illario M, Koskinen S, Laatikainen T, Onorato GL, Palkonen S, Patella V, Pham-Thi N, Puggioni F, Ventura MT, Joos G, Kuna P, Louis R, Makris M, Zalud P, Zuberbier T, Bachert C, Brussino L, Carreiro-Martins P, Carrion Y Ribas C, Chalubinski M, Costa EM, de Vries G, Gemcioglu B, Gennimata D, Micheli Y, Niedoszytko M, Regateiro FS, Romantowski J, Taborda-Barata L, Toppila-Salmi S, Tsiligianni I, Viart F, Laune D. Digital Health Europe (DHE) Twinning on severe asthma-kick-off meeting report. *J Thorac Dis*. 2021 May;13(5):3215-3225.
81. Bousquet J, Pfaar O, Agache I, Bedbrook A, Akdis CA, Canonica GW, Chivato T, Al-Ahmad M, Abdul Latiff AH, Ansotegui IJ, Bachert C, Baharuddin A, Bergmann KC, Bindslev-Jensen C, Bjerner L, Bonini M, Bosnic-Anticevich S, Bosse I, Brough HA, Brussino L, Calderon MA, Caraballo L, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Cepeda Sarabia AM, Chkhartishvili E, Chu DK, Cirule I, Cruz AA, Czarlewski W, Del Giacco S, Demoly P, Devillier P, Dokic D, Durham SL, Ebisawa M, El-Gamal Y, Emuzyte R, Gamkrelidze A, Fauquert JL, Fiocchi A, Fokkens WJ, Fonseca JA, Fontaine JF, Gawlik R, Gelincik A, Gemcioglu B, Gereda JE, Gerth van Wijk R, Gomez RM, Gotua M, Grisile I, Guzmán MA, Haahtela T, Halken S, Heffler E, Hoffmann-Sommergruber K, Hossny E, Hrubiško M, Irani C, Ivancevich JC, Ispayeva Z, Julge K, Kaidashev I, Kalayci O, Khaitov M, Klimek L, Knol E, Kowalski ML, Kraxner H, Kull I, Kuna P, Kvedariene V, Kritikos V, Lauferma A, Lau S, Laune D, Levin M, Larenas-Linnemann DE, Lodrup Carlsen KC, Lombardi C, Lourenço OM, Mahboub B, Malling HJ, Manning P, Marshall GD, Melén E, Meltzer EO, Miculicic N, Milenkovic B, Moin M, Montefort S, Morais-Almeida M, Mortz CG, Mösges R, Mullol J, Namazova Baranova L, Neffen H, Nekam K, Niedoszytko M, Odemir M, O'Hehir RE, Ollert M, O'Mahony L, Ohta K, Okamoto Y, Okubo K, Pajno GB, Palomares O, Palkonen S, Panzner P, G Papadopoulos N, Park HS, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Plavec D, Popov TA, Recto M, Regateiro FS, Riggioni C, Roberts G, Rodriguez-Gonzales M, Rosario N, Rottem M, Rouadi PW, Ryan D, Samolinski B, Sanchez-Borges M, Serpa FS, Sastre J, Scadding GK, Shamji MH, Schmid-Grendelmeier P, Schünemann HJ, Sheikh A, Scichilone N, Sisul JC, Sofiev M, Solé D, Sooronaev T, Soto-Martinez M, Soto-Quiros M, Sova M, Schwarze J, Skypala I, Suppli-Ulrik C, Taborda-Barata L, Todo-Bom A, Torres MJ, Valentín-Rostan M, Tomazic PV, Valero A, Toppila-Salmi S, Tsiligianni I, Untersmayr E, Urrutia-Pereira M, Valiulis A, Valovirta E, Vandenplas O, Ventura MT, Vichyanond P, Wagenmann M, Wallace D, Walusiak-Skorupa J, Wang Y, Waserman S, Wong GW, Yorgancioglu A, Yusuf OM, Zernotti M, Zhang L, Zidarn M, Zuberbier T, Jutel M. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. *Clin Transl Allergy*. 2021 Jun 9;11(4):e12014.
82. IF 10.793 Gevaert P, Rebecca Saenz, Jonathan Corren, Joseph K. Han, Joaquim Mullol, Stella E. Lee, Randall A. Ow, Rui Zhao, Monet Howard, Kit Wong, Lutaf Islam, Monica Ligueros-Saylan, Theodore A. Omachi, Claus Bachert. Long-term efficacy and /safety of omalizumab for nasal polyposis in an open-label extension study. *JACI* 2021 Sep 13:S0091-6749(21)01364-6. doi: 10.1016/j.jaci.2021.07.045
83. Sharon Van Nevel, Judith Van Ovost, Gabrielle Holtappels, Natalie Deruyck, Nan Zhang, Natalie de Ruyck, Harald Braun, Tania Maes, Claus Bachert, Olga Krysko. Neutrophils affect IL-33 processing in response to the respiratory allergen Alternaria alternata. *Frontiers in Immunology* 2021, 12:677848.
84. IF 13.146 Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, Maspero JF, Picado C, Daizadeh N, Ortiz B, Li Y, Ruddy M, Laws E, Amin N. Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials. *Allergy*. 2021 Aug 30. doi: 10.1111/all.15067.
85. Du K, Wang M, Zhang N, Yu P, Wang P, Li Y, Wang X, Zhang L, Bachert C. Involvement of the extracellular matrix proteins periostin and tenascin C in nasal polyp remodeling by regulating the expression of MMPs. *Clin Transl Allergy*. 2021 Sep 6;11(7):e12059.

86. IF 13.146 Maurer DJ, Liu C, Xepapadaki P, Stanic B, Bachert C, Finotto S, Gao YD, Graser A, Jartti T, Kistler W, Kowalski M, Lukkarinen H, Paszto M, Tan G, Villiger M, Zhang L, Zhang N, Akdis M, Papadopoulos NG, Akdis CA. Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers. *Allergy*. 2021 Sep 21. doi: 10.1111/all.15105.
87. Klimek L, Förster-Ruhrmann U, Beule AG, Becker S, Chaker AM, Huppertz T, Hagemann J, Hoffmann TK, Dazert S, Deitmer T, Wrede H, Schlenten W, Welkoborsky HJ, Wollenberg B, Olze H, Rudack C, Sperl A, Casper I, Dietz A, Wagenmann M, Zuberbier T, Bergmann KC, Bedbrook A, Bousquet J, Bachert C, Bergmann C. Positionspapier: Hinweise zur Patienteninformation und -aufklärung vor Anwendung von Biologika bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) – Teil 2: Omalizumab – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC). *Laryngorhinootologie*. 2021 Sep 14. doi: 10.1055/a-1592-0316.
88. Krysko O, Kondakova E, Vershinina O, Galova E, Blagonravova A, Gorshkova E, Bachert C, Ivanchenko M, Krysko DV, Vedunova M. Artificial Intelligence Predicts Severity of COVID-19 Based on Correlation of Exaggerated Monocyte Activation, Excessive Organ Damage and Hyperinflammatory Syndrome: A Prospective Clinical Study. *Front Immunol*. 2021 Aug 27;12:715072.
89. IF 10.793 Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, Tversky JR, Barker P, Cohen D, Emson C, Martin UJ, Shih VH, Necander S, Kreindler JL, Jison M, Werkström V. Efficacy and Safety of Benralizumab in Chronic Rhinosinusitis with Nasal Polyps: A Randomized, Placebo-controlled Trial. *J Allergy Clin Immunol*. 2021 Sep 29:S0091-6749(21)01459-7.
90. IF 13.146 Bousquet J, Agache I, Blain H, Jutel M, Ventura MT, Worm M, Del Giacco S, Benetos A, Bilo BM, Czarlewski W, Abdul Latiff AH, Al-Ahmad M, Angier E, Annesi-Maesano I, Atanaskovic-Markovic M, Bachert C, Barbaud A, Bedbrook A, Bennoor KS, Berghea EC, Bindslev-Jensen C, Bonini S, Bosnic-Anticevich S, Brockow K, Brussino L, Camargos P, Canonica GW, Cardona V, Carreiro-Martins P, Carrizo A, Casale T, Caubet JC, Cecchi L, Cherubini A, Christoff G, Chu DK, Cruz AA, Dokic D, El-Gamal Y, Ebisawa M, Eberlein B, Farrell J, Fernandez-Rivas M, Fokkens WJ, Fonseca JA, Gao Y, Gavazzi G, Gawlik R, Gelincik A, Gemicioğlu B, Gotua M, Guérin O, Haahela T, Hoffmann-Sommergruber K, Hoffmann HJ, Hofmann M, Hrubisko M, Illario M, Irani C, Ispayeva Z, Ivancevich JC, Julge K, Kaidashev I, Khaitov M, Knol E, Kraxner H, Kuna P, Kvedariene V, Lauferma A, Le LTT, Le Moing V, Levin M, Louis R, Lourenco O, Mahler V, Martin FC, Matucci A, Milenkovic B, Miot S, Montella E, Moraes-Almeida M, Mortz CG, Mullol J, Namazova-Baranova L, Neffen H, Nekam K, Niedoszytko M, Odemyr M, O’Hehir RE, Okamoto Y, Ollert M, Palomares O, Papadopoulos NG, Panzner P, Passalacqua G, Patella V, Petrovic M, Pfaar O, Pham-Thi N, Plavec D, Popov TA, Recto MT, Regateiro FS, Reynes J, Roller-Winsberger RE, Rolland Y, Romano A, Rondon C, Rottem M, Rouadi PW, Salles N, Samolinski B, Santos AF, S Sarquis F, Sastre J, M G A Schols J, Scichilone N, Sediva A, Shamji MH, Sheikh A, Skypala I, Smolinska S, Sokolowska M, Sousa-Pinto B, Sova M, Stelmach R, Sturm G, Suppli Ulrik C, Todo-Bom AM, Toppila-Salmi S, Tsiligianni I, Torres M, Untersmayr E, Urrutia Pereira M, Valiulis A, Vitte J, Vultaggio A, Wallace D, Walusiak-Skorupa J, Wang DY, Waserman S, Yorgancioglu A, Yusuf OM, Zernotti M, Zidarn M, Chivato T, Akdis CA, Zuberbier T, Klimek L. Management of anaphylaxis due to COVID-19 vaccines in the elderly. *Allergy*. 2021 Oct;76(10):2952-2964.
91. IF 25.094 Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med*. 2021 Oct;9(10):1141-1153.
92. Dasari P, Nordengrün M, Vilhena C, Steil L, Abdurrahman G, Surmann K, Dhople V, Lahrberg J, Bachert C, Skerka C, Völker U, Bröker BM, Zipfel PF. The protease SpIB of *Staphylococcus aureus* targets host complement components and inhibits complement-mediated bacterial opsonophagocytosis. *J Bacteriol*. 2022 Jan 18;204(1):e0018421.
93. IF 10.793 Mullol J, Bachert C, Amin N, Desrosiers M, Hellings PW, Han JK, Jankowski R, Vodicka J, Gevaert P, Daizadeh N, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP. Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps. *J Allergy Clin Immunol Pract*. 2021 Oct 7:S2213-2198(21)01104-1.
94. Price D, Menzies-Gow A, Bachert C, Canonica GW, Kocks J, Khan AH, Ye F, Rowe PJ, Lu Y, Kamat S, Carter V, Voorham J. Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma. *J Asthma Allergy*. 2021 Sep 29;14:1173-1183.
95. IF 10.793 Huang Y, Zhang N, Xu Z, Zhang L, Bachert C. The development of the mucosal concept in chronic rhinosinusitis and its clinical implications. *J Allergy Clin Immunol Pract*. 2021 Nov 3:S2213-2198(21)01244-7
96. Li N, Mirzakhani H, Kiefer A, Koelle J, Vuorinen T, Rauh M, Yang Z, Krammer S, Xepapadaki P, Lewandowska-Polak A, Lukkarinen H, Zhang N, Stanic B, Zimmermann T, Kowalski ML, Jartti T, Bachert C, Akdis M, Papadopoulos NG, Raby BA, Weiss ST, Finotto S. Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) drives the resolution of allergic asthma. *iScience*. 2021 Sep 25;24(10):103163.
97. Klimek L, Chaker A, Deitmer T, Plontke SK, Wollenberg B, Bousquet J, Bachert C. Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps. *HNO*. 2021 Nov;69(11):868-877.
98. Förster-Ruhrmann U, Beule AG, Becker S, Chaker AM, Huppertz T, Hagemann J, Hoffmann TK, Dazert S, Deitmer T, Wrede H, Schlenten W, Welkoborsky HJ, Wollenberg B, Olze H, Rudack C, Sperl A, Casper I, Dietz A, Wagenmann M, Zuberbier T, Bergmann KC, Bedbrook A, Bousquet J, Bachert C, Bergmann C, Klimek L. Positionspapier: Hinweise zur Patienteninformation und -aufklärung vor Anwendung von Biologika bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) – Teil 2: Omalizumab – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC). *Laryngorhinootologie*. 2021 Nov;100(11):864-872.
99. Masieri S, Bachert C, Ojeda P, Kim CK, Carlo C, Giorgio C; Study Group on AIT & Vaccinations. Allergen Immunotherapy management during vaccinations: An international survey. *World Allergy Organ J*. 2021 Nov;14(11):100601.
100. Chuang CC, Guillemin I, Bachert C, Lee SE, Hellings PW, Fokkens WJ, Duverger N, Fan C, Daizadeh N, Amin N, Mannent LP, Khan AH, Kamat S. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds. *Laryngoscope*. 2021 2022 Feb;132(2):259-264.
101. IF 10.793 Geng B, Bachert C, Busse WW, Gevaert P, Lee SE, Niederman MS, Chen Z, Lu X, Khokhar FA, Kapoor U, Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. *J Allergy Clin Immunol Pract*. 2021 Dec 22:S2213-2198.
102. Khan AH, Abbe A, Falissard B, Carita P, Bachert C, Mullol J, Reaney M, Chao J, Mannent LP, Amin N, Mahajan P, Pirozzi G, Eckert L. Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab. *Patient Prefer Adherence*. 2021 Nov 19;15:2577-2586.
103. Han JK, Bachert C, Lee SE, Hopkins C, Heffler E, Hellings PW, Peters AT, Kamat S, Whalley D, Qin S, Nelson L, Siddiqui S, Khan AH, Li Y, Mannent LP, Guillemin I, Chuang CC. Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis. *Laryngoscope*. 2022 Feb;132(2):265-271.
104. Tian R, Yang Y, Liu L, Sun Y, Tang N, Zhang Y, Zhang N, Song X, Bachert C. Seasonal distribution of inhaled allergens in allergic asthma patients with or without allergic rhinitis. *Chin Med J (Engl)*. 2021 Dec 15.

105. Bachert C, Corren J, Lee SE, Zhang H, Harel S, Cunoosamy D, Khan AH, Jacob-Nara JA, Siddiqui S, Nash S, Rowe PJ, Deniz Y. Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials. *Int Forum Allergy Rhinol.* 2021 Dec 30.
106. IF10.793 Xu Z, Huang Y, Delemarre T, Cavaliere C, Zhang N, Bachert C. Advances in Chronic Rhinosinusitis 2020/2021. *J Allergy Clin Immunol.* 2021 Dec 29:S0091-6749(21)02744-5.
107. IF 13.146 Fujieda S, Matsune S, Takeno S, Ohta N, Asako M, Bachert C, Inoue T, Takahashi Y, Fujita H, Deniz Y, Rowe P, Ortiz B, Li Y, Mannent LP. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. *Allergy.* 2022 Jan;77(1):186-196.
108. IF 10.793 Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, Maspero JF, Smith SG, Kante O, Karidi-Andrioti DE, Mayer B, Chan RH, Yancey SW, Chaker AM. Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. *J Allergy Clin Immunol.* 2022 Jan 7:S0091-6749(22)00001-X.
109. Bachert C, Peters AT, Heffler E, Han JK, Olze H, Pfaar O, Chuang CC, Rout R, Attre R, Goga L, Jacob-Nara JA, Rowe PJ, Deniz Y, Chen Z, Kamat S, Siddiqui S. Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. *Clin Exp Allergy.* 2022 Feb;52(2):244-249. doi: 10.1111/cea.14051.
110. IF10.793 Gevaert P, Bachert C, Maspero JF, Cuevas M, Steele D, Acharya S, Altman PJ Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER). *Allergy Clin Immunol.* 2022 Jan 27:S0091-6749(21)02599-9.
111. Klimek L, Olze H, Förster-Ruhrmann U, Beule AG, Chaker AM, Hagemann J, Huppertz T, Hoffmann TK, Dazert S, Deitmer T, Strieth S, Wrede H, Schlenter W, Welkoborsky HJ, Wollenberg B, Becker S, Klimek F, Zuberbier J, Rudack C, Cuevas M, Hintschich CA, Guntinas-Lichius O, Stöver T, Bergmann C, Bachert C. Positionspapier: Empfehlungen zur Anwendung von Mepolizumab bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des ÄDA und DGHNO. *Laryngorhinootologie.* 2022 Feb 15.
112. IF10.793 Sharon Van Nevel, Jozefien Declercq, Gabriele Holtappels, Bart Lambrecht, Claus Bachert. Granulocyte Colony-Stimulating Factor: Missing Link for Stratification of Type 2 and Non-type 2 Chronic Rhinosinusitis Patients. *J Allergy Clin Immunol.* 2022 Mar 9:S0091-6749(22)00288-3.
113. Xu Z, Zhang N, Huang Y, Wen W, Bachert C. Is surgery for severe type 2 nasal polyps safe under the treatment with biologics? *Ann Allergy Asthma Immunol.* 2022 Mar;128(3):328-330
114. Gevaert P, Han JK, Smith SG, Sousa AR, Howarth PH, W Yancey S, Chan R, Bachert C. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. *Int Forum Allergy Rhinol.* 2022 Mar 4. doi: 10.1002/alr.22994. Online ahead of print. PMID: 35243803 Review.
115. Canonica GW, Bourdin A, Peters AT, Desrosiers M, Bachert C, Weidinger S, Simpson EL, Daizadeh N, Chen Z, Kamat S, Khan AH, Chao J, Graham NMH, Laws E, Rossi AB, Ardeleanu M, Mannent LP, Amin N, Ortiz B, Deniz Y, Djandji M, Rowe PJ. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases. *J Allergy Clin Immunol Pract.* 2022 Mar 5:S2213-2198(22)00227-6.
116. Van Nevel S, Declercq J, Holtappels G, Lambrecht BN, Bachert C. Granulocyte Colony-Stimulating Factor: Missing Link for Stratification of Type 2-high and Type 2-low Chronic Rhinosinusitis Patients. *J Allergy Clin Immunol.* 2022 Mar 9:S0091-6749(22)00288-3.
117. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, Klimek L, Pfaar O, Wallace D, Ansotegui I, Agache I, Bedbrook A, Bergmann KC, Bewick M, Bonniaud P, Bosnic-Anticevich S, Bossé I, Bouchard J, Boulet LP, Brozek J, Brusselle G, Calderon MA, Canonica WG, Caraballo L, Cardona V, Casale T, Cecchi L, Chu DK, Costa EM, Cruz AA, Czarlewski W, D'Amato G, Devillier P, Dykewicz M, Ebisawa M, Fauquert JL, Fokkens WJ, Fonseca JA, Fontaine JF, Gemicioglu B, van Wijk RG, Haahtela T, Halken S, Ierodiakonou D, Iinuma T, Ivancevich JC, Jutel M, Kaidashev I, Khaitov M, Kalayci O, Kleine Tebbe J, Kowalski ML, Kuna P, Kvedariene V, La Grutta S, Larenas-Linnemann D, Lau S, Laune D, Le L, Lieberman P, Lodrup Carlsen KC, Lourenço O, Marien G, Carreiro-Martins P, Melén E, Menditto E, Neffen H, Mercier G, Mosqués R, Mullol J, Muraro A, Namazova L, Novellino E, O'Hehir R, Okamoto Y, Ohta K, Park HS, Panzner P, Passalacqua G, Pham-Thi N, Price D, Roberts G, Roche N, Rolland C, Rosario N, Ryan D, Samolinski B, Sanchez-Borges M, Scadding GK, Shamji MH, Sheikh A, Bom AT, Toppila-Salmi S, Tsiligianni I, Valentin-Rostan M, Valiulis A, Valovirta E, Ventura MT, Walker S, Waserman S, Yorgancioglu A, Zuberbier T; Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. *J Allergy Clin Immunol.* 2020 Jan;145(1):70-80.e3.
118. Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, Azar A, Baroody FM, Bachert C, Canonica GW, Chacko T, Cingi C, Ciprandi G, Corey J, Cox LS, Creticos PS, Custovic A, Damask C, DeConde A, DelGaudio JM, Ebert CS, Eloy JA, Flanagan CE, Fokkens WJ, Franzese C, Gosepath J, Halderman A, Hamilton RG, Hoffman HJ, Hohlfeld JM, Houser SM, Hwang PH, Incorvia C, Jarvis D, Khalid AN, Kilpeläinen M, Kingdom TT, Krouse H, Larenas-Linnemann D, Laury AM, Lee SE, Levy JM, Luong AU, Marple BF, McCoul ED, McMains KC, Melén E, Mims JW, Moscato G, Mullol J, Nelson HS, Patadia M, Pawankar R, Pfaar O, Platt MP, Reisacher W, Rondón C, Rudmik L, Ryan M, Sastre J, Schlosser RJ, Settipane RA, Sharma HP, Sheikh A, Smith TL, Tantilipikorn P, Tversky JR, Veling MC, Wang Y, Westman M, Wickman M, Zacharek M. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. *Int Forum Allergy Rhinol.* 2018 Feb;8(2):108-352.
119. Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Walter Canonica G, Melén E, Palomares O, Scadding GK, Togias A, Toppila-Salmi S. Allergic rhinitis. *Nat Rev Dis Primers.* 2020 Dec 3;6(1):95.
120. Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, Poetker DM, Soler Z, Welch KC, Wise SK, Adappa N, Alt JA, Anselmo-Lima WT, Bachert C, Baroody FM, Batra PS, Bernal-Sprekelsen M, Beswick D, Bhattacharyya N, Chandra RK, Chang EH, Chiu A, Chowdhury N, Citardi MJ, Cohen NA, Conley DB, DelGaudio J, Desrosiers M, Douglas R, Eloy JA, Fokkens WJ, Gray ST, Gudis DA, Hamilos DL, Han JK, Harvey R, Hellings P, Holbrook EH, Hopkins C, Hwang P, Javer AR, Jiang RS, Kennedy D, Kern R, Laidlaw T, Lal D, Lane A, Lee HM, Lee JT, Levy JM, Lin SY, Lund V, McMains KC, Metson R, Mullol J, Naclerio R, Oakley G, Otori N, Palmer JN, Parikh SR, Passali D, Patel Z, Peters A, Philpott C, Psaltis AJ, Ramakrishnan VR, Ramanathan M Jr, Roh HJ, Rudmik L, Sacks R, Schlosser RJ, Sedaghat AR, Senior BA, Sindwani R, Smith K, Snidvongs K, Stewart M, Suh JD, Tan BK, Turner JH, van Drunen CM, Voegels R, Wang Y, Woodworth BA, Wormald PJ, Wright ED, Yan C, Zhang L, Zhou B. International consensus statement on allergy and rhinology: rhinosinusitis 2021. *Int Forum Allergy Rhinol.* 2021 Mar;11(3):213-739.

121. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Iacobaltzeta I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, Lødrup Carlsen KC, Manning PJ, Meltzer E, Mullol J, Muraro A, O’Hehir R, Ohta K, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Price D, Riva JJ, Roldán Y, Ryan D, Sadeghirad B, Samolinski B, Schmid-Grendelmeier P, Sheikh A, Togias A, Valero A, Valiulis A, Valovirta E, Ventresca M, Wallace D, Waserman S, Wickman M, Wiercioch W, Yepes-Nuñez JJ, Zhang L, Zhang Y, Zidarn M, Zuberbier T, Schünemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. *J Allergy Clin Immunol*. 2017 Oct;140(4):950-958.
122. Dasari P, Nordengrün M, Vilhena C, Steil L, Abdurrahman G, Surmann K, Dhople V, Lahrberg J, Bachert C, Skerka C, Völker U, Bröker BM, Zipfel PF. The Protease SplB of *Staphylococcus aureus* Targets Host Complement Components and Inhibits Complement-Mediated Bacterial Opsonophagocytosis. *J Bacteriol*. 2022 Jan 18;204(1):e0018421
123. Bachert C, Khan AH, Hopkins C, Blaiss MS, Soler ZM, Nash S, Siddiqui S, Praestgaard A, Deniz Y, Rowe PJ, Jacob-Nara JA. Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP. *J Asthma Allergy*. 2022 May 4;15:557-563
124. Förster-Ruhrmann U, Szczepak AJ, Pierchalla G, Fluhr JW, Artuc M, Zuberbier T, Bachert C, Olze H. Chemokine Expression-Based Endotype Clustering of Chronic Rhinosinusitis. Reboot surgery for chronic rhinosinusitis with nasal polyposis: recurrence and smell kinetics. *J Pers Med*. 2022 Apr 18;12(4):646.
125. Gomes SC, Cavaliere C, Masieri S, Van Zele T, Gevaert P, Holtappels G, Zhang N, Ramasamy P, Voegels RL, Bachert C. Reboot surgery for CRSwNP: Recurrence and smell kinetics. *Eur Arch Otorhinolaryngol*. 2022 Dec;279(12):5691-5699
126. Busse WW, Wellman A, Diamant Z, Cohen NA, Chaker AM, Bachert C, Siddiqui S, Zhang H, Nash S, Khan AH, Jacob-Nara JA, Rowe PJ, Deniz Y. Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP. *J Allergy Clin Immunol Pract*. 2022 May 24:S2213-2198(22)00501-3.
127. De Prado Gomez L, Khan AH, Peters AT, Bachert C, Wagenmann M, Heffler E, Hopkins C, Hellings PW, Zhang M, Xing J, Rowe P, Jacob-Nara JA. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. *Am J Rhinol Allergy*. 2022 Jul 15:1945892422112211.
128. De Prins L, Raap U, Mueller T, Schmid-Grendelmeier P, Haase CH, Backer V, Fokkens W, Benoit LB, Prokopakis E, Hopkins C, Claeys N, Teeling T, Cypers L, Cools L, Bjermer LH, Diamant Z, Wahn U, Scadding G, Bachert C, Patel SR, Van Staeyen E, Hellings P. White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA. *Front Allergy*. 2022 Jun 2;3:889221.
129. Xuan L, Zhang N, Wang X, Zhang L, Bachert C (2022) IL-10 family cytokines in chronic rhinosinusitis with nasal polyps: From experiments to the clinic. *Front. Immunol*. 2022;13:947983.
130. Krysko O, Bourne JH, Kondakova E, Galova EA, Whitworth K, Newby ML, Bachert C, Hill H, Crispin M, Stamatakis Z, Cunningham AF, Pugh M, Khan AO, Rayes J, Vedunova M, Krysko DV, Brill A. Severity of SARS-CoV-2 infection is associated with high numbers of alveolar mast cells and their degranulation. *Front Immunol*. 2022 Sep 26;13:968981.
131. Shen Y, Zhang N, Yang Y, Hong S, Bachert C. Local Immunoglobulin E in nasal polyps: Role and modulation. *Front Immunol*. 2022 Sep 8;13:961503
132. Gao YD, Xepapadaki P, Cui YW, Stanic B, Maurer DJ, Bachert C, Zhang N, Finotto S, Chalubinski M, Lukkarinen H, Pasotti M, Graser A, Jartti T, Kowalski M, Ogulur I, Shi ZW, Akdis M, Papadopoulos NG, Akdis CA. Effect of *Haemophilus influenzae*, *Streptococcus pneumoniae* and influenza vaccinations on infections, immune response, and asthma control in preschool children with asthma. *Allergy*. 2022 Oct 13.
133. Seys SF, Hellings PW, Alobid I, Backer V, Bequignon E, von Buchwald C, Cavaliere C, Coste A, Deneyer L, Diamant Z, Eckl-Dorna J, Fokkens WJ, Gane S, Gevaert P, Holbaek-Haase C, Holzmeister C, Hopkins C, Hox V, Huart C, Jankowski R, Jorissen M, Kjeldsen A, Knipps L, Lange B, van der Lans R, Laulajainen-Hongisto A, Larsen K, Liu D, Lund V, Mariën G, Masieri S, Mortuaire G, Mullol J, Reitsma S, Rombaux P, Schneider S, Steinsvik A, Tomazic PV, Toppila-Salmi SK, Van Gerven L, Van Zele T, Virkkula P, Wagenmann M, Bachert C. Chronic RhINOSinusitis Outcome Registry (CHRINOSOR): establishment of an international outcome registry driven by mHealth technology. *J Allergy Clin Immunol Pract*. 2022 Oct 19:S2213-2198(22)01039-X.
134. Plath M, Derycke L, Sand M, Van de Vyvere D, Delemarre T, Cavaliere C, Plinkert P, Holtappels G, Bachert C. Can Patient-Reported Outcomes and Inflammatory Markers Define Endotype 2 in Chronic Rhinosinusitis without Nasal Polyps? *Annals of Allergy, Asthma & Immunology*. 2022 Nov 25;S1081-1206(22)01961-5.
135. Bachert C, Hellings PW, Lund VJ, Fokkens WJ, Hopkins C, Mayer B, Chan RH, Smith SG, Sousa AR, Alfonso-Cristancho R, Yang S, On Behalf Of The Synapse Study Group. Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP. *RhinoLOGY*. 2022 Dec 1;60(6):474-478.
136. Vedunova M, Victoria Turubanova, Olga Vershinina, Maria Savuk, Iullia Efimova, Tatiana Mishchenko, Robrecht Raedt, Anne Vral, Christian Vanhove, Daria Korsakova, Claus Bachert, Frauke Coppieters, Patrizia Agostinis, Abhishek Garg, Mikhail Ivanchenko, Olga Krysko, and Dmitri Krysko. DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis. *Cell Death & Disease* 2022: Dec 21;13(12):1062
137. Siddiqui S, Bachert C, Chaker AM, Han JK, Hellings PW, Peters AT, Heffler E, Kamat S, Zhang H, Nash S, Khan AH, De Prado Gomez L, Jacob-Nara JA, Rowe PJ, Deniz Y. AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps. *ERJ Open Res*. 2022 Nov 28;8(4):00085-2022
138. Peeters S, Wang C, Bijnens EM, Bullens DMA, Fokkens WJ, Bachert C, Hellings PW, Nawrot TS, Seys SF. Association between outdoor air pollution and chronic rhinosinusitis patient reported outcomes. *Environ Health*. 2022 Dec 21;21(1):134.
139. Wang Z, Wang Q, Duan S, Zhang Y, Zhao L, Zhang S, Hao L, Li Y, Wang X, Wang C, Zhang N, Bachert C, Zhang L, Lan F. A diagnostic model for predicting type 2 nasal polyps using biomarkers in nasal secretion. *Front Immunol*. 2022 Dec 21;13:1054201.
140. Migueres N, Poirot A, Zhang N, Bachert C, de Blay F. Omalizumab effectiveness is independent of Staphylococcal Enterotoxin sensitization. *Respir Med Res*. 2022 Dec 13;83:100986.
141. Bachert C, Khan A, Hopkins C, Blaiss M, Soler Z, Nash S, Siddiqui S, Praestgaard A, Deniz Y, Rowe PJ, Jacob-Nara JA. Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP. *J Asthma Allergy*. 2022;15:557-563

Rusana Bark

MD, PhD.

+46 8 517 76020

rusana.bark@regionstockholm.se



## Head & Neck Cancer

### Ongoing projects:

- Prospective study: Use of anchor in extirpation of non-palpable lymph nodes and cysts in the neck.
- Marginal vs. segmental resection of the mandible in gingival cancer patients- comparison study including patients from Karolinska and Örebro?
- The risk for regional metastasis in patients with gingival cancer in relation to tumor size, localization (maxilla/mandible), T-class and histopathology.
- Sentinel-node assisted neck dissection in N+ oral cancer patients. Prevalence of occult metastases.
- Salivary gland tumors- the use of sentinel node technique to predict lymphatic drainage
- Prevalence of regional recurrence/disease free survival in oral cancer N+ patients after SN-assisted neck dissection: 2 years follow up.
- Prospective study: Can HPV be used as a predictor in differentiating between cystic metastasis and lateral branchial cleft cyst?

### Future projects:

- -Clinical predicting biomarkers in oropharyngeal cancer patients whith goal to decrease the side effect profile.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Evelina Jörtsö

### Ethical permit No.

2020-00448	2021-00697	2021-01265	
------------	------------	------------	--

### Publications 2020, 2021, 2022

1. Vujasinovic M, Marsk E, Tsolakis AV, Hynning B, Nordberg M, Lindblad M, Lindqvist C, Hammarstedt- Nordenvall L, Bark R, Elbe P. Complications of gastrostomy tubes in patients with head and neck cancer. *Laryngoscope*. 2022 Sep;132(9):1778-1784.
2. Hammarstedt-Nordenvall L, Evelina J, Beckerath M, Tani E, Nordemar S, Bark R. Prevalence of cystic metastases in a consecutive cohort of surgically removed branchial cleft cysts. *Acta Otolaryngol*. 2022 Jan;142(1)100-105.
3. Ullman J, Karling J, Bark R, Nelson D, Waneczek M, Margolin G. Navigation system in percutaneous tracheotomy. *Acta OtoLaryngol*. 2021. Sep 27:1-7.
4. Vujasinovic M, Öst Å, Bark R, Brismar T, Hynning B, Lindblad M, Elbe P. Metastasis to the gastrostomy site in a patient with pharynx cancer after percutaneous endoscopic gastrostomy: a case report. *Scand J Gastroenterol*. 2020 Aug;55(8):1002-1004



**Mikael Benson**  
Affiliated Professor  
+46 722276505  
mikael.benson@ki.se

## Digital Twins for personalised medicine

One of the greatest health care problems today is that many patients do not respond to drug treatment. This reflects the complexity of the human body, which consists of trillions of cells, each of which may express thousands of genes, in different combinations, at different time points, before and during disease. There is a wide gap between this complexity and modern health care. The Swedish Digital Twin Consortium ([sdtc.se](http://sdtc.se)) proposes that this gap can be bridged by digital twins of individual patients. Each twin is computationally treated (computreated) with thousands of drugs, in order to find the best treatment for the patient. The twins are constructed and treated by applying network tools and artificial intelligence (AI) to single cell RNA-seq (scRNA-seq) and clinical data from each patient. We have shown clinical feasibility by treating a mouse model of arthritis, and diagnostic studies of multiple diseases (all references are found in [sdtc.se](http://sdtc.se)). Recent case reports support the clinical applicability of scRNA-guided treatment of patients that do not respond to conventional treatment. However, that treatment was based on empirical analyses of the data. By contrast, our digital twin strategy is based on systematic prioritization of drugs and computreatment of the twins with those drugs, before actually treating individual patients. We are now planning to show clinical feasibility by treating individual patients. The ultimate aim is that each healthy individual should have her/his digital twin for predictive, preventive, personalised and participatory medicine.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Martin Smelik	Simon Söderholm
Samuel Schäfer	
Yelin Zhao	

### Ethical permit No.

--	--	--	--

### Publications 2020, 2021, 2022

1. Lilja S, Li X, Lee EJ, Loscalzo J, Zhang H, Zhao Y, Gawel D, Wang H, Benson M. Multi-organ single cell analysis reveals an on/off switch system with potential for personalized treatment of immunological diseases. *Cell Reports Medicine* 2023
2. Li X, Lee EJ, Lilja S, Loscalzo J, Schäfer S, Zhang H, Gustafsson M, Zhao Y, Gawel D, Wang H, Benson M. A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets. *Genome Med.* 2022
3. Li X, Lee EJ, Lilja S, Loscalzo J, Schäfer S, Zhang H, Gustafsson M, Zhao Y, Gawel D, Wang H, Benson M. A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets. *Genome Med.* 2022
4. Bensberg M, Rundquist O, Selimovic A, Benson M, Gustafsson M, Nestor C. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. *PNAS* 2021;118(34):e2110758118.
5. Lee EJ, Lilja S, Li X, Schäfer S, Zhang H, Benson M. Bulk and single cell transcriptomic data indicate that a dichotomy between inflammatory pathways in peripheral blood and arthritic joints complicates biomarker discovery. *Cytokine* 2020;127:154960
6. Lee EJ, Lilja S, Li X, Schäfer S, Zhang H, Benson M. Analysis of expression profiling data suggests explanation for difficulties in finding biomarkers for nasal polyps. *Rhinology* 2020;58:360-67
7. Li X, Lilja S, Lee EJ, Schäfer S, Benson M. Meta-analysis of expression profiling data indicates need for combinatorial biomarkers in pediatric ulcerative colitis. *J Infl Research* 2020;127:154960

### Review articles

1. Digital Twins for personalized medicine. *ATVB* 2023
2. Franks P....multiple authors from Genomic Medicine Sweden, including M Benson. Strategies for Implementing Genomic-Driven Precision Medicine for Complex Diseases in Sweden. *J Int Med* 2021
3. Gawel D, Jacobsson B, Jönsson JI, Melen E, Sysoev O, Ynnander A, Benson M. Clinical implementation of genomic and digital technologies for precision medicine. *Swedish Med J* 2021
4. Björnsson B, ..Benson M; Swedish Digital Twin Consortium. Digital twins to personalize medicine. *Genome Med.* 2020;12(1):4.

**Erik Berninger**

Associate Professor

+73 699 41 01

erik.berninger@ki.se



## Hearing impairment in newborns. New objective technologies and intervention strategies during a sensitive period of development to improve subsequent communication

Our research project aims at very early diagnosis and intervention to reduce or reverse disability and thus improve the communication capacity of the hearing-impaired child. The long-term goal is to find the causes and mechanisms behind various nonsyndromic congenital sensorineural hearing losses (SNHL) and to develop future treatment options. The main research directions are:

- A. Causes and mechanisms behind nonsyndromic congenital SNHL
- B. Impact of early intervention during a critical period of development
- C. Sound localization as a clinical tool
- D. Rapid and objective ABR technique for newborns and infants

Overall aims of the research directions are: A.) To identify and precisely diagnose various forms of congenital SNHL, as determined at the level of specific anatomical structures down to the molecular level. To identify and develop future treatment options on the basis of highly specific diagnoses, as determined at birth. B.) To study the impact of relevant auditory stimulation during a sensitive period of development, and to identify the extent of that period. C.) To study the relationship between behavioural development and maturation of the central auditory pathways and the physiology of binaural interaction at the brainstem level. Development of a new rapid noninvasive and objective test for e.g. central auditory processing dysfunction from 6 months of age. Evaluation of various intervention/care strategies. D.) To develop a rapid, valid, and reliable electrophysiological technique applicable in newborns and infants for diagnostics and as a basis for fine-tuning of e.g. nonlinear hearing aids.

Part of the studies will be supervised by PhD Filip Asp and Senior Professor Sten Hellström. All the studies will be performed at the recently established Scientific Center for Advanced Pediatric Audiology (SCAPA), Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Marlin Johansson	

### Ethical permit No.

2012/494-31/1; 2018/1500-31 (Approved addendum, 2020-06-10)	2014/1162-31/1; 2015/1878-21/2	2012/189-31/3; 2013/2248-3	2013/104-31/4; 2017/293-31/4	2008/1961-31; 2019-03826
--	-----------------------------------	-------------------------------	---------------------------------	-----------------------------

### Publications 2020, 2021, 2022

1. Asp F, Karlsson E, Berninger E. Development of Sound Localization in Infants and Young Children with Cochlear Implants. Journal of clinical medicine. 2022;11(22).
2. Berninger E, Drott M, Romanian M, Tranebjærg L, Hellström S. Congenital Nonprofound Bilateral Sensorineural Hearing Loss in Children: Comprehensive Characterization of Auditory Function and Hearing Aid Benefit. Audiology research. 2022;12(5):539-63.
3. Eklöf M, Asp F, Berninger E. Sound localization latency in normal hearing and simulated unilateral hearing loss. Hear Res. 2020;395:108011.(doi):10.1016/j.heares.2020.108011. Epub 2020 Jun 11.
4. Eklöf M, Asp F, Berninger E. The Development of Sound Localization Latency in Infants and Young Children with Normal Hearing. Trends in hearing. 2022;26:23312165221088398.
5. Johansson M, Asp F, Berninger E. Children With Congenital Unilateral Sensorineural Hearing Loss: Effects of Late Hearing Aid Amplification-A Pilot Study. Ear Hear. 2020;41(1):55-66. doi: 10.1097/AUD.0000000000000730.
6. Johansson M, Karlsson E, Asp F, Berninger E. A Prospective Study of Genetic Variants in Infants with Congenital Unilateral Sensorineural Hearing Loss. Journal of clinical medicine. 2023;12.
7. Johansson M, Karlsson E, Edholm K, Drott M, Berninger E. A Prospective Study of Etiology and Auditory Profiles in Infants with Congenital Unilateral Sensorineural Hearing Loss. Journal of clinical medicine. 2022;11(14).
8. Johansson M, Olofsson Å, Berninger E. Twin study of neonatal transient-evoked otoacoustic emissions. Hear Res. 2020;398:108108.(doi):10.1016/j.heares.2020.108108. Epub 2020 Oct 28.
9. Marlin Johansson, Åke Olofsson, Erik Berninger. Twin study of neonatal transient-evoked otoacoustic emissions, 2021 MidWinter Research Meeting, Association for Research in Otolaryngology, Virtual Meeting, USA, February 20-24, 2021.
10. Marlin Johansson, Eva Karlsson, Kaija Edholm, Maria Drott, Erik Berninger. A prospective study on etiology and auditory profiles in infants with congenital unilateral sensorineural hearing loss, 2023 MidWinter Research Meeting, Association for Research in Otolaryngology, Orlando, FL, USA, February 11-15, 2023.



**Åsa Bonnard**  
MD, PhD.  
+46 8 123 87447  
asa.bonnard@regionstockholm.se

## Cholesteatoma in Sweden and Results from the Swedish Quality Registry of Ear Surgery, SwedEar

1. Surgery for Cholesteatoma is a quite common ear procedure at the ENT-department and the disease is known as a non-hereditary disease. But recently our researchgroup showed that there is an almost 4-times higher risk for having surgery for cholesteatoma in individuals with a first-degree relative surgically treated for the disease. The number of individuals with hereditary disease is quite low but this group will be of special interest for further studies regarding the genetic background of the disease.

Cholesteatoma is accompanied with risks for severe side effects as meningitis, intracranial abscess, sinus thrombosis, hearing loss, facial palsy and dizziness if not treated. Unfortunately, the surgical procedure also have side effects due to the need for extensive surgery to eradicate the disease.

In this nationwide study, the Swedish Patient Registry will be used to map cholesteatoma surgery in Sweden in regard to incidence and prevalence, risks with surgery, factors increasing risk for disease and recurrency of disease. A combination with the Swedish Patient Registry and The Swedish Multiple Generation Register will be used to identify different aspects of hereditary cholesteatoma. This sub study will be followed by a genetic study regarding families in Stockholm County with multiple family members with cholesteatoma. A longside with this, a regional follow-up study will be performed in regard to hearing, balance and quality of life after cholesteatoma surgery.

2. The Swedish Quality Registry of Ear Surgery, SwedEar, is a nationwide registry collecting pre- and postoperative data in regard to ear surgery for all types of chronic otitis including cholesteatoma. Several papers based on this registry has been published showing the outcome of Myringoplasty and the risk for complications regarding tinnitus and taste disturbances related to surgery. New studies regarding the hearing results, patient satisfaction and complications after Ossiculoplasty are ongoing.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Agnes Modée	Sara Olaison, Örebro Universitetssjukhus Kvalitetsregisterkopplat projekt om ossikuloplastik

### Ethical permit No.

2014/2203-31/4	2019-05190	2020-00245	2021-05727-02	2020-05935
----------------	------------	------------	---------------	------------

### Publications 2020, 2021, 2022

1. Bonnard Å, Bark R, Hederstierna C. Clinical update on sensorineural hearing loss in Turner syndrome and the X-chromosome. Am J Med Genet C Semin Med Genet. 2019 Mar;181(1):18-24. doi: 10.1002/ajmg.c.31673. Epub 2019 Jan 10. Review. PMID: 30632288
2. Prakash SK, San Roman AK, Crenshaw M, Flink B, Earle K, Los E, Bonnard Å, Lin AE. "Donating our bodies to science": A discussion about autopsy and organ donation in Turner syndrome. Am J Med Genet C Semin Med Genet. 2019 Mar;181(1):36-42. doi: 10.1002/ajmg.c.31671. Epub 2019 Jan 11. Review. PMID: 30633443
3. Berglund M, Olaison S, Bonnard Å, Fransson M, Hultcrantz M, Florentzson R, Dahlin C, Olof Eriksson P, Westman E1. Hearing outcome after myringoplasty in Sweden. A nationwide registry-based cohort study. Clin Otolaryngol. 2020 Jan 23. doi: 10.1111/coa.13506.
4. Bonnard Å, Engmér Berglin C., Wincent J., Eriksson PO., Westman E., Feychting M., Mogensen H., JAMA Otolaryngology - Head and Neck Surgery 2023 Accepted in press.
5. Bonnard Å; Karltop E; Verrecchia L. Vestibular loss in children affected with LVAS and IP2 malformation and operated with cochlear implant. Audiology Research. 2023 Accepted, in press. DOI: 10.3390/audiolres13010013

**Anna Borgström**  
MD, PhD  
Södermalms Läkarhus  
anna.borgstrom.1@ki.se

## **Evaluation and surgical treatment of children with tonsil hypertrophy and sleep disordered breathing**

Research in the field of pediatric obstructive sleep apnea, with evaluation of diagnostic tools and of surgical treatment. The focus has been on tonsil surgery and a randomized clinical trial comparing tonsillectomy and tonsillotomy in children with OSA. Data for long-term follow-up from this trial are now being analyzed

### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>
	Isabella Sjölander

### **Ethical permit No.**

--	--	--	--

### **Publications 2019, 2020, 2021**

1. Borgström A, Nerfeldt P, Friberg D; Postoperative pain and bleeding after adenotonsillectomy vs adenotonsillotomy in pediatric obstructive sleep apnea: an RCT; European Archives of Oto-Rhino-Laryngology, 2019 Aug (3), 1-8
2. Sjölander I, Borgström A, Larsson JO, Smedje H, Friberg D. Sjölander I, et al. Randomised trial showed no difference in behavioural symptoms between surgical methods treating paediatric obstructive sleep apnoea. Acta Paediatr. 2020 Oct;109(10):2099-2104. doi: 10.1111/apa.15210. Epub 2020 Mar 6



**Nanna Browaldh**

MD., Ph.D.

nanna.browaldh@ki.se

## **Effects on Cardiovascular Parameters in Children with Severe Obstructive Sleep Apnea before and after Adenotonsillectomy**

Obstructive sleep apnea (OSA) is a common disorder and recognized as a significant cause of morbidity in children. The intermittent episodes of airway obstruction and desaturations may result in changes within the autonomic nervous system, which results in significant changes in the cardiovascular system.

In this study we will investigate cardiovascular sequelae of severe OSA in children (for example changes in heart rate, blood pressure, and cardiac morphology by echocardiography) and changes before and after treatment with adenotonsillectomy (removal of the tonsils and adenoid).

The children in the study will be 2-5 years of age with apneahypopnea index >19.9 and tonsil size 2-4.

1. Substudy 1 is a descriptive study with 25 patients with polysomnography before and after adenotonsillectomy. In connection to the polysomnography the patients will also undergo echocardiography and blood pressure measurement (24-h ambulatory blood pressure monitoring, or in some cases office (in house) blood pressure monitoring for 3-4 hours).
2. Substudy 2 is a randomised controlled study with 60-80 patients. The patients will be randomised to either adenotonsillectomy within 1-2 weeks or delayed surgery/expectancy for 4 weeks. As in substudy 1, the children will undergo echocardiography and blood pressure measurement in connection to the polysomnography pre- and postoperatively.

Primary outcome in both studies: change in blood pressure.

Secondary outcomes in both studies: changes in cardiac functions and structures

### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>

### **Ethical permit No.**

2019-04851			
------------	--	--	--

### **Publications 2020, 2021, 2022**

1. Sundman J, Friberg D, Bring J, Lowden A, Nagai R, Browaldh N. Sleep Quality After Modified Uvulopalatopharyngoplasty: Results From the SKUP3 Randomized Controlled Trial. *Sleep*. 2018 Sep 25.
2. Fehrm J, Nerfeldt P, Browaldh N, Friberg D. Effectiveness of adenotonsillectomy vs watchful waiting in young children with mild to moderate obstructive sleep apnea: a randomized clinical trial. *JAMA Otolaryngol - Head Neck Surg.* May 28, 2020.
3. Friberg D, Sundman J, Browaldh N. Long-term evaluation of satisfaction and side effects after modified uvulopalatopharyngoplasty. *Laryngoscope*. 2020;130(1):263–8.
4. Sundman J, Browaldh N, Fehrm J, Friberg D. Eight-year Follow-up of Modified Uvulopalatopharyngoplasty in Patients with Obstructive Sleep Apnea. *Laryngoscope*. 2020, 24 July. doi:10.1002/lary.28960

**Lars Olaf Cardell**  
 Professor, Head of the Division  
 +46 70 770 99 26  
 lars-olaf.cardell@ki.se



## Neutrophils, T- and B-cells in the development and progression of allergic airway and head and neck squamous cell cancer inflammation

Research in allergy immunotherapy and cancer immunology have shown that the tolerance development that takes place in both diseases, involves the same type of immune cells. It is also evident that it is dysregulation and dysfunction in these pathways that causes a significant part of the disease burden in both allergy and cancer. To simplify, these diseases represent two opposite poles in a tolerance spectrum. In allergy, the immune system over-reacts causing a continues on-going local inflammation, whereas in cancer the natural defence mechanisms are circumvented and turned down in order to let malignantly transformed cells roam free and unhindered. Hence, the modern concept of treatment in both allergy and cancer aims at eradicating these illnesses by inducing permanent local tolerance in the former and by breaking the local tolerance in the latter. Notably, this can be achieved in both situations by affecting various types of T-cells. The role of B-cells is well established in similar way in allergy, whereas their role in cancer is far less researched. Furthermore, there is a long-standing notion that neutrophils play a notable role in cancer immunology (even though exactly how remains to be elucidated), whereas the potential role of these cells in allergy has been hidden behind a towering interest for the eosinophils.

The overall goal is to investigate the role of neutrophils, T-cells and B-cells in the development and progress of allergic airway inflammation and head and neck squamous cell cancer with special reference to immunological events taking place in lymph nodes.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Magnus Starkhammar	
Krzysztof Piersiala	
Aeneas Kolev	
Carl Skröder	
Vilma Lagebro	

### Ethical permit No.

2021-03633	2021-00325	2021-01265	2020-02579	2019-03518	
------------	------------	------------	------------	------------	--

### Publications 2020, 2021, 2022

- 1) Cardenas EI, Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO, Lindén A. Increased IL-26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID-19. *Front Immunol.* 2022;13:1016991.
- 2) Piersiala K, da Silva PFN, Lagebro V, Kolev A, Starkhammar M, Elliot A, Marklund L, Munck-Wikland E, Margolin G, Georén SK, Cardell LO. Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. *Transl Oncol.* 2022;23:101469.
- 3) Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO. A prolonged innate systemic immune response in COVID-19. *Sci Rep.* 2022;12:9915.
- 4) Piersiala K, Kakabas I, Bruckova A, Starkhammar M, Cardell LO. Acute odynophagia: A new symptom of COVID-19 during the SARS-CoV-2 Omicron variant wave in Sweden. *J Intern Med.* 2022;292:154
- 5) Westerberg J, Granath A, Drakskog C, Tideholm E, Kumlien Georén S, Weitzberg E, Cardell LO. Nitric Oxide Is Locally Produced in the Human Middle Ear and Is Reduced by Acquired Cholesteatoma. *Otol Neurotol.* 2022 ;43:e198
- 6) Hellkvist L, Hjalmarsson E, Weinfeld D, Dahl Å, Karlsson A, Westman M, Lundkvist K, Winqvist O, Georén SK, Westin U, Cardell LO. High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase. *Allergy.* 2022;77:883
- 7) Ma J, Tibbitt CA, Georén SK, Christian M, Murrell B, Cardell LO, Bachert C, Coquet JM. Single-cell analysis pinpoints distinct

- populations of cytotoxic CD4+ T cells and an IL-10+CD109+ TH2 cell population in nasal polyps. *Sci Immunol*. 2021;6:eabg6356.
8. 8) Che KF, Paulsson M, Piersiala K, Sax J, Mboob I, Rahman M, Rekha RS, Säfholm J, Adner M, Bergman P, Cardell LO, Riesbeck K, Lindén A. Complex Involvement of Interleukin-26 in Bacterial Lung Infection. *Front Immunol*. 2021;12:761317.
  9. 9) Olsson P, Skröder C, Ahlbeck L, Hjalte F, Welin KO, Westin U, Andersson M, Ahlström-Emanuelsson C, Cardell LO. HealthSWE-DE: costs with sublingual immunotherapy-a Swedish questionnaire study. *Allergy Asthma Clin Immunol*. 2021;17:55.
  10. 10) Larsson O, Sunnergren O, Bachert C, Kumlien Georén S, Cardell LO. The SP-TLR axis, which locally primes the nasal mucosa, is impeded in patients with allergic rhinitis. *Clin Transl Allergy*. 2021;11:e12009.
  11. 11) Piersiala K, Farrajota Neves da Silva P, Hjalmarsson E, Kolev A, Kågedal Å, Starkhammar M, Elliot A, Marklund L, Margolin G, Munck-Wikland E, Kumlien Georén S, Cardell LO. CD4+ and CD8+ T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. *Cancer Sci*. 2021;112:1048.
  12. 12) Larsson OJ, Kumlien Georén S, Cardell LO. Rapid activation of brainstem nuclei following TLR stimulation of the nasal mucosa. *Acta Neurobiol Exp (Wars)*. 2020;80:353.
  13. 13) Kågedal Å, Hjalmarsson E, Farrajota Neves da Silva P, Piersiala K, Georén SK, Margolin G, Munck-Wikland E, Winqvist O, Häyry V, Cardell LO. Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. *Sci Rep*. 2020;10:22352.
  14. 14) Westerberg J, Tideholm E, Piersiala K, Drakskog C, Kumlien Georén S, Mäki-Torkko E, Cardell LO. JAK/STAT Dysregulation With SOCS1 Overexpression in Acquired Cholesteatoma-Adjacent Mucosa. *Otol Neurotol*. 2021;42:e94.
  15. 15) Hellings PW, Scadding G, Bachert C, Bjermer L, Canonica GW, Cardell LO, et al., . EUFOREA treatment algorithm for allergic rhinitis. *Rhinology*. 2020;58:618.
  16. 16) Karin J, Tim D, Gabriele H, Cardell LO, Marit W, Claus B. Type 2 Inflammatory Shift in Chronic Rhinosinusitis During 2007–2018 in Belgium. *Laryngoscope*. 2021;13:E1408.
  17. 17) Drakskog C, de Klerk N, Westerberg J, Mäki-Torkko E, Georén SK, Cardell LO. Extensive qPCR analysis reveals altered gene expression in middle ear mucosa from cholesteatoma patients. *PLoS One*. 2020;15:e0239161.
  18. 18) Ekstedt S, Kumlien Georén S, Cardell LO. Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R. *Allergy Asthma Clin Immunol*. 2020;16:45.
  19. 19) Seys SF, De Bont S, Fokkens WJ, Bachert C, Allobid I, Bernal-Sprekelsen M, Bjermer L, Callebaut I, Cardell LO, Carrie S, et al., . Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. *Allergy*. 2020;7:2867.
  20. 20) Weinfeld D, Westin U, Hellkvist L, Mellqvist UH, Jacobsson I, Cardell LO. A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralympathic immunotherapy, against grass pollen seasonal allergy. *Allergy Asthma Clin Immunol*. 2020;16:31.
  21. 21) Ekstedt S, Larsson O, Kumlien Georén S, Cardell LO. CD16high CD62Ldim neutrophils induce nerve-mediated airway hyper-reactivity. *Clin Exp Allergy*. 2020;50:756.
  22. 22) Kågedal Å, Margolin G, Held C, da Silva PFN, Piersiala K, Munck-Wikland E, Jacobsson H, Häyry V, Cardell LO. A Novel Sentinel Lymph Node Approach in Oral Squamous Cell Carcinoma. *Curr Pharm Des*. 2020;26:3834.

**Maoli Duan**  
Docent, M.D.  
+46 73 9826888  
maoli.duan@ki.se



## Disorders affecting hearing and balance in children - the importance of early diagnosis and early intervention

Early diagnosis and intervention of HI and vestibularis dysfunction/disorders (VD) in infants and young children is a still hot topic in audiology and neurotology. There are needs for an increasing knowledge on how to optimize the care for as well as to improve development of the child. The majority of HI and VD infants still do not get a specific genetic diagnosis of their illness despite 50% being genetic. NGS methods will dramatically improve the possibilities to identify different genetic causes of HI and VD. Furthermore, despite quite high prevalence of VD in HI children this has not been paid too high attention.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Niki Karpeta	Anna-Karin Strömberg
Andra Lazar	

### Ethical permit No.

2013/1177-31	2015/1296-31/2	2019-02019	
--------------	----------------	------------	--

### Publications 2020, 2021, 2022

1. Niu K, Brandström A, Skenbäck S, Duan M, Uhlén I. Risk factors and etiology of childhood hearing loss: a cohort review of 296 subjects. *Acta Otolaryngol.* 2020 May 13;1-7. doi: 10.1080/00016489.2020.1757753.
2. Xie W, Dai Q, Liu J, Liu Y, Hellström S, Duan M. Analysis of Clinical and Laboratory Findings of Idiopathic Sudden Sensorineural Hearing Loss. *Sci Rep.* 2020 Apr 8;10(1):6057. doi: 10.1038/s41598-020-63046-z. PMID: 32269282
3. Dai Q, Chen Q, Yin L, Zheng H, Liu SX, Duan M. The long-term follow-up of 61 horizontal canal BPPV after Gufoni and Barbecue maneuver: a prospective study. *Acta Otolaryngol.* 2020; 140(6):463-466. doi: 10.1080/00016489.2020.1725114. Epub 2020 Feb 12. PMID: 32049574
4. Tong B, Niu K, Ku W, Xie W, Dai Q, Hellström S, Duan M. Comparison of Therapeutic Results with/without Additional Hyperbaric Oxygen Therapy in Idiopathic Sudden Sensorineuronal Hearing Loss: A Randomized Prospective Study. *Audiol Neurotol.* 2020 Jun 12;1-6. doi: 10.1159/000507911. Online ahead of print. PMID: 32535600
5. Tong B, Wang Q, Hellstrom S, Duan M. Efficacy of Different Administrations for the Initial Treatment of Idiopathic Sudden Hearing Loss: A Prospective, Randomized, Controlled Trial. *Audiol Neurotol.* 2020 Jul 15;1-8. doi: 10.1159/000508124. Online ahead of print. PMID: 32668428
6. Zhou L, Duan M and Huang X. Primary transglottic mucosal melanoma of the larynx, a very rare entity. *American Journal of Biomedical Science & Research.* 2020, aug. 59-62. DOI:1034297/AJBSR2020.10.001475.
7. Xie W, Shu T, Liu J, Peng H, Karpeta N, Marques P, Liu Y, Duan M. The relationship between clinical characteristics and magnetic resonance imaging results of Ménière disease: a prospective study. *Scientific Reports,* 2021. PMID: 33785791 PMCID: PMC8010013 DOI: 10.1038/s41598-021-86589-1
8. He B, Zhang F, Zheng H, Sun X, Chen J, Chen J, Liu Y, Wang L, Wang W, Li S, Yang J, Duan M. The correlation of a new endolymphatic-hydrops grading system with extra-tympanic electrocochleography in patients with definite Ménière's disease. *Frontiers in Neurology,* 2021. PMID: 33551957 PMCID: PMC7856148 DOI: 10.3389/fneur.2020.595038
9. Qin H, He B , Wu H, Li Y Chen J, Wang W , Zhang F, Duan M, Yang J. Visualization of Endolymphatic Hydrops in Patients with Unilateral Idiopathic Sudden Sensorineuronal Hearing Loss with Four Types According to Chinese Criterion. *Front Surg.* 2021 Jun 21;8: 682245. doi: 10.3389/fsurg.2021.682245. eCollection 2021. PMID: 34235173. PMCID: PMC8255360DOI: 10.3389/fsurg.2021.682245
10. Liu Y, Zhang F, He B, He J, Zhang Q, Yang J, Duan M. Vestibular Endolymphatic Hydrops Visualized by Magnetic Resonance Imaging and Its Correlation with Vestibular Functional Test in Patients with Unilateral Meniere's Disease. *Front Surg.* 2021 Jun 4;8:673811. doi: 10.3389/fsurg.2021.673811. eCollection.
11. Yao W, Zhao Z, Wang J, Duan M. Time-domain analysis of a three-dimensional numerical model of the human spiral cochlea at medium intensity. *Comput Biol Med.* 2021 Sep;136:104756. doi: 10.1016/j.combiomed.2021.104756. PMID: 34388464. DOI: 10.1016/j.combiomed.2021.104756

12. Diao T, Ma X, Zhang J, Duan M, Yu L. The Correlation Between Hearing Loss, Especially High-Frequency Hearing Loss and Cognitive Decline Among the Elderly. *Front Neurosci*. 2021 Nov 15;15:750874. doi: 10.3389/fnins.2021.750874. eCollection 2021.
13. Zhou L, Shen N, Feng M, Liu H, Duan M, Huang X. Morphology of human ear canal and its effect on sound transmission. *Int J Numer Method Biomed Eng*. 2021 Dec 24; e3567. doi: 10.1002/cnm.3567.
14. Dai Q, Dai W, Wang D, Liu X, Zou L, Chen J, Zheng H, Duan M. Molecular screening of patients with profound hearing loss from Chengdu, China. *Acta Otolaryngol*. 2022 Jan;142(1): 57-60. doi: 10.1080/00016489.2021.2014564.
15. Duan M, Xie W, Persson L, Hellstrom S, Uhlén I. Postnatal hearing loss: a study of children who passed neonatal TEOAE hearing screening bilaterally. *Acta Otolaryngol*. 2022 Jan;142(1):61-66. doi: 10.1080/00016489.2021.2017476.
16. Diao T, Duan M, Ma X, Liu J, Yu L, Jing Y, Wang M. The impairment of speech perception in noise following pure tone hearing recovery in patients with sudden sensorineural hearing loss. *Sci Rep*. 2022 Jan 17;12(1):866. doi: 10.1038/s41598-021-03847-y. PMID: 35039548
17. Yao W, Gao L, Su J, Karpeta N, Xie W, Duan M. Effects of lesions of the organ of corti on hearing. *Acta Otolaryngol* 2022 Jan 29;1-9 doi: 10.1080/00016489.2022.2027517.
18. Zheng G, Liu Y, He J, Li S, Zhang Q, Duan M, Yang J, Jin Y. A Comparison of Local Endolymphatic Sac Decompression, Endolymphatic Mastoid Shunt, and Wide Endolymphatic Sac Decompression in the Treatment of Intractable Meniere's Disease: A Short-Term Follow-Up Investigation. *Front Neurol* 2022 Feb 10; 13:810352. doi: 10.3389/fneur.2022.810352.
19. Yupeng Liu, Ilmari Pyykkö, Shinji Naganawa, Pedro Marques, Robert Gürkov JunYang, Maoli Duan. Consensus on MR Imaging of Endolymphatic Hydrops in Patients with suspected Hydropic Ear Disease (Meniere). *Frontiers in Surgery* 2022. In press
20. Jun Yang, Maoli Duan. Consensus on Intratympanic drug delivery for Meniere's disease. *European Archives of Oto-Rhino-Laryngology* 2022. Aug;279(8):3795-3799. doi: 10.1007/s00405-022-07374-y. Epub 2022 Apr 26.
21. Jiali Shen, Lu Wang, Xiaobao Ma, Zichen Chen, Jianyong Chen, Xueyan Wang, Kuan He, Wei Wang, Jin Sun, Qin Zhang, Min Shen, Xiangping Chen, Qing Zhang, Kimitaka Kaga, Maoli Duan, Jun Yang, Yulian Jin. Cervical vestibular evoked myogenic potentials in 3-month-old infants: Comparative characteristics and feasibility for infant vestibular screening. *Front Neurol* 2022 Sep 29;13:992392. doi: 10.3389/fneur.2022.992392. eCollection 2022.
22. Liu Y, Pyykkö I, Naganawa S, Marques P, Gürkov R, Yang J, Duan M. Consensus on MR Imaging of Endolymphatic Hydrops in Patients With Suspected Hydropic Ear Disease (Meniere). *Front Surg*. 2022 Apr 28;9:874971. doi: 0.3389/fsurg.2022.874971. eCollection 2022.
23. Niu X, Han P, Duan M, Chen Z, Hu J, Chen Y, Xu M, Ren P, Zhang Q. Bilateral Dysfunction of Otolith Pathway in Patients With Unilateral Idiopathic BPPV Detected by ACS-VEMPs. *Front Neurol*. 2022 Aug 26;13:921133. doi: 10.3389/fneur.2022.921133. eCollection 2022. PMID: 36090849
24. Zhang F, Shen J, Zhu Q, Wang L, Ma X, He B, Yang Y, Wang W, Chen X, Zhang Q, Jin Y, Duan M, Chen J, Yang J. Evaluating children with vestibular migraine through vestibular test battery: A cross-sectional investigation. *Front Neurol*. 2022 Oct 31;13:997217. doi: 10.3389/fneur.2022.997217. eCollection 2022. PMID: 36388219
25. Shen J, Wang L, Ma X, Chen Z, Chen J, Wang X, He K, Wang W, Sun J, Zhang Q, Shen M, Chen X, Zhang Q, Kaga K, Duan M, Yang J, Jin Y. Cervical vestibular evoked myogenic potentials in 3-month-old infants: Comparative characteristics and feasibility for infant vestibular screening. *Front Neurol*. 2022 Sep 29;13:992392. doi: 10.3389/fneur.2022.992392. eCollection 2022. PMID: 36247765
26. Liang M, Wu H, Chen J, Zhang Q, Li S, Zheng G, He J, Chen X, Duan M, Yang J, Jin Y. Vestibular evoked myogenic potential may predict the hearing recovery in patients with unilateral idiopathic sudden sensorineural hearing loss. *Front Neurol*. 2022 Nov 2;13:1017608. doi: 10.3389/fneur.2022.1017608. eCollection 2022. PMID: 36408508
27. Yang Yang, Dekun Gao, Xiaobao Ma, Jiali Shen, Qin Zhang, Xiangping Chen, Qing Zhang, Yulian Jin, Jianyong Chen, Maoli Duan, Jun Yang. 2023. Abnormal posterior semicircular canal function may predict poor prognosis in patients with severe and profound ISSNHL" In press in *Frontiers in Neurology*, section Neuro-Otology
28. Jifang Zhang, Qi Zhu, Jiali Shen, Jianyong Chen, Yulian Jin, Qing Zhang, Maoli Duan and Jun Yang. 2023. Etiological classification and management of dizziness in children: a systematic review and meta-analysis. In press in *Frontiers in Neurology*, section Neuro-Otology.
29. Yang J, Liu Y, Duan M. Editorial: Intratympanic and surgical treatment for Meniere's disease. *Front Neurol*. 2022 Dec 21;13:1072659. doi: 10.3389/fneur.2022.1072659. eCollection 2022
30. Jun Yang, Yupeng Liu, Qing Zhang, Lisheng Yu, Toshihisa Murofushi, Klaus Jahn, Maoli Duan\*. 2023. Editorial: Vestibular Disorders in Children. In press in *Frontiers in Neurology*.
31. Nishan Chen, Niki Karpeta, Xin Ma, Xianhui Ning, Xiaoling Liu, Jijun Song, Zigang Jiang, Xiulan Ma, Xiuli Liu, Shixun Zhong, QING SUN, Jun Liu, Ganggang Chen, Maoli Duan, Lisheng Yu. 2023. Diagnosis, differential diagnosis and treatment for sudden sensorineural hearing loss: current otolaryngology practices in China

Review articles in international journal:

1. 1.Liu H, Yang J and Duan M. Current status on researches of Meniere's disease. *Acta Otolaryngologica*. 2020;140(10):808-812. doi: 10.1080/00016489.2020.1776385. Epub 2020 Jun 21.
2. 2. Huang Y, Yang J, Duan. Auditory neuropathy: from etiology to management. *M.Curr Opin Otolaryngol Head Neck Surg*. 2022 Oct 1;30(5):332-338. doi: 10.1097/MOO.0000000000000829. Epub 2022 Jul 18. PMID: 35939320.
3. 3. Dai Q, Long L, Zhao H, Wang R, Zheng H, Duan M. Genetic advances in Meniere Disease. *Mol Biol Rep*. 2022 Dec 24. doi: 10.1007/s11033-022-08149-8. Online ahead of print. PMID: 36565421.

**Anders Ehnhage**  
MD, PhD.  
+46 70 6570223  
anders.ehnage@ki.se

## **Hereditary hemorrhagic telangiectasia, HHT, in Sweden- a registerbased study about mortality, morbidity, prevalence and treatment**

### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>

### **Ethical permit No.**

--	--	--	--	--

### **Publications 2020, ,2021, 2022**

1. Control of allergic rhinitis with MP-AzeFlu: an interventional study of a Swedish cohort. Stjärne, P ; Strand, V ; Theman, K ; Ehnhage, A. *Rhinology*, 01 August 2019, Vol.57(4), pp.279-286
2. Does the oral steroid treatment of patients with nasal polyposis cause osteopenia or osteoporosis? Sahlstrand-Johnson, P; Holmström, M; Ehnhage, A. *Oto-Rhino-Laryngology & Cervico-Facial Surgery*, 17 September 2019
3. Treatment of idiopathic rhinitis with kinetic oscillations - a multi-centre randomized controlled study. Ehnhage A, Johnsson PS, Ahlström-Emanuelsson C, Andersson M, Knutsson J, Lien J, Norlander T, Olsson P, Friis-Liby JE, Holmström M. *Acta Otolaryngol*. 2016 Aug;136(8):852-9. doi: 10.3109/00016489.2016.1155231. Epub 2016 Apr 7.
4. Healthcare provider contact for children with symptoms of sleep-disordered breathing: a population survey. Gudnadottir G, Ehnhage A, Bende M, Andersson M, Cervin A, Cardell LO, Hellgren J. *J Laryngol Otol*. 2016 Mar;130(3):296-301. doi: 10.1017/S0022215115003370. Epub 2015 Dec 17.
5. Real-life Effectiveness of a new allergic rhinitis therapy (MP29-02) in Sweden. Stjärne P, Strand V, Theman K, Kuhl Hans Christian, Ehnhage A. *Clinical and Translational Allergy* 2015 December, 5:P37
6. Effects of FESS and additional fluticasone propionate nasal drops on psychological well-being in nasal polyposis with asthma. Nordin S, Olsson P, Hedén Blomqvist E, Stjärne P, Ehnhage A; NAF2S2 Study Group†. *Acta Otolaryngologica*



**Martin Eklöf**  
MD, PhD.  
+46 8 123 89329  
martin.eklof@ki.se

## Long time outcomes after early cochlear implant intervention

The first patients with early cochlear implant intervention have now become adolescent. We assess and analyze the outcomes in terms of hearing, language, and balance in a prospective study. Cochlear implant programming and mastoid morphology will be correlated to speech perception and interaural abilities. Furthermore, novel methods of the diagnostics of balance disorders is developed using inertial motion sensors.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

2022-03381-01	2021-04345			
---------------	------------	--	--	--

### Publications 2020, ,2021, 2022

1. Eklöf, M., Asp, F., & Berninger, E. (2022). The Development of Sound Localization Latency in Infants and Young Children with Normal Hearing. *Trends in Hearing*, 26, 233121652210883. <https://doi.org/10.1177/23312165221088398>
2. Karlsson, E., Eklöf, M., Östlund, E., Asp, F., Tideholm, B., & Löfkvist, U. (2020). Cochlear implants before 9 months of age led to more natural spoken language development without increased surgical risks. *Acta Paediatrica*, 109(2), 332–341. <https://doi.org/10.1111/apa.14954>

**Sandra Ekstedt**

Postdoc

+46 70 206511

sandra.ekstedt@ki.se



## Neutrophils in airway inflammation and head and neck cancer

Neutrophils are part of the first lines of defence against invading microbes. They play an essential role in antimicrobial host defence by recognizing microorganisms through the various receptor that can be expressed on its surface. Novel subsets with different functions of already classified cells are continuously discovered. In line with this, four different neutrophil subsets have been identified based on their expression of CD16 and CD62L. The subsets reflect different stages of cell maturity and activity. My research focuses on these four subsets.

We have in the past characterised neutrophil subsets in blood before and after an inhaled allergen provocation. The fraction of CD16high/CD62Lhigh neutrophils decreased and the CD16high/CD62Ldim neutrophils increased as a result of the challenge. We have also seen functional changes in the airways after co-cultures between segments of airways and the subset CD16high/CD62Ldim. These neutrophil subsets seem to have different roles during inflammation and we are now focusing on their role during head and neck cancer and their presence in lymph nodes.

These new findings may lead to a better understanding of the role of neutrophil subset in inflammation, and potentially to new treatments

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

--	--	--	--

### Publications 2020, 2021, 2022

1. van der Burg N, Stenberg H, Ekstedt S, Diamant Z, Bornesund D, Ankerst J, Kumlien Georén S, Cardell LO, Bjermer L, Erjefält J, Tufvesson E. Neutrophil phenotypes in bronchial airways differentiate single from dual responding allergic asthmatics. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2023;53;1 65-77
2. Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO. A prolonged innate systemic immune response in COVID-19. *Scientific reports* 2022;12;1 9915-
3. Cardenas EI, Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO, Lindén A. Increased IL-26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID-19. *Frontiers in immunology* 2022;13; 1016991-
4. Ekstedt S, Tufvesson E, Bjermer L, Georen SK, Cardell LO. A new role for "eat me" and "don't eat me" markers on neutrophils in asthmatic airway inflammation. *ALLERGY* 2020;75;6 1510-1512
5. Ekstedt S, Larsson O, Georen SK, Cardell LO. CD16(high)CD62L(dim) neutrophils induce nerve-mediated airway hyper-reactivity. *CLINICAL AND EXPERIMENTAL ALLERGY* 2020;50;6 756-759
6. Ekstedt S, Georen SK, Cardell LO. Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R. *ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY* 2020;16;1 45-

**Alexandra Elliot**  
MD, PhD.  
+46 8 1237 6126  
alexandra.elliot@regionstockholm.se

## Optimizing use of sentinel node technique in head and neck cancer

Head and neck cancer treatment is associated with difficult side-effects. The treatment and prevention of regional metastasis and recurrences is not always successful. The use of sentinel node technique for head and neck cancers is increasing both as an investigation tool to find micro-metastasis and single tumour cells but also as a treatment to avoid more extensive surgery. Studies conducted in our group assess the benefits of the sentinel node techniques for different head and neck cancer subsites and different clinical cases and analyze the immunological features and of the sentinel nodes evaluating the predictive-ness of different markers.

The overall aim of the studies is to assess tumour biology and interaction with the immune system, to assess tumour spread-patterns for different tumour types and to individualize their treatment aiming to improve treatment effects and minimize their related complications.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

2017/1333-31/1	2012/49-31/2	2019/03518		
----------------	--------------	------------	--	--

### Publications 2020, 2021, 2022

1. Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells Krzysztof Piersiala , Pedro Farrajota Neves da Silva , Vilma Lagebro , Aeneas Kolev , Magnus Starkhammar , Alexandra Elliot , Linda Marklund , Eva Munck-Wikland , Gregori Margolin , Susanna Kumlien Georén , Lars-Olaf Cardell . Transl Oncol. 2022 Jun 14;23:101469. doi: 10.1016/j.tranon.2022.101469. Online ahead of print.
2. Piersiala K, Farrajota Neves da Silva P, Hjalmarsson E, Kolev A, Kågedal Å, Starkhammar M, Elliot A, Marklund L, Margolin G, Munck-Wikland E, Kumlien Georén S, Cardell LO. CD4+ and CD8+ T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. Cancer Sci. 2021 Mar;112(3):1048-1059. doi: 10.1111/cas.14816. Epub 2021 Feb 15. PMID: 33462898; PMCID: PMC7935788.

**Cecilia Engmér Berglin**

M.D., PhD

+46 8 517 798 17

cecilia.engmer-berglind@regionstockholm.se



## **Assessment and activation of tympanic membrane progenitor/stem cells - clinical and laboratory studies**

With this project we aim to increase knowledge about the normal healing process and to improve the treatment of tympanic membrane perforations with the ultimate goal to design a simple, out-patient procedure without the need for advanced surgery.

We will identify stem cells and proliferative zones in normal human tympanic membranes as well as in tympanic membranes that has been mechanically and chemically injured. The goal is to better understand the healing mechanism of the tympanic membrane.

Plasminogen is an endogenous protein and has a role in cell migration and wound healing and has been identified as a possible drug for medical treatment of chronic tympanic membrane perforation. In a clinical trial different doses of plasminogen are injected close to the tympanic membrane in the ear canal in patients with chronic perforations and the effect on healing of the ear drum is evaluated.

## **Development of central auditory pathways in patients with unilateral conductive hearing loss and effects of early intervention**

The main purpose of this project is to evaluate the effect on the brain in individuals with unilateral canal atresia, which is when a child is born without a developed hearing canal causing a severe conductive hearing loss. Children with hearing habilitation and untreated adults are included in the study. An animal model will also be used for longitudinal studies to achieve information about when to expect changes in the auditory pathways of the brain. Methods used in the project are different types of audiometric testing including corneal reflection eye-tracking, questionnaires, diffusion MRI and resting state functional MRI. The hearing outcome in children with unilateral canal atresia treated with active middle ear implants and active transcutaneous bone conduction devices will be evaluated regarding to directional hearing and speech in competing speech as well as assessment of quality of life through questionnaires.

### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>
Elnaz Sepehri	Agnes Modée
Malin Siegbahn	
Hanna Josefsson	

### **Ethical permit No.**

2021-02984	2018/364	2017/2011-31	2012/1661-31/3	N191/14	N113/15
------------	----------	--------------	----------------	---------	---------

### **Publications 2020, 2021, 2022**

S

1. Siegbahn M, Engmér Berglin C, Moreno R. Automatic segmentation of the core of the acoustic radiation in humans. *Front Neurol.* 2022 Sep 23;13:934650. doi: 10.3389/fneur.2022.934650.
2. Siegbahn M, Engmér Berglin C, Hultcrantz M & Asp F. Adults with unilateral congenital ear canal atresia – sound localization ability and recognition of speech in competing speech in unaided condition, *Acta Otolaryngol.* 2021 Jul;141(7):689-694. doi: 10.1080/00016489.2021.1921843.
3. Cortés Fuentes IA, Pierre PV, Berglin CE. Improving Clinical Outcomes in Cochlear Implantation Using Glucocorticoid Therapy: A Review. *Ear Hear.* 2020 Jan/Feb;41(1):17-24. doi: 10.1097/AUD.0000000000000740.

**Johan Fehrm**  
M.D., PhD  
+46 70 7418997  
johan.fehrm@ki.se

## Surgical Treatment of Obstructive Sleep Apnea - Randomized Controlled Studies in Children and Adults

Obstructive sleep apnea (OSA) is a common disorder in both children and adults. Surgery is the primary treatment for children and an alternative for adults in selected cases.

This project consists of three RCTs and aims to evaluate:

- If surgery (uvulopalatopharyngoplasty) decreases blood pressure in adult patients with OSA.
- If adenotonsillectomy (ATE, the primary surgical treatment for pediatric OSA) is more effective than no treatment for young children with mild to moderate OSA.
- If a modified ATE is more effective for treating children with severe OSA.

Results from the project shows that:

- Surgery decreases blood pressure in adult patients with OSA.
- ATE is more effective in improving quality of life but not objective respiratory parameters in children with mild to moderate OSA
- Modified ATE is not more effective to treat children with severe OSA.

Future studies include:

- Long-term follow-ups
- Analyses of tonsillar tissue to better understand the etiology of tonsillar growth
- The effect on other cardiovascular endpoints (eg. blood lipids and systemic inflammatory markers) after surgery in adults.

### Ethical permit No.

2007/449-31/3	Ö21-2007	2014/1000-31/1	
---------------	----------	----------------	--

### Publications 2020, 2021, 2022

1. Fehrm J, Nerfeldt P, Browaldh N, Friberg D. Effectiveness of Adenotonsillectomy vs Watchful Waiting in Young Children with Mild to Moderate Obstructive Sleep Apnea: A Randomized Clinical Trial. *JAMA Otolaryngol - Head Neck Surg.* 2020;146(7):647-654.
2. Fehrm J, Borgström A, Nerfeldt P, Friberg D. Postoperative morbidity after adenotonsillectomy versus adenopharyngoplasty in young children with obstructive sleep apnea: an RCT. *Eur Arch Oto-Rhino-Laryngology.* May 2020;1-
3. Sundman J, Browaldh N, Fehrm J, Friberg D. Eight-Year Follow-up of Modified Uvulopalatopharyngoplasty in Patients With Obstructive Sleep Apnea. *Laryngoscope.* 2021;131(1):E307-E313.
4. Carrasco A, Sjölander I, Van Acker A, Dernstedt A, Fehrm J, Forsell M, Friberg D, Mjösberg J, Rao A. The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia and Obstructive Sleep Apnea. *Front Immunol.* 2021 Oct 22;12:674080.
5. Niessl J, Sekine T, Lange J, Konya V, Forkel M, Maric J, Rao A, Mazzurana L, Kokkinou E, Weigel W, Llewellyn-Lacey S, Hodcroft EB, Karlsson AC, Fehrm J, Sundman J, Price DA, Mjösberg J, Friberg D, Buggert M. Identification of resident memory CD8+ T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. *Sci Immunol.* 2021 Oct 22;6(64):eabk0894.
6. Sundman J, Nerfeldt P, Fehrm J, Bring J, Browaldh N, Friberg D. Effectiveness of Tonsillectomy vs Modified Uvulopalatopharyngoplasty in Patients With Tonsillar Hypertrophy and Obstructive Sleep Apnea: The TEAMUP Randomized Clinical Trial. *JAMA Otolaryngol Head Neck Surg.* 2022 Dec 1;148(12):1173-1181. doi: 10.1001/jamaoto.2022.3432. PMID: 36326742; PMCID: PMC9634593.
7. Correlations between objective and subjective outcomes after adenotonsillar surgery in children with OSA. *Laryngoscope Investig Otolaryngol.* 2022 Nov 4;7(6):2161-2170. doi: 10.1002/lio2.967. PMID: 36544930; PMCID: PMC9764786.

**Christina Forshell Hederstierna**  
MD, PhD.

christina.forshell-hederstierna@regionstockholm.se



## Hearing in the elderly and cognition

Hearing in the elderly and cognition, noise and, diet. Epidemiological studies where the influence of various factors on hearing function is assessed in patients, and in population databases such as H70.

## Hearing preservation in subjects with vestibular schwannoma

Hearing in vestibular schwannoma - Gamma knife surgery vs initial conservative treatment for vestibular schwannoma patients with preserved hearing, a prospective randomized study. PI Ass Prof Förrander, Department of Neurosurgery, Karolinska.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Jenny Häggström

### Ethical permit No.

--	--	--	--	--

## Publications 2020, 2021, 2022

1. Haggstrom J, Hederstierna C, Rosenhall U, Ostberg P, Idrizbegovic E. Prognostic Value of a Test of Central Auditory Function in Conversion from Mild Cognitive Impairment to Dementia. *Audiology & neuro-otology*. 2020;1-7.



**Pia Froissart Nerfeldt**  
MD, PhD.  
+46 8 58581516  
pia.froissart-nerfeldt@regionstockholm.se

## **Obstructive Sleep Apnea in children and adults, a surgical therapeutic perspective. Subglottic stenosis in adults, measurements and treatment efficiency.**

Within surgical treatment for obstructive sleep apnea (OSA), the group has performed five randomized controlled trials. The main focus for adult sleep apnea is on uvulopalatopharyngoplasty including tonsillectomy, which we have compared to expectancy and to plain tonsillectomy. In children, the main focus is on different techniques and additions to tonsill surgery. We compare expectancy, tonsillotomy, tonsillectomy and tonsillectomy with additional suturing of the pillars. Patients are evaluated with both objective and subjective parameters such as polysomnography findings (the gold standard sleep registration), vigilans, daytime sleepiness, quality of life, blood pressure, inflammatory markers etc.

Further the Swedish National Tonsill Surgery Registra is another field of research were we evaluate incidence, morbitidy and symptom relief etc using the regista as source of epidemiology research and possibility to evaluate rare consequences etc.

Within the field of subglottic stenosis we have a project evaluating intralesional steroid injections, as well as retrospective and prospective evaluations of other treatment forms, for the adult population with subglottic stenosis. We are investigating the diagnostic method of a handheld peak inspiratory flow meter (PIF-meter) gathering a healthy population besides our subglottic stenosis patients

### **Supervision of PhD-students:**

Main Supervisor	Co-supervisor

### **Ethical permit No.**

2021-02110	2015/755-31/2	2013/2274-32	2021-00716	2014/1000-31/1
------------	---------------	--------------	------------	----------------

### **Publications 2020, 2021, 2022**

1. Adenopharyngoplasty vs. adenotonsillectomy in children with severe obstructive sleep apnea: a randomized controlled trial Johan Fehrm, MD; Pia Nerfeldt, MD, PhD; Joar Sundman, MD; Danielle Friberg, MD, PhD JAMA ORL 2018;144(7):580-586
2. Postoperative pain and bleeding after adenotonsillectomy versus adenotonsillotomy in pediatric obstructive sleep apnea: an RCT Borgström Anna, MD; Nerfeldt Pia MD, PhD; Friberg Danielle, MD, PhD Eur Arch Otorhinolaryngol 2019 doi.org/10.1007/s00405-019-05571-ww
3. Obstructive sleep apnea in children with Down syndrome - Prevalence and evaluation of surgical treatment Nerfeldt Pia MD PhD, Sundelin Amalia MD Int J Pediatr Otorhinolaryngol. 2020 Feb 26;133:109968. doi:10.1016/j.ijporl.2020.109968.
4. Postoperative morbidity after adenotonsillectomy versus adenopharyngoplasty in young children with obstructive sleep apnea: an RCT Johan Fehrm, MD; Pia Nerfeldt, MD, PhD; Anna Borgström, MD, PhD; Danielle Friberg, MD, PhD Eur Arch Otorhinolaryngol 2020 Oct;277(10):2821-2827
5. Effectiveness of Adenotonsillectomy vs Watchful Waiting in Young Children With Mild to Moderate Obstructive Sleep Apnea: A Randomized Clinical Trial. Fehrm J, Nerfeldt P, Browaldh N, Friberg D. JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):647-654

6. A validation study of data in the National Tonsil Surgery Register in Sweden: High agreement with medical records ensures that data can be used to monitor clinical practices and outcomes Filip Lundström, Erik Odhagen, Fredrik Alm, Claes Hemlin, Pia Nerfeldt, Ola Sunnergren. *BMC Med Res Methodol.* 2022 Jan 7;22(1):3. doi: 10.1186/s12874-021-01467-8
7. Adenotonsillotomy versus adenotonsillectomy in pediatric obstructive sleep apnea: a 5-year RCT Isabella Sjölander, Anna Borgström, Pia Nerfeldt, Danielle Friberg. *Sleep Med X.* 2022 Sep 8;4:100055. doi:0.1016/j.sleepx.2022.100055.
8. Tonsillectomy vs Modified Uvulopalatopharyngoplasty in Patients with Tonsillar Hypertrophy and Obstructive Sleep Apnea - The TEAMUP Randomized Controlled Trial. Joar Sundman, MD, PhD1; Pia Nerfeldt, MD, PhD1; Johan Fehrm, MD, PhD1; Johan Bring, PhD2 Nanna Browaldh, MD, PhD1; Danielle Friberg, MD, PhD3 Accepted for publication in JAMA ORL September 2022.
9. Correlations between objective and subjective outcomes after adenotonsillar surgery in children with OSA. Sjölander I, Borgström A, Nerfeldt P, Fehrm J, Friberg D. *Laryngoscope Investigative Otolaryngology* 2022 doi.org/10.1002/lio2.967



**Caroline Gahm**  
M.D., Ph.D.  
+46 8 12370404  
caroline.gahm@regionstockholm.se

## **Radiotherapy induced tissue inflammation, treatment of salivary gland cancer and reconstructive laryngotracheal airway surgery**

- I) Studies on patients treated for salivary gland cancer
  - To validate the sentinel node technique in salivary gland cancer
  - To validate a histopathological risk model for patients with salivary gland cancer
- II) Studies on radiotherapy-induced tissue inflammation. The project is a multidisciplinary collaboration between surgeons, dermatologists, pathologists and oncologists. The main area of interest is clinical outcome in patients treated for head and neck malignancies.
  - The impact of irradiation on acute and long-term changes in tissues (blood vessels, fat, bone and skin) following radiotherapy treatment.
  - Underlying mechanisms in human tissue and in an experimental mouse model
- III) Studies on laryngotracheal airway diseases.
  - Long-term outcome of reconstructive airway surgery in pediatric and adult patients
  - Studies on surgical outcome after supraglottoplasty for laryngomalacia

### **Supervision of PhD-students:**

Main Supervisor	Co-supervisor
Björn Eriksson	

### **Ethical permit No.**

2019-05211	2008/114-31	2012/1663-32	2018/1972-31	2021-06074-02
------------	-------------	--------------	--------------	---------------

### **Publications 2020, 2021, 2022**

1. Supraglottoplasty for severe laryngomalacia was successful and safe also in children with high-risk comorbidities -experience from Karolinska University Hospital. Submitted January 2023.
2. Segmental congenital deficiency of tracheal rings in cervical trachea managed by tracheal resection: A case report and literature review. Int J Pediatr Otorhinolaryngol. 2021 Sep;148:110844. Gahm C, Näsman A, Papatziamos G. Int J Ped Otorhinolaryngol. 2021 Sept;148
3. Osteoradionecrosis, an increasing indication for microvascular head and neck reconstruction. Danielsson D, Gahm C, Hagedoost S, Munck-Wiklund E, Halle M. Int J Oral Maxillofac Surg. 2019 Jul 8. S0901-5027 (19)31185-3
4. Eriksson B, Gahm, C, Halle M. Upregulation of Plasminogen Activator Inhibitor-1 in irradiated recipient arteries and veins from free tissue transfer reconstruction” Mediators of inflammation. Oct 4;2018:4058986.

**Anna Granath**

MD, PhD.

+46 8 123 87303

anna.2.granath@regionstockholm.se



## Effects of ageing on treatment with cochlear implants.

Study on effects of cochlear implants in adults with special respect to vestibular functions, hearing outcomes and cognitive abilities in the elderly. Vestibular evaluation before and after cochlear implantation is completed and analysis of these results is underway. Studies on the outcomes of treatment (quality of life, hearing outcomes) with cochlear implants related to age at surgery, cognitive abilities as performed in MoCA test and the impact of social environment are in the pipeline. The study is performed in cooperation with staff and researchers at Karolinska Ear and Hearing and the department for Physiotherapy.

## Mastoiditis in Stockholm 2003-2016

A study on mastoiditis in Region Stockholm before and after the introduction of conjugate pneumococcal vaccine for infants is recently being completed and covers all cases of mastoiditis in children at Karolinska University Hospital 2003-2016. This study is a cooperation between the ENT-department, Astrid Lindgren Children Hospital and the Swedish Public Health Agency.

## Deep neck infections at Karolinska University Hospital

A recently finished master thesis (Mia Hermansson, study programme in Medicine, 30p) on epiglottitis at the medical Karolinska and KI has been performed as a quality control. An ethical permit has been acquired, in cooperation with the Department for Oral and Maxillofacial Surgery and Jaw Orthopedics, to enable future studies on deep neck infections originating from the upper airways and from the teeth and oral cavity. This study is still on the drawing board.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

2018/1032-31	2011/44-31/1	2022-03398-01	
--------------	--------------	---------------	--

## Publications 2020, 2020, 2022

1. Westerberg J, Granath A, Drakskog C, Tideholm E, Kumlien Georén S, Weitzberg E, Cardell LO. Nitric Oxide Is Locally Produced in the Human Middle Ear and Is Reduced by Acquired Cholesteatoma. *Otology & Neurotology* : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2022 43;2 e198-e204
2. Hultman Dennison S, Hertting O, Bennet R, Eriksson M, Holmström M, Schollin Ask L, Lindstrand A, Dimitriou P, Stjärne P, Granath A. A Swedish population-based study of complications due to acute rhinosinusitis in children 5-18 years old. *International journal of pediatric otorhinolaryngology* 2021 150; 110866-
3. Submitted 2022 (under review): Sofia Hultman Dennisona, Anna Granatha,Mats Holmström, Pär Stjärne, Olof Hertting: Complications to acute bacterial rhinosinusitis in children - a prospective study; bacterial cultures, virus detection, allergy sensitization and immunoglobulins

**Lalle Hammarstedt Nordenvall**  
M.D., Ph.D.  
+46 8 12371554  
lalle.hammarstedt-nordenvall@regionstockholm.se

## Studier på H&N Cancer

1. Studier i ACCROBAT-studien på prediktiva markörer vid HPV positiv orofarynxcancer, immunologiska samt radiologiska, i syfte att kunna de eskalera behandling
2. Sentinel node studier vid spottkörteltumörer
3. Multicenterstudie om livskvalitet efter tungresektion, med eller utan rekonstruktion.
4. Retrospektiva studier på tungcancer, sentinel node och prediktiva faktorer
5. Sinonasala SNUC och SmarqB1-deficient, genomgång av nationellt material.
6. Studier på patienter ur svenska kvalitetsregister för huvud halscancer, i nuläget hypofarynx, spottkörlar och larynx T1 samt T4.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Evelina Gille	Björn Eriksson
	Rasmus Blomqvist
	Clara Svenberg Lind
	Caroline de Flon

### Ethical permit No.

--	--	--	--	--

### Publications 2020, 2021, 2022

1. Carpén T, Gille E, Hammarstedt-Nordenvall L, Hansen J, Heikkinen S, Lynge E, Selander J, Mehlum IS, Torfadottir JE, Mäkitie A, Pukkala E. BMC Occupational risk variation of nasopharyngeal cancer in the Nordic countries. *Cancer*. 2022 Nov 4;22(1):1130. doi: 10.1186/s12885-022-10209-y. PMID: 36333796
2. Landin D, Nasman A, Jonmarker Jaraj S, Hammarstedt-Nordenvall L, Munck-Wiklund E, Dalianis T, Marklund L. Post-Treatment Neck Dissection of Tonsillar and Base of Tongue Squamous Cell Carcinoma in the Era of PET-CT, HPV, and p16 Viruses 2022, 14(8), 1693; <https://doi.org/10.3390/v14081693> - 30 Jul 2022
3. Vujsinovic M, Marsk E, Tsolakis AV, Hynning B, Nordberg M, Lindblad M, Lindqvist C, Nordenvall LH, Bark R, Elbe P Complications of Gastrostomy Tubes in Patients With Head and Neck Cancer. *Laryngoscope*. 2022 Jan 18. doi: 10.1002/lary.30017. Online ahead of print. PMID: 35041225
4. Högmo A, Holmberg E, Haugen Cange H, Reizenstein J, Wennerberg J, Beran M, Söderkvist K, Hammerlid E, Sjödin H, Farnebo L, Sandström K, Hammarstedt-Nordenvall L, Zborayova K, Brun E. Base of tongue squamous cell carcinomas, outcome depending on treatment strategy and p16 status. A population-based study from the Swedish Head and Neck Cancer Register. *Acta Oncol*. 2022 Apr;61(4):433-440. doi: 10.1080/0284186X.2022.2027516. Epub 2022 Jan 26. PMID: 35081863
5. Hammarstedt Nordenvall L, Jörtsö E, von Beckerath M, Tani E, Nordemar S, Bark R. Prevalence of cystic metastases in a consecutive cohort of surgically removed branchial cleft cysts. *Acta Otolaryngol*. 2022 Jan;142(1):100-105. doi: 10.1080/00016489.2021.2016951. Epub 2021 Dec 28. PMID: 34962438
6. Wu S, Hammarstedt-Nordenvall L, Jangard M, Cheng L, Radu SA, Angelidou P, Zha Y, Hamsten M, Engstrand L, Du J, Ternhag A. Tonsillar Microbiota: a Cross-Sectional Study of Patients with Chronic Tonsillitis or Tonsillar Hypertrophy. *mSystems*. 2021 Mar 9;6(2):e01302-20. doi: 10.1128/mSystems.01302-20. PMID: 33688019
7. Kamali A, Docherty Skogh AC, Edsander Nord Å, Lundgren K, Jergovic D, Hammarstedt Nordenvall L, Sommar P, Halle M.J. Increased salvage rates with early reexploration: A retrospective analysis of 547 free flap cases. *Plast Reconstr Aesthet Surg*. 2021 Oct;74(10):2479-2485. doi: 10.1016/j.bjps.2021.03.001. Epub 2021 Mar 19. PMID: 33879412

8. Wendt M, Hammarstedt-Nordenvall L, Zupancic M, Friesland S, Landin D, Munck-Wiklund E, Dalianis T, Näsman A, Marklund L Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status. *Cancers (Basel)*. 2021 May 23;13(11):2553. doi: 10.3390/cancers13112553. PMID: 34070952
9. Ilmarinen T, Hammarstedt-Nordenvall L, Bäck L, Mäkitie A. Enteral tube feeding of head and neck cancer patients undergoing definitive chemoradiotherapy in the Nordic Countries: Survey of the Scandinavian Society for Head and Neck Oncology. *Eur Arch Otorhinolaryngol*. 2021 Sep;278(9):3489-3496. doi: 10.1007/s00405-020-06545-z. Epub 2021 Jan 2. PMID: 33389006
10. Hammarstedt L, Holzhauser S, Zupancic M, Kapoulitsa F, Ursu RG, Ramqvist T, Haeggblom L, Näsman A, Dalianis T, Marklund L. The value of p16 and HPV DNA in non-tonsillar, non-base of tongue oropharyngeal cancer. *Acta Otolaryngol*. 2020 Sep 17:1-6. doi: 10.1080/00016489.2020.1813906. Online ahead of print. PMID: 32940116
11. Gebre-Medhin M, Brun E, Engström P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, Nyman J, Abel E, Friesland S, Sjödin H, Carlsson H, Söderkvist K, Thomasson M, Zackrisson B, Nilsson P.J ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. *Clin Oncol*. 2020 Oct 14:JCO2002072. doi: 10.1200/JCO.20.02072. Online ahead of print. PMID: 33052757
12. Marklund L, Holzhauser S, de Flon C, Zupancic M, Landin D, Kolev A, Haeggblom L, Munck-Wiklund E, Hammarstedt-Nordenvall L, Dalianis T, Näsman A Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 - Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas. *Eur J Cancer*. 2020 Nov;139:192-200. doi: 10.1016/j.ejca.2020.08.003. Epub 2020 Sep 17. PMID: 32951963



**Barbro Hedin Skogman**  
MD, associate professor  
+46 70 3091101  
barbro.hedin.skogman@ki.se

## The FACE study - a randomized double-blinded placebo-controlled multicenter trial for evaluation of cortisone treatment in children with acute facial nerve palsy

**Background:** Acute facial nerve palsy occur in 15-20/100 000 children/year in Sweden. The facial nerve palsy may be associated to Borrelia infection or idiopathic. About 20 % of these children get a persistent impairment of the facial nerve with problems with excessive tear secretion, pronunciation, drooling on top of social/cosmetic problems due to asymmetry in the face. Studies on cortisone treatment to adult patients with acute facial nerve palsy have shown beneficial effects, but no studies with strong quality have been performed in children. The overall purpose is to assess the utility of cortisone treatment to children with acute facial nerve palsy in a well-designed RCT.

**Material/methods:** We now perform a double-blind randomized double blinded placebo-controlled multicenter trial on children with acute facial nerve palsy. Patients are being recruited consecutively at 18 study centers in Sweden during 2019-2023 and a total of 500 patients will be included. Prednisolone 1 mg/kg x 1 orally in 10 days will be evaluated vs placebo. Clinical data, including clinical outcome (House-Brackmann, Sunnybrook, FaCE scale and FDI) will be documented up until the 12-months follow-up.

The primary outcome is defined as total recovery of the facial nerve palsy, measured with the House-Brackmann scale (grade 1) at 12-months follow-up.

**Clinical relevance:** If the total recovery rate is significantly improved in the prednisolone group as compared to the placebo group, prednisolone treatment will be introduced in clinical practice for children with acute facial nerve palsy in order to reduce the risk of persistent impairment and disability. National and international guidelines will be published for evidence-based treatment of children with acute facial nerve palsy.

The study protocol is published at ClinicalTrials.gov NCT03781700

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Sofia Karlsson	
Sigurdur Arnason	

### Ethical permit No.

2017/554			
----------	--	--	--

### Publications 2020, 2021, 2022

1. Bruinsma RA, Zomer TP, Skogman BH, Boele van Hensbroek M, Hovius JW. Clinical manifestations of Lyme neuroborreliosis in children: a review. Eur J Pediatr. 2023 (<https://doi.org/10.1007/s00431-023-04811-w>)
2. Borgstrom M, Bergsten A, Tunebjör M, Skogman BH, Nevéus T. Fecal disimpaction in children with enuresis and constipation does not make them dry at night. J Pediatr Urol. 2022 May 19; (doi: 10.1016/j.jpurol.2022.05.008, online ahead of print).
3. Arnason S, Molewijk K, Henningsson AJ, Tjernberg I, Skogman BH. Brain damage markers neuron-specific enolase (NSE) and S100B in serum in children with Lyme neuroborreliosis—detection and evaluation as prognostic biomarkers for clinical outcome. Eur J Clin Microbiol Infect Dis. 2022 (doi: 10.1007/s10096-022-04460-1)
4. Arnason S, Skogman BH. Effectiveness of antibiotic treatment in children with Lyme neuroborreliosis - a retrospective study. BMC Pediatr. 2022; 22:332 (doi: 10.1186/s12887-022-03335-w)
5. Nilsson T, Leijon A, Sillén U, Hellström AL, Skogman BH. Bowel and bladder function in infant toilet training (BABITT) – protocol for a randomized, two-armed intervention study. BMC Pediatr. 2022;22:294 (doi:10.1186/s12887-022-03355-6)

6. Borgström M, Bergsten A, Turbjer M, Skogman BH, Nevéus T. Daytime urotherapy in nocturnal enuresis: a randomized, controlled trial. *Arch Dis Child* 2022; 0: 1-5 (doi: 10.1136/archdischild-2021-323488)
7. Lindstrom BE, Skogman BH, Lindstrom AK, Nilsson K, Tallstedt L. Borrelia ocular infection—a case report and a systematic review of published cases. *Ophthalmic Res.* 2022 (doi: 10.1159/000521307)
8. Henningsson AJ, Aase A, Bavelaar H, Flottorp S, Forsberg P, Kirkehei I, Lövmar M, Nilsson K, Nyman D, Ornstein K, Sjöwall J, Skogman BH, Tjernberg I, Aaberge I. Laboratory Methods for Detection of Infectious Agents and Serological Response in Humans With Tick-Borne Infections: A Systematic Review of Evaluations Based on Clinical Patient Samples. *Front. Public Health*, 2021; 9: 580102 (doi:10.3389/fpubh.2021.580102)
9. Karlsson S, Arnason S, Hadziosmanovic N, Laestadius A , Hultcrantz M, Marsk E, Skogman BH. The facial nerve palsy and cortisone evaluation (FACE) study in children: protocol for a randomized, placebo-controlled, multicenter trial, in a *Borrelia burgdorferi* endemic area. *BMC Pediatrics.* 2021; 21 (1) :220 (doi: 10.1186/s12887-021-02571-w)
10. Skogman BH, Wilhelmsson P, Atallah S, Petersson AC, Lindgren PE. Lyme neuroborreliosis in Swedish children—PCR as a complementary diagnostic method for detection of *Borrelia burgdorferi* sensu lato in cerebrospinal fluid. *Eur J Clin Microbiol Infect Dis.* 2021; 40:1003–12 (doi: 10.1007/s10096-020-04129-7)
11. Appelgren D, Enocsson H, Skogman BH, Nordberg M, Perander L, Nyman D, Nyberg C, Knopf J, Munoz LE, Sjowall C, Sjowall J. Neutrophil Extracellular Traps (NETs) in the Cerebrospinal Fluid Samples from Children and Adults with Central Nervous System Infections. *Cells.* 2020;9(43):1-14 (doi: 10.3390/cells9010043)
12. Skogman BH, Lager M, Brudin L, Jenmalm MC, Tjernberg I, Henningsson AJ. Cytokines and chemokines in cerebrospinal fluid in relation to diagnosis, clinical presentation and recovery in children being evaluated for Lyme neuroborreliosis. *Ticks and tick-borne diseases.* 2020; 11 (3):1-11 (doi: 10.1016/j.ttbdis.2020.101390)

**Laila Hellkvist**  
M.D, Ph.D.  
+46 8 123 706 95  
laila.hellkvist@regionstockholm.se

## Allergy vaccination- novel strategies and biomarkers for outcome

Allergic rhinitis deprives quality of life, work capacity and social activities and costs the Swedish society about 1.3 billion SEK annually. Allergen-specific immunotherapy (AIT) gives a significant symptom reduction and also improves the course of the disease. Conventional AIT involves more than 50 subcutaneous injections at hospital or daily sublingual tablets, during 3-4 years. The long treatment duration, problems with side-effects and lack of allergology specialists limits the use; only a minority of the patients eligible for AIT gets the treatment.

Intralymphatic immunotherapy (ILIT) is an emerging form of AIT, which requires only 3 ultrasound guided lymph node injections during a period of 12 weeks. The overall aims for this project are to optimize the ILIT treatment protocol and explore the immunological mechanisms behind tolerance induction in ILIT as well as in conventional AIT. We will investigate if concomitant medication can enhance the treatment effect. In the search for biomarkers for treatment outcome, immune cells sampled from the blood, lymph nodes and nasal mucosa will be characterized, mainly using flow cytometry.

If the treatment protocol in ILIT can be optimized, more patients with allergic rhinitis could benefit from the treatment, to a lower cost for the health care system.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Maryam Jafari

### Ethical permit No.

2009/714	2021-03633		
----------	------------	--	--

### Publications 2020, 2021, 2022

1. A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy. Weinfeld D, Westin U, Hellkvist L, Mellqvist U-H, Jacobsson I, Cardell L-O. *Allergy Asthma Clin Immunol*. 2020 Apr 28;16:31. doi: 10.1186/s13223-020-00427-z. eCollection 2020.
2. High dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase. Hellkvist L, Hjalmarsson E, Weinfeld D, Dahl Å, Karlsson A, Lundkvist K, Westman M, Kumlien Georén S, Winqvist O, Westin U, Cardell LO. *Allergy*. 2021; 00:1-14
3. A five-year open follow up of a randomized, double-blind placebo-controlled trial of intralymphatic immunotherapy for birch and grass reveals remaining beneficial effects. Hjalmarsson E, Hellkvist L, Karlsson A, Winquist O, Kumlien Georén S, Westin U, Olaf Cardell L. *J Investig Allergol Clin Immunol*. 2022 Jun 2:0. doi: 10.18176/jiaci.0832. Epub ahead of print. PMID: 35671100.

**Sten Hellström**  
Senior Professor  
+46 70 496 2432  
sten.hellstrom@ki.se



## Ear and Hearing

The ear and hearing research focuses on three avenues.

1. To study quality and benefit of audiological rehabilitation for patients with severe-to-profound hearing loss with or without vision impairment. The study also aims at investigating the type of audiological rehabilitation received by patients and whether it is necessary to improve rehabilitation efforts, for example, in terms of gender perspective. Other questions regard e.g. do all patients which qualify for CI-implantation get a CI? An important basis for the studies is the National Quality Register for severe-to-profound hearing loss.
2. To further support the development of Scientific Center for Advanced Pediatric Audiology (SCAPA). The hearing and vestibular research in children at Karolinska has an enormous potential to become a national and international frontline research area.
3. To study plasminogen (plg), a preinflammatory protein, and its involvement in healing wounds like chronic tympanic membrane perforation. The focus is now on the production of recombinant plg for use in humans. Within one year a large clinical trial on healing of diabetic foot ulcers will be started. The project is directed from Umeå University.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Niki Karpeta
	Fatima Moumén Denanto
	Marlin Johansson

### Ethical permit No.

2012/057	2014/2101-31		
----------	--------------	--	--

### Publications 2020, 2021, 2022

4. Xie W, Dai Q, Liu J, Liu Y, Hellström S, Duan M. Analysis of Clinical and Laboratory Findings of Idiopathic Sudden Sensorineural Hearing Loss. *Sci Rep.* 2020 Apr 8;10(1):6057.
5. Tong B, Niu K, Ku W, Xie W, Dai Q, Hellström S, Duan M. Comparison of Therapeutic Results with/without Additional Hyperbaric Oxygen Therapy in Idiopathic Sudden Sensorineural Hearing Loss: A Randomized Prospective Study. *Audiol Neurotol.* 2021;26(1):11-16.
6. Tong B, Wang Q, Dai Q, Hellstrom S, Duan M. Efficacy of Various Corticosteroid Treatment Modalities for the Initial Treatment of Idiopathic Sudden Hearing Loss: A Prospective Randomized Controlled Trial. *Audiol Neurotol.* 2021;26(1):45-52.
7. Berninger E, Drott M, Romanitan M, Tranebjærg L, Hellström S. Congenital Nonprofound Bilateral Sensorineural Hearing Loss in Children: Comprehensive Characterization of Auditory Function and Hearing Aid Benefit. *Audiol Res.* 2022 Oct 7;12(5):539-563.
8. Duan M, Xie W, Persson L, Hellstrom S, Uhlén I. Postnatal hearing loss: a study of children who passed neonatal TEOAE hearing screening bilaterally. *Acta Otolaryngol.* 2022 Jan;142(1):61-66.

**Gert Henriksson**  
Senior Consultant, MD. PhD.  
+46 8 123 81463  
gert.henriksson@regionstockholm.se

**Evaluation of the treatment of subglottic stenosis. Quality follow-up and evaluation of the result of treatment inclusive Establishment of normalmaterial for oral Peak Inspiratory Flow measurements used in the study.**

Patients with subglottal stenosis and proximal tracheal stenosis undergoing surgery or local treatment with cortisone between 1998 and today and onwards will be monitored regarding improvement in breathing, PIF, PEF, health inquiry, dyspnea index, voice handicap index and other clinical observations as years between surgery (if reoperated) and possible explanations to the upcome of their stenosis (as Wegener/GPA och earlier intubation). In a separate study we will obtain normal values for the oral Peak Inspiratory Flow apparatus we use in this clinic

**Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>

**Ethical permit No.**

2021-02110			
------------	--	--	--

**Publications 2020, 2021, 2022**

1.

**Stellan Hertegård**  
Adjunct Professor in Phoniatrics  
+46 8 123 80000 vx  
stellan.hertegard@ki.se



## Reconstruction of vocal fold scarring with mesenchymal stem cells

This project aims to find a treatment for severe voice disorders caused by vocal fold scar. This may be the result of surgery cancer treatment severe inflammation of congenital disorders affecting voice. At present effective treatment is lacking. In a series of animal experiments since 2004 we have shown positive effects, regeneration and prevention of scar formation after injection of human mesenchymal stem cells, MSC (and embryonic stem cells).

From 2012 an ongoing study in cooperation with Professor Katarina LeBlanc at KI is including and treating patients with severe hoarseness and scarring of the vocal folds. The patients are recruited from Karolinska and other parts of Sweden. Vocal folds are dissected and scar tissue is reduced/removed followed by a local injection of autologous MSCs. Sixteen patients were treated. Preliminary results at 1 year follow up for the patients show clearly improved vocal fold function without side effects.

At present a clinical trial approved by EPM and Swedish Product Agency (Läkemedelsverket) is ongoing. We are recruiting up to 15 patients with severe dysphonia and vocal fold scarring which are treated with an autologous MSC product injected into the operated scarred vocal folds.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Emma Malmström	Erik Bergström Börlin

### Ethical permit No.

2019-06160	2020-04565	2021-00933	2021-03904
------------	------------	------------	------------

### Publications 2020, 2021, 2022

1. Hertegård S., Nagubothu S.R., Malmström E., LeBlanc K. Treatment of Vocal Fold Scarring with Autologous Bone Marrow Derived Human Mesenchymal Stromal Cells- First Phase I/II Human Clinical Study. *Stem Cell Research and Therapy*. 2020 Mar 20;11(1):128. doi: 10.1186/s13287-020-01632-8. DOI:10.1186/s13287-020-01632-8. SCRT-D-20-00039R22020
2. Hertegård S., LeBlanc K. Treatment of vocal fold scarring with autologous bone marrow-derived human mesenchymal stromal cells—first phase I/II human clinical study: commentary to response. *Stem Cell Res Ther*. 2020 Jun 16;11(1):235. doi: 10.1186/s13287-020-01748-x. PMID: 32546218
3. Björck G., Hertegård S., Ekelund J., Marsk E. Voice rest after vocal fold polyp surgery: a study of 588 patients in the Swedish National Register for Phonosurgery. Accepted for publication in *Laryngoscope Investigative Otolaryngology*. 2021



**Eric Hjalmarsson**  
Research specialist, PhD  
[eric.hjalmarsson@ki.se](mailto:eric.hjalmarsson@ki.se)

## Dendritic cells in tumor-draining lymph nodes and their involvement in tumor escape in head and neck cancer

Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer globally. This cancer has a poor prognosis, especially in patients with nodal involvement, the most important factor adversely affects the treatment and outcome. The treatment for HNSCC has evolved considerably over the past decades, with new surgical techniques, radiation oncology, and chemotherapeutics. However, a new era was the introduction of immune checkpoint inhibitors (ICI). ICIs targeting programmed cell death protein 1 (PD1), and its ligand (PDL-1) has substantially impacted survival and quality of life. However, only 20% experience a positive treatment response despite these improvements.

Dysfunctional CD8+ T-cells are believed to be fundamental for cancer immune escape. In this process, PD-L1 is integral by changing the differentiation of CD8+ T cells into a dysfunctional state. PDL1 expression on tumor cells and tumor-infiltrating leukocytes has been shown to correlate with clinical response. Yet, some patients that are PDL-1 negative in the tumor still benefit from treatment, and vice versa, implying that the mechanism is more complex than blocking PD-1 activation on CD8+ T-cells in the tumor. Dendritic cells are central for initiating and maintaining a T-cell immune response in lymph nodes, yet their involvement in tumor immune escape and ICI treatment response is largely unknown. We hypothesize that DCs in tumor-draining lymph nodes promotes tumor immune escape by increased expression of PDL-1.

This research project aims to evaluate the presence and function of DC and CD8+ T-cells in tumor-draining lymph nodes. The goal is to understand the mechanisms that drive immune escape and restoration of cancer immunity by ICI in tumor-draining lymph nodes. We aim to detect prognostic markers and introduce an improved selection of patients who need more rigorous follow-up and those who would benefit from ICI.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

2019-03518	019-03518		
------------	-----------	--	--

### Publications 2021, 2022, 2022

1. Kågedal Å, Hjalmarsson E, Farrajota Neves da Silva P, Piersiala K, Georén SK, Margolin G, et al. Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. *Sci Rep.* 2020;10(1):22352.
2. Piersiala K, Farrajota Neves da Silva P, Hjalmarsson E, Kolev A, Kågedal Å, Starkhammar M, et al. CD4(+) and CD8(+) T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. *Cancer Sci.* 2021;112(3):1048-59.

**Mats Holmström**

Assoc. Professor

Tel. +46 73441 4466

mats.holmstrom@ki.se



## Different aspects on nasal physiology and disease

1. 1. Rhinomanometry - to create normal values on a national basis and to estimate the use as a tool to select patients for septoplasty
2. 2. Hereditary Hemorrhagic Telangiectasi (HHT) in Sweden - a register based study about mortality, morbidity, prevalence and treatment
3. 3. Chronic rhinosinusitis in adolescence: prevalence, clinical characteristics and inflammatory markers. Predictors of upper airway symptoms in the BAMSE birth cohort.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Karin Åberg

### Ethical permit No.

2019-06015	2016/1380 - 31/2			
------------	------------------	--	--	--

### Publications 2020, 2021, 2022

1. Bengtsson C, Jonsson L, Theorell-Haglöw J, Holmström M, Jansson C, Lindberg E. Sinonasal outcome test-22 and peak nasal inspiratory flow –valuable tools in obstructive sleep apnoea. *Rhinology* 2020; 58(4); 341-8
2. S Hultman Dennison , Olof Hertting , Rutger Bennet , Margareta Eriksson , Mats Holmström , Lina Schollin Ask , Ann Lindstrand , Praxitelis Dimitriou , Pär Stjärne , Anna Granath . A Swedish population-based study of complications to acute rhinosinusitis in children 5 to 18 years old. *J Pediatr Otorhinolaryngol* 2021; Aug 5
3. Hultman-Dennison S, Granath A, Holmström M, Stjärne P, Hertting O. Bacterial cultures, virus detection, allergy sensitization and immunoglobulins in children with complications to acute bacterial rhinosinusitis – a prospective study. Submitted
4. Morén S, Lindestad P-Å, Stålhammar L, Holmström M, Mani, M. Speech in Adults Treated for Unilateral Cleft Lip and Palate as Rated by Naïve Listeners, Speech-Language Pathologists and Patients. *J Plast Reconstr Aesthet Surg* Oct;75(10):3804-3812; 2022

**Sofia Hultman Dennison**  
MD, PhD  
+46 8 1238 1408  
sofia.hultman-dennison@regionstockholm.se

## **Complications to acute rhinosinusitis in children**

PhD june 2021: Complication to acute rhinosinusitis in children.

### **Mastoiditis**

Currently working on article regarding mastoiditis.

#### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>
	Jenny Häggström

#### **Ethical permit No.**

2011/44-31/1	2011/1407-32	2012/144-2/1	2013/1428-32 2017/296-31	2015/779-32 2016/1475-32
--------------	--------------	--------------	-----------------------------	-----------------------------

#### **Publications 2020, 2021, 2022**

1. C "A Swedish population-based study of complications due to acute rhinosinusitis in children 5-18 years old." Int J Pediatr Otorhinolaryngol. 2021 Aug 5;150:110866. doi: 10.1016/j.ijporl.2021.110866. Online ahead of print. PMID: 34416439

**Esma Idrizbegovic**  
MD, PhD  
+46 72 515 2166  
esma.idrizbegovic@ki.se



The goal of this project is to establish an assessment method by which central auditory function can be verified in patients with cognitive impairment, thereby allowing for prevention of accelerated cognitive decline and hearing rehabilitation adapted to cognitive level.

The hypothesis is that combined measures of central auditory function and cognitive function will accurately identify persons with both hearing impairment and cognitive deficits.

In our recent studies (Häggström et al., 2018 and 2020) it has been suggested that the Dichotic Digit Test (DDT) as a central auditory test, may reflect ongoing process resulting in dementia and may be suitable when evaluating cognitive decline.

The aim of the ongoing study is to determine the relationship between central auditory function, measured by DDT, and the cerebrospinal fluid (CSF) markers concentrations of total tau (T-tau), phosphorylated tau (P-tau) and beta amyloid 42 ( $\beta$ A42) in individuals with subjective memory complaints (SMC), Mild Cognitive Impairment (MCI) and Alzheimer disease (AD).

The preliminary results have showed that subjects with pathological levels of the CSF markers T-tau, P-tau, and  $\beta$ A42 perform significantly worse on DDT, independent of clinical diagnosis. This further strengthens the relationship between the central auditory processing dysfunction (CAPD) and cognitive function.

#### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>
	Jenny Häggström

#### **Ethical permit No.**

2005/914-3	2014/2087-31-2	2018/1291-32	
------------	----------------	--------------	--

#### **Publications 2020, 2021, 2022**

1. Cederroth CR, PirouziFard M, Trpchevska N, Idrizbegovic E, Canlon B, Sundquist J, Sundquist K, Zöller B. Association of Genetic vs Environmental Factors in Swedish Adoptees With Clinically Significant Tinnitus. *JAMA Otolaryngol Head Neck Surg.* 2019 Mar 1;145(3):222-229. doi: 10.1001/jamaoto.2018.3852.
2. Häggström J, Hederstierna C, Rosenhall U, Östberg P, Idrizbegovic E. Prognostic Value of a Test of Central Auditory Function in Conversion from Mild Cognitive Impairment to Dementia. *Audiol Neurotol.* 2020; 25 (5): 276-282. doi: 10.1159/000506621. Epub 2020 May.



**Karin Jonstam**  
MD, PhD  
+46 8 12370000  
karin.jonstam@ki.se

## **Studies in chronic rhinosinusitis and in pediatric patients with tracheostomy**

1. I) Long term follow-up in Swedish patients with chronic rhinosinusitis with nasal polyps participating in the GA2LEN cohort.
2. II) Long term follow up in pediatric patients with tracheostomy - morbidity, mortality and long-term outcome.

### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>

### **Ethical permit No.**

--	--	--	--	--

### **Publications 2020, 2021, 2022**

1. Cardell LO, Stjärne P, Jonstam K, Bachert C. Endotypes of chronic rhinosinusitis: Impact on management. *J Allergy Clin Immunol* 2020; 145:752-6.
2. Jonstam K, Alsharif S, Bogaert S, Suchonos N, Holtappels G, Jae-Hyun Park J,
3. et al. Extent of inflammation in severe nasal polyposis and effect of sinus surgery on inflammation. *Allergy* 2020.
4. Jonstam K, Delemarre T, Holtappels G, Cardell LO, Westamn M, Bachert C. Type 2 Inflammatory Shift in Chronic Rhinosinusitis During 2007-2018 in Belgium. *Laryngoscope* 2020.

**Susanna Kumlien Georén**  
 Senior Lab. Manager, Ph.D.  
 +46 704 225 908  
 susanna.georen@ki.se



## Immune responses in airway inflammatory diseases and head- and neckcancer.

1. Cancer immunotherapies (CPI) have revolutionised the field of oncology and significantly improved survival in a wide range of malignancies. Tumour draining lymph nodes (TDLNs) have generally been overlooked in the initial phase of the research in immunotherapy in cancer. We will characterise the cellular architecture and immunological function of immunological cells such as T and B lymphocytes in TDLNs in head and neck carcinoma (HNSCC). Furthermore, we will describe how CPI changes the immunology of TDLNs using an in vitro model based on human TDLNs and in vivo by conducting a clinical trial using neoadjuvant treatment with anti-PD-1 in patients with locally advanced HNSCC and analysing their TDLNs
2. Intralymphatic AIT (ILIT) conjure a novel route of delivery with shorter duration and good compliance (3 injections over 8 weeks). Our previous studies have demonstrated that ILIT is safe with a sustained ability to reduce symptoms and medication during the pollen season. No studies have compared ILIT with traditional AIT. A recent study has shown that oral vitamin D (vitD) given in parallel to SLIT improves the symptom reduction. Our aim is to investigate if supplementation of vitD in parallel with ILIT can further improve the efficacy. We will also, for the first time, compare ILIT with SLIT
3. We aim to elucidate the role of neutrophils in inflammatory resolution and how this process differs between patients with allergic asthma and healthy controls. Special attention will be given to mechanisms related to these differences and the identification of key targets for future therapeutic development. The goal is to highlight neutrophils as a heterogeneous cell population and to demonstrate that an imbalance between its various subgroups can be the basis of a defective resolution of inflammation within the lower airways

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Magnus Starkhammar
	Krzysztof Piersiala
	Vilma Lagebro
	Maryam Jafari

### Ethical permit No.

2017_1791	2021_01265	2021_00325	2022_002039
-----------	------------	------------	-------------

### Publications 2020, 2021, 2022

1. van der Burg N, Stenberg H, Ekstedt S, Diamant Z, Bornesund D, Ankerst J, Kumlien Georén S, Cardell LO, Bjermer L, Erjefält J, Tufvesson E. Neutrophil phenotypes in bronchial airways differentiate single from dual responding allergic asthmatics. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2023;53;1 65-77
2. Hjalmarsson E, Hellkvist L, Karlsson A, Winquist O, Kumlien Georén S, Westin U, Olaf Cardell L. A five-year open follow up of a randomized, double-blind placebo-controlled trial of intralymphatic immunotherapy for birch and grass reveals remaining beneficial effects. Journal of investigational allergology & clinical immunology 2022 ;
3. Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO. A prolonged innate systemic immune response in COVID-19. Scientific reports 2022;12;1 9915-
4. Hellkvist L, Hjalmarsson E, Weinfeld D, Dahl Å, Karlsson A, Westman M, Lundkvist K, Winqvist O, Georén SK, Westin U, Cardell LO. High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase. Allergy 2022;77;3 883-896

5. Cardenas EI, Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO, Lindén A. Increased IL-26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID-19. *Frontiers in immunology* 2022; 13; 1016991-
6. Westerberg J, Granath A, Drakskog C, Tideholm E, Kumlien Georén S, Weitzberg E, Cardell LO. Nitric Oxide Is Locally Produced in the Human Middle Ear and Is Reduced by Acquired Cholesteatoma. *Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology* 2022; 43;2 e198-e204
7. Piersiala K, da Silva PFN, Lagebro V, Kolev A, Starkhammar M, Elliot A, Marklund L, Munck-Wikland E, Margolin G, Georén SK, Cardell LO. Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. *Translational oncology* 2022; 23; 101469-
8. Piersiala K, Farrajota Neves da Silva P, Hjalmarsson E, Kolev A, Kågedal Å, Starkhammar M, Elliot A, Marklund L, Margolin G, Munck-Wikland E, Kumlien Georén S, Cardell LO. CD4+ and CD8+ T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. *Cancer science* 2021; 112;3 1048-1059
9. Westerberg J, Tideholm E, Piersiala K, Drakskog C, Kumlien Georén S, Mäki-Torkko E, Cardell LO. JAK/STAT Dysregulation With SOCS1 Overexpression in Acquired Cholesteatoma-Adjacent Mucosa. *Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology* 2021; 42;1 e94-e100
10. Ma JJ, Tibbitt CA, Georen SK, Christian M, Murrell B, Cardell LO, Bachert C, Coquet JM. Single-cell analysis pinpoints distinct populations of cytotoxic CD4(+) T cells and an IL-10(+)CD109(+) T(H)2 cell population in nasal polyps. *SCIENCE IMMUNOLOGY* 2021; 6;62
11. Larsson O, Sunnergren O, Bachert C, Kumlien Georén S, Cardell LO. The SP-TLR axis, which locally primes the nasal mucosa, is impeded in patients with allergic rhinitis. *Clinical and translational allergy* 2021; 11;1 e12009-
12. Kagedal A, Hjalmarsson E, da Silva PFN, Piersiala K, Georen SK, Margolin G, Munck-Wikland E, Winqvist O, Hayry V, Cardell LO. Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. *SCIENTIFIC REPORTS* 2020; 10;1 22352-
13. Ekstedt S, Tufvesson E, Bjermer L, Georen SK, Cardell LO. A new role for "eat me" and "don't eat me" markers on neutrophils in asthmatic airway inflammation. *ALLERGY* 2020; 75;6 1510-1512
14. Ekstedt S, Larsson O, Kumlien Georén S, Cardell LO. CD16high CD62Ldim neutrophils induce nerve-mediated airway hyperreactivity. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2020; 50;6 756-759
15. Ekstedt S, Georen SK, Cardell LO. Effects of MP-AzeFlu enhanced by activation of bitter taste receptor TAS2R. *ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY* 2020; 16;1 45-
16. Drakskog C, de Clerk N, Westerberg J, Mäki-Torkko E, Georén SK, Cardell LO. Extensive qPCR analysis reveals altered gene expression in middle ear mucosa from cholesteatoma patients. *PloS one* 2020; 15;9 e0239161-
17. Larsson OJ, Georen SK, Cardell LO. Rapid activation of brainstem nuclei following TLR stimulation of the nasal mucosa. *ACTA NEUROBIOLOGIAE EXPERIMENTALIS* 2020; 80;4 353-357

Åsa Kågedal

MD, PhD

+46 72 5968330

asa.kagedal@regionstockholm.se



## Sentinel Node detection in patients with Sinonasal Tumours

Sinonasal malignancies are rare but have a high mortality and the post treatment morbidity is severe with mutilating surgery and radiotherapy. The lymphatic drainage from the nasal cavity and the paranasal sinuses are not well studied. With sentinel node procedure and flow cytometry technique for early detection of metastases and new immunological biomarkers we hope to gain knowledge for better treatment both in terms of limiting the field of radiotherapy and improve the possibilities for immune therapy.

## Immune response in COVID 19 patients.

COVID 19 patients presents with a high immune response. In our study we examine the immune response in blood with flow cytometry and main focus on neutrophils, with an aim to predict the severity of the disease

## Immune Respons and Tumour Cell Detection in Head and Neck Cancer

Metastases in lymph nodes are an important factor for outcome in oral cancer patients. The development of the new immune therapies has changed the field of cancer medicine and it is important to define the selection of patients for these new treatments. The overall goal of this research is to study the immune response in tumour tissue, lymph nodes and blood in patients with oral cancer. We use sentinel node technique to find the draining lymph node where we detect tumour cells with flow cytometry and identify immunological biomarkers..

### Ethical permit No.

2011/717-31-1	2013/1943-3-4	2015/1650-31-2	2018/811-32	
---------------	---------------	----------------	-------------	--

## Publications 2020, 2021, 2022

1. Kågedal Å, Margolin G, Held C, Farrajota Neves da Silva P, Piersiala K, Munck-Wikland E, Jacobsson H, Häyry V, Cardell LO. A novel sentinel lymph node biopsy approach in oral squamous cell carcinoma. *Curr Pharm Des.* 2020;26(31):3834-3839
2. Kågedal Å, Hjalmarsson E, Farrajota Neves da Silva P, Piersiala K, Georén SK, Margolin G, Munck-Wikland E, Winqvist O, Häyry V, Cardell LO. Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. *Sci Rep.* 2020 Dec 18;10(1):22352.
3. Piersiala, K; Farrajota Neves da Silva, P; Hjalmarsson, E; Kolev, A; Kågedal, Å; Starkhammar, M; Elliot, A; Marklund, L; Margolin, G; Munck af Rosenschold Wikland, E; Kumlien Georén, S; Cardell, L O T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69 and HLA-DR expression compared to tumour tissue in OSCC. *Cancer Sci.* 2021 Mar;112(3):1048-1059.
4. A prolonged innate systemic immune response in COVID-19. Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO. *Sci Rep.* 2022 Jun 15;12(1):9915. doi: 10.1038/s41598-022-13986-5. PMID: 35705573
5. Increased IL-26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID-19. Cardenas EI, Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO, Lindén A. *Front Immunol.* 2022 Nov 17;13:1016991. doi: 10.3389/fimmu.2022.1016991. eCollection 2022. PMID: 36466824



**David Landin**  
MD, PhD.  
+46 8 1237 6774  
david.landing@regionstockholm.se

## The use of HPV in post treatment surveillance in Head- and Neck Cancer

Numerous reports in recent decades have shown that, in addition to smoking and alcohol, human papilloma virus (HPV) is also associated with the development of oropharyngeal squamous cell carcinoma, predominantly in the tonsils and base of the tongue. In addition, patients with HPV-positive oropharyngeal SCC have a better clinical response to therapy than patients with HPV-negative oropharyngeal cancer.

Our studies aim to use HPV in surveillance of HPV-positive cancer, this together with radiology and clinical examination

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

2009/1278-31/4			
----------------	--	--	--

### Publications 2020, 2021, 2022

1. Landin D, Näsman A, Jaraj SJ, Hammarstedt-Nordenvall L, Munck-Wiklund E, Dalianis T, Marklund L. Post-Treatment Neck Dissection of Tonsillar and Base of Tongue Squamous Cell Carcinoma in the Era of PET-CT, HPV, and p16. *Viruses*. 2022 Jul 30;14(8):1693. doi: 10.3390/v14081693. PMID: 36016315; PMCID: PMC9413897.
2. Wendt M, Hammarstedt-Nordenvall L, Zupancic M, Friesland S, Landin D, Munck-Wiklund E, Dalianis T, Näsman A, Marklund L. Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status. *Cancers (Basel)*. 2021 May 23;13(11):2553. doi: 10.3390/cancers13112553. PMID: 34070952; PMCID: PMC8196945.
3. Zupancic M, Haeggblom L, Landin D, Marklund L, Dalianis T, Näsman A. Psoriasin expression is associated with survival in patients with human papillomavirus-positive base of tongue squamous cell carcinoma. *Oncol Lett*. 2021 Apr;21(4):277. doi: 10.3892/ol.2021.12538. Epub 2021 Feb 10. PMID: 33732353; PMCID: PMC7905654.
4. Mints M, Landin D, Näsman A, Mirzaie L, Ursu RG, Zupancic M, Marklund L, Dalianis T, Munck-Wiklund E, Ramqvist T. Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer. *Sci Rep*. 2021 Jan 19;11(1):1782. doi: 10.1038/s41598-020-80226-z. PMID: 33469045; PMCID: PMC7815817.
5. Marklund L, Holzhauser S, de Flon C, Zupancic M, Landin D, Kolev A, Haeggblom L, Munck-Wiklund E, Hammarstedt-Nordenvall L, Dalianis T, Näsman A. Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 - Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas. *Eur J Cancer*. 2020 Sep 17:S0959-8049(20)30447-0. doi: 10.1016/j.ejca.2020.08.003. Epub ahead of print. PMID: 32951963.
6. Landin D, Ährlund-Richter A, Mirzaie L, et al. Immune related proteins and tumor infiltrating CD8+ lymphocytes in hypopharyngeal cancer in relation to human papillomavirus (HPV) and clinical outcome [published online ahead of print, 2020 Jul 1]. *Head Neck*. 2020;10.1002/hed.26364. doi:10.1002/hed.26364

Xinxiu Li

PhD.

+46 76 4525150

xinxiu.li@ki.se



## Pancreatic cancer

LncRNA as RNA molecules not only can participant in regulating apoptosis and autophagy cancer, also can promote and decrease the proliferation of tumor cells. Recent studies also showed that lncRNAs have critical role in the pathogenesis, prognosis and diagnosis of pancreatic cancer. As we know, single-cell omics technologies provide an unprecedented opportunity to decipher molecular mechanisms underlying various biological processes in a cell-heterogeneous manner. The emergence of such technique can promote the exploration of mRNA, meanwhile provide the opportunity to capture and/ decipher lncRNA in a specific cell type or a certain cellular state. So different layers of single-cell omics data for lncRNA of pancreatic cancer will be used in a combination way to construct gene regulatory networks using bioinformatic tools. Genomic, chromatinal, transcriptome data of pancreatic cancer will be combined to reveal patterns of lncRNAs in specific expression and regulation of pancreatic cancer and predict potential biomarker and drug targets.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

--	--	--	--	--

### Publications 2020, 2021, 2022

1. Li, X., Lee, E.J., Lilja, S. et al. A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets. *Genome Med* 14, 48 (2022).
2. Bergthor Björnsson, Carl Borrebaeck, Nils Elander, Thomas Gasslander, Danuta R. Gawel, Mika Gustafsson, Rebecka Jörnsten, Eun Jung Lee, Xinxiu Li, andra Lilja et al. Digital twins to personalize medicine. *Genome Med* 12, 4 (2020).
3. Lee EJ, Lilja S, Li X, Schäfer S, Zhang H, Benson M. Corrigendum to "Bulk and single cell transcriptomic data indicate that a dichotomy between inflammatory pathways in peripheral blood and arthritic joints complicates biomarker discovery" [Cytokine 127 (2020) 154960]. *Cytokine*. 2020;133:155087.
4. Li X, Lee EJ, Gawel DR, et al. Meta-Analysis of Expression Profiling Data Indicates Need for Combinatorial Biomarkers in Pediatric Ulcerative Colitis. *J Immunol Res*. 2020;2020:8279619.
5. Lee EJ, Gawel DR, Lilja S, Li X, et al. Analysis of expression profiling data suggests explanation for difficulties in finding biomarkers for nasal polyps. *Rhinology*. 2020;58(4):360-367.
6. Gawel DR, Serra-Musach J, Lilja S, et al. Correction to: A validated single-cell-based strategy to identify diagnostic and therapeutic targets in complex diseases. *Genome Med*. 2020;12(1):37. Published 2020 Apr 28.



**Ulrika Löfkvist**  
MD, Assoc. Professor  
[ulrika.lofkvist@ki.se](mailto:ulrika.lofkvist@ki.se)

## Long-term follow-up of adolescents and young adults who have undergone surgery with cochlear implants during early childhood

We have previously reported that cochlear implantation in infancy is safe and highly important for children who are congenitally hard-of-hearing/deaf to develop early spoken language abilities (Karlsson et al., 2019), which is in line with the current literature. However, long-term outcomes are relatively unknown, for example finer language competence, psychosocial well-being, and listening skills in more complex listening conditions reflecting everyday life. In addition, it is unclear whether the chronic electrical stimulation in the inner ear and the CI procedure itself affects vestibular function. The ongoing multi-disciplinary research program aims to investigate possible effects of early age at 1st cochlear implantation (CI) in a larger cohort of adolescents who received their 1st CI before 30 months of age, and in relation to typical hearing controls.

The overall two PICO-questions motivating the multi-disciplinary research program (including five study projects):

1. How do adolescents with mono- or multilingual background implanted before 30 months with cochlear implant(s), perform long-term in linguistics, cognition, hearing, balance, self-efficacy and HRQoL, and in comparison to age-, socioeconomic and language-matched controls with typical hearing?
2. How do adolescents and young adults with CIs perceive their listening and communication experiences with CIs in different everyday life situations and activities (school, work, leisure), and in relation to controls with typical hearing?

Data collection is ongoing: multidisciplinary follow-up visits and questionnaire studies in participants with CI and in age-matched typical hearing controls. During spring 2023 we will also conduct focus group interviews for adolescents with CI.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Malin Dahlby Skoog	Jonas Fogels
	Karolina Falkenius Schmidt

### Ethical permit No.

2015/992-31	2022-01159-01				
-------------	---------------	--	--	--	--

### Publications 2020, 2021, 2022


1. Bonati, M., Levy, C., Löfkvist, U. (2022). Home language environment in relation to language outcome in Brazilian toddlers who are hard of hearing and controls with typical hearing – a pilot study including reliability analyses of the LENA recording system. CoDAS. <https://doi.org/10.1590/2317-1782/20212021250>
2. de Melo, M.E., Soman, U., Voss, J., Hinojosa Valencia, M.F., Noll, D., Clark, F., Hutsell Guignard, G., Löfkvist, U. (2022). Listening and Spoken Language Specialist (LSLS) Auditory-Verbal Certification: Self-perceived Benefits and Barriers to Inform Change. Perspectives SIG 9,
3. Socher, M., Löfkvist, U., Wass, M. (2022). Comparing the semantic networks of children with cochlear implants and children with typical hearing: Effects of length of language access. *J of Communication Disorders*. 99(2): 106247. <https://doi.org/10.1016/j.jcomdis.2022.106247>
4. Löfkvist, U., Nilsson, S., Thalen, Y., Östlund, E., Mared, H., Johansson, C., Anmyr, L., Karlsson, E. (2022). Gender differences in Caregiver's Use of Spoken Language close to young children who are Hard-of-Hearing, *Int J of Ped Otorhinolaryngology*. May;156:111103. <https://doi.org/10.1016/j.ijporl.2022.111103>
5. Jakhelln-Laugen N., Erixon, E., Huttunen, K., Määki-Torkko, E., Löfkvist, U. (2021). Newborn Hearing Screening and Intervention in Children with Unilateral Hearing Impairment: Clinical Practices in Three Nordic Countries. *Journal of Clinical Medicine*, Nov 2;10(21):5152, <https://www.researchgate.net/deref/https%3A%2F%2Fdoi.org%2F10.3390%2Fjcm10215152>
6. Smeds, H., Wales, J., Karlsson, E., Anderlid, B-M., Henricson, C., Asp, F., Anmyr, L., Lagerstedt-Robinson, K., Löfkvist, U. (2021). Xlinked Malformation Deafness – neurodevelopmental symptoms are common in children with IP3 malformation and mutation in POU3F4. *Ear and Hearing*. Jan/Feb;43(1):53-69. doi: 10.1097/AUD.0000000000001073.
7. Lazar, A., Löfkvist, U., Verrecchia, L., Karlsson, E. (2021). Identical twins affected by congenital cytomegalovirus infections showed different audio-vestibular profiles. *Acta Paediatr*. Jan;110(1):30-35. doi: 10.1111/apa.15561.
8. Löfkvist, U., Anmyr, L., Henricson, C., Karlsson, E. (2020). Executive Functions, Pragmatic Skills and Mental Health in Children with Congenital Cytomegalovirus (CMV) infection With Cochlear Implants – a pilot study. *Frontiers in Psychology*. Jan;10:2808. doi:10.3389/fpsyg.2019.02808. eCollection 2019.

**Linda Marklund**

M.D., Assoc. Professor

+46 8 51770000

[linda.marklund@regionstockholm.se](mailto:linda.marklund@regionstockholm.se)



## **Studies on tumour markers and surgical techniques to individualize treatment and improve outcome for patients with head neck tumours**

Treatment of head and neck tumors consists surgery, radiotherapy and chemotherapy, used as single treatment or combined in advanced tumors. Today treatment is standardized and mainly based on TNM-status although the tumors vary in aggressiveness and sensitivity to treatment. Complications to treatment is loss of nerve function, pain, stiffness, swallowing problems, dryness of mouth which have major impact of the quality of life. A number of molecular markers have been evaluated for predictive value at head and neck tumors. However, few studies have been performed specifically for each subgroup of tumors although these differ considerably in terms of treatment response and prognosis. Therefore, the overall aim of all studies is to optimize and individualize the treatment for patients with head and neck tumors. We evaluate the predictive value of a number of markers in order to be able to select patients for surgery or oncologic treatment, and also be able to better select type and intensity of oncologic treatment and also the extent of surgery, both on the tumor site and the neck.

### **Supervision of PhD-students:**

Main Supervisor	Co-supervisor
Rasmus Blomqvist	Aeneas Kolev
Evelina Jörtsö	

### **Ethical permit No.**

2017/1333-31/1	2012/49-31/2	2019/03518		
----------------	--------------	------------	--	--

### **Publications 2020, 2021, 2022**

1. Landin D, Näsman A, Jara SJ, Hammarstedt-Nordenvall L, Munck-Wikland E, Dalianis T, Marklund L. Post-Treatment Neck Dissection of Tonsillar and Base of Tongue Squamous Cell Carcinoma in the Era of PET-CT, HPV, and p16. *Viruses*. 2022 Jul 30;14(8):1693. doi: 10.3390/v14081693.
2. Piersiala K, da Silva PFN, Lagebro V, Kolev A, Starkhammar M, Elliot A, Marklund L, Munck-Wikland E, Margolin G, Georén SK, Cardell LO. Tumor-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. *Transl Oncol*. 2022 Jun 14;23:101469. doi: 10.1016/j.tranon.2022.101469. PMID: 35714487
3. Malin Wendt, David Landin, Lalle Hammarstedt, Tina Dalianis, Eva Munck-Wikland, Anders Näsman and Linda Marklund. Long-term survival and recurrence in oropharyngeal squamous cell carcinoma, in relation to subsites, HPV and p16-status. *Cancers* 2021, 13(11), 2553; <https://doi.org/10.3390/cancers13112553> (registering DOI) - 23 May 2021
4. Zupancic M, Haeggblom L, Landin D, Marklund L, Dalianis T, Näsman A. Psoriasin expression is associated with survival in patients with human papillomavirus-positive base of tongue squamous cell carcinoma. *Oncol Lett*. 2021 Apr;21(4):277. doi: 10.3892/ol.2021.12538. Epub 2021 Feb 10. PMID: 33732353
5. Mints M, Landin D, Näsman A, Mirzaie L, Ursu RG, Zupancic M, Marklund L, Dalianis T, Munck-Wikland E, Ramqvist T. Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer. *Sci Rep*. 2021 Jan 19;11(1):1782. doi: 10.1038/s41598-020-80226-z. PMID: 33469045
6. Wendt M, Papatzamos G, Munck-Wikland E, Marklund L. Sclerotherapy of ranulas with OK 432 – a prospective, randomised, double-blinded placebo-controlled study. *Acta Otolaryngol*. 2021 Mar 27:1-6. doi: 10.1080/00016489.2021.1889660. Online ahead of print. PMID: 33775200
7. Piersiala K, Farrajota Neves da Silva P, Hjalmarsson E, Kolev A, Kågedal Å, Starkhammar M, Elliot A, Marklund L, Margolin G, Munck-Wikland E, Kumlien Georén S, Cardell LO. CD4+ and CD8+ T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. *Cancer Sci*. 2021 Mar;112(3):1048-1059. doi: 10.1111/cas.14816. Epub 2021 Feb 15. PMID: 33462898

8. Marklund L, Holzhauser S, Flon C, Zupancic M, Haeggblom L, Munck-Wikland E, Hammarstedt-Nordenvall L, Dalianis T, Näsmann A. Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 – Risk of misclassification of HPV-mediated non-tonsillar, non-base of tongue carcinomas. *Eur J Cancer*. 2020 Nov;139:192-200. doi: 10.1016/j.ejca.2020.08.003. Epub 2020 Sep 17. PMID: 32951963
9. Lalle Hammarstedt-Nordenvall, Fani Kapoulitsa, Stefan Holzhauser, Mark Zupancic, Ramona Ursu, Linnea Haeggblom, Torbjörn Ramqvist, Anders Näsmann, Tina Dalianis, and Linda Marklund. The value of p16 and HPV in non-tonsillar, non-base of tongue oropharyngeal cancer. *Acta Otolaryngol*. 2021 Jan;141(1):89-94. doi: 10.1080/00016489.2020.1813906. Epub 2020 Sep 17. PMID: 32940116
10. David Landin , Andreas Ährlund-Richter , Leila Mirzaie, Michael Mints, Anders Näsmann , Aeneas Kolev, Linda Marklund, Tina Dalianis , Eva Munck-Wikland, Torbjörn Ramqvist. Immune related proteins and tumor infiltrating CD8+ lymphocytes in hypopharyngeal cancer in relation to human papillomavirus (HPV) and clinical outcome. *Head Neck*. 2020 Jul 1. doi: 10.1002/hed.26364.
11. Elliot A, Näsmann A, Westman A, Hammarstedt-Nordenvall L, Stjärne P, Marklund L, Stathmin and EGFR expression and its correlation to HPV status and clinical outcome in sinonasal inverted papilloma. *Rhinology*. 2020 Feb 1;58(1):74-79. doi: 10.4193/Rhin19.078. PMID: 31710049

**Elin Marsk**

M.D., Ph.D.

+46 8 123 70000

elin.marsk@regionstockholm.se



- **Bells palsy during pregnancy and puerperium**
- **Surgical intervention in patients with peripheral facial palsy**
- **Facial nerve palsy in children; treatment and clinical outcome**

Bell's palsy is an acute peripheral facial nerve palsy with unknown etiology that can affect both adults and children. There is a higher incidence among pregnant women and in the puerperium. The disease can cause severe disfigurement of the face, impair the ability to eat, drink and speak, and seriously affect the patient's quality of life. Many patients need surgical interventions or botox injections.

In our work, we study different aspects of Bell's palsy in both adults (especially among pregnant women) and children. Surgical interventions with nerve transfers and neurotomy on adults with severe facial palsies is studied. A multi-center randomised, clinical trial is performed on children with acute facial palsy to study the effect of prednisolone on the facial outcome.

**Supervision of PhD-students:**

Main Supervisor	Co-supervisor
Lovisa Lansing	Rebecka Ohm
	Sigurdur Arnason
	Sofia Karlsson

**Ethical permit No.**

--	--	--	--	--

**Publications 2020, 2021, 2022**

1. Bell's palsy in pregnancy and postpartum: a retrospective case control study of 182 patients. Lansing L, Brismar Wendel S, Hultcrantz M, Marsk E Accepted Otolaryngology- Head and Neck Surgery Oktober 2022
2. Voice rest after vocal fold polyp surgery: a study of 588 patients in the Swedish National Register for Voice improving vocal fold surgery Björck G, Hertegård S, Marsk E Laryngoscope, Investigative Otolaryngology 2022 Mar 16;7(2):486-493
3. Complications of Gastrostomy Tubes in Patients with Head and Neck Cancer. Vujasinovic M, Marsk E, Tsolakis AV, Hynning B, Nordberg M, Lindblad M, Lindqvist C, Nordenvall LH, Bark R, Elbe P. Laryngoscope. 2022 Jan 18.
4. The facial nerve palsy and cortisone evaluation (FACE) study in children: protocol for a randomized, placebo-controlled, multicenter trial, in a Borrelia burgdorferi endemic area. Karlsson S, Arnason S, Hadziosmanovic N, Laestadius Å, Hultcrantz M, Marsk E, Skogman BH. BMC Pediatr. 2021 May 4;21(1):220.
5. Quality of Life in Bell's Palsy: FaCE Scale and FDI Correlation with Sunnybrook and House-Brackmann over Time. Bylund N, Hultcrantz M, Jonsson L, Marsk E Laryngoscope. 2021 Feb;131(2):E612-E618.



**Eva Munck-Wikland**  
Adjunct Professor, Consultant  
+46 730 379 684  
eva.munck-wikland@ki.se

## Head and neck cancer

We study predictive and prognostic markers in head and neck cancer aiming at individualized and optimized treatment for our patients.

Daniel studies "Osteoradionecrosis (ORN) - riskfactors and reconstructive outcome" including biomarkers for increased risk for ORN, proportion of ORN in reconstructive surgery, quality of life after reconstruction and the risk for ORN in patients with base of tongue cancer treated with brachytherapy.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Daniel Danielsson	Krzysztof Piersiala
	Vilma Lagebro

### Ethical permit No.

2009/129-32	2012/1663-32	2016/27-32	2016/506
-------------	--------------	------------	----------

### Publications 2020, 2021, 2022

1. Danielsson D, Hagel E, Dybeck Udd S, Sjöström M, Kjeller G, Bengtsson M, Abtahi J, von Beckerath M, Thor A, Halle M, Friesland S, Mercke C, Westermark A, Höglmo A, Munck-Wikland E. Brachytherapy and osteoradionecrosis in patients with base of tongue cancer. *Acta Otolaryngol*. 2023 Jan;143(1):77-84. doi: 10.1080/00016489.2022.2161627. Epub 2023 Jan.
2. Sjöström M, Danielsson D, Munck-Wikland E, Nyberg J, Sandström K, Thor A, Johansson H, Ceghafi P, Dybeck Udd S, Emanuelsson J, Forsberg Pettersson L, Halle M, Laurell G. Mandibular resection in patients with head and neck cancer: acute and long-term complications after reconstruction. *Acta Otolaryngol*. 2022 Jan;142(1):78-83. doi: 10.1080/00016489.2021.2021283. Epub 2022 Jan 13. PMID: 35023428
3. Landin D, Näsman A, Jara SJ, Hammarstedt-Nordenvall L, Munck-Wikland E, Dalianis T, Marklund L. Post-Treatment Neck Dissection of Tonsillar and Base of Tongue Squamous Cell Carcinoma in the Era of PET-CT, HPV, and p16. *Viruses*. 2022 Jul 30;14(8):1693. doi: 10.3390/v14081693. PMID: 36016315 Free PMC article.
4. Piersiala K, da Silva PFN, Lagebro V, Kolev A, Starkhammar M, Elliot A, Marklund L, Munck-Wikland E, Margolin G, Georén SK, Cardell LO. Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. *Transl Oncol*. 2022 Jun 14;23:101469. doi: 10.1016/j.tranon.2022.101469. Online ahead of print. PMID: 35714487
5. Wendt M, Hammarstedt-Nordenvall L, Zupancic M, Friesland S, Landin D, Munck-Wikland E, Dalianis T, Näsman A, Marklund L. Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status. *Cancers (Basel)*. 2021 May 23;13(11):2553. doi: 10.3390/cancers13112553. PMID: 34070952 Free PMC article.
6. Mints M, Landin D, Näsman A, Mirzaie L, Ursu RG, Zupancic M, Marklund L, Dalianis T, Munck-Wikland E, Ramqvist T. Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer. *Sci Rep*. 2021 Jan 19;11(1):1782. doi: 10.1038/s41598-020-80226-z. PMID: 33469045 Free PMC article.
7. Piersiala K, Farrajota Neves da Silva P, Hjalmarsson E, Kolev A, Kågedal Å, Starkhammar M, Elliot A, Marklund L, Margolin G, Munck-Wikland E, Kumlien Georén S, Cardell LO. CD4+ and CD8+ T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. *Cancer Sci*. 2021 Mar;112(3):1048-1059.
8. Wendt M, Papatzamos G, Munck-Wikland E, Marklund L. Sclerotherapy of ranulas with OK-432 - a prospective, randomized, double-blinded-placebo-controlled study. *Acta Otolaryngol*. 2021 May;141(5):531-536. doi: 10.1080/00016489.2021.1889660. Epub 2021 Mar 27.
9. Kågedal Å, Hjalmarsson E, Farrajota Neves da Silva P, Piersiala K, Georén SK, Margolin G, Munck-Wikland E, Winqvist O, Häyry V, Cardell LO. Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. *Sci Rep*. 2020 Dec 18;10(1):22352
10. Marklund L, Holzhauser S, de Flon C, Zupancic M, Landin D, Kolev A, Haeggblom L, Munck-Wikland E, Hammarstedt-Nordenvall L, Dalianis T, Näsman A. Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 - Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas. *Eur J Cancer*. 2020 Nov;139:192-200.
11. Landin D, Ährlund-Richter A, Mirzaie L, Mints M, Näsman A, Kolev A, Marklund L, Dalianis T, Munck-Wikland E, Ramqvist T. Immune related proteins and tumor infiltrating CD8+ lymphocytes in hypopharyngeal cancer in relation to human papillomavirus (HPV) and clinical outcome. *Head Neck*. 2020 Jul 1. doi: 10.1002/hed.26364. Online ahead of print. PMID: 32613643
12. Kågedal Å, Margolin G, Held C, da Silva PFN, Piersiala K, Munck-Wikland E, Jacobsson H, Häyry V, Cardell LO. A Novel Sentinel Lymph Node Approach in Oral Squamous Cell Carcinoma. *Curr Pharm Des*. 2020;26(31):3834- 3839.
13. Danielsson D, Gahm C, Haghdoost S, Munck-Wikland E, Halle M. Osteoradionecrosis, an increasing indication for microvascular head and neck reconstruction. *Int J Oral Maxillofac Surg*. 2020 Jan;49(1):1-6

**Antti Mäkitie**  
 Professor, Visiting Scientist  
 ++358 44 32 22 051  
 antti.makitie@ki.se



## Diagnostic and Prognostic Markers for Head and Neck Cancer management

- Identification of early diagnostic and prognostic markers (both clinical and biomarkers) that predict HNSCC treatment outcome. This collaborative project aims to identify markers that predict treatment response and can be analyzed in a tissue biopsy from a suspected tumor and/or in the patient's blood sample or saliva. The ultimate goal is to find combinations of markers, which could guide clinicians to provide cancer patients with a more adequate, individualized, and effective treatment. We also apply machine learning applications to better overcome challenges encountered in the management of HNSCC.
- The Nordic Head and Neck Cancer (HNC) Study: management and outcome of various subsites of HNC in the Nordic countries. Our aim is to evaluate current treatment outcome of HNC in the Nordic countries and to form a recommendation for a unified treatment protocol for this entity to be used in this area. The secondary aim is to find prognostic markers for clinical use by using multi-institutional series of HNC patients and available samples.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Evelina Gille
	Rasmus Blomkvist

### Publications 2020, 2021, 2022

For complete list please, see: <https://pubmed.ncbi.nlm.nih.gov/?term=Makitie+>

- Carpén T, Gille E, Hammarstedt-Nordenvall L, Hansen J, Heikkinen S, Lyngé E, Selander J, Mehlum IS, Torfadottir JE, Mäkitie A, Pukkala E. Occupational risk variation of nasopharyngeal cancer in the Nordic countries. *BMC Cancer*. 2022 Nov 4;22(1):1130.
- Nieminen T, Tolvi M, Lassus P, Wilkman T, Lehtonen L, Mäkitie A. Risk factors for evaluating early mortality after microvascular reconstruction of head and neck cancers. *Scand J Surg*. 2022 Dec;111(4):83-91.
- Alabi RO, Almangush A, Elmusrati M, Leivo I, Mäkitie A. Measuring the Usability and Quality of Explanations of a Machine Learning Web-Based Tool for Oral Tongue Cancer Prognostication. *Int J Environ Res Public Health*. 2022 Jul 8;19(14):8366.
- Pukkala E, Peltomaa M, Mäkitie A, Heikkinen S, Kjærheim K, Martinsen JI, Sparén P, Tryggvadottir L, Weiderpass E. Cancer incidence among musicians: 45 years of follow-up in four Nordic countries. *Acta Oncol*. 2021 Jul;60(7):835-841.
- Almangush A, Alabi RO, Mäkitie AA, Leivo I. Machine learning in head and neck cancer: Importance of a web-based prognostic tool for improved decision making. *Oral Oncol*. 2021 Jul 12:105452.
- Tuomainen K, Hyttiäinen A, Al-Samadi A, Ianevski P, Ianevski A, Potdar S, Turunen L, Saarela J, Kuznetsov S, Wahbi W, Risteli M, Mäkitie A, Monni O, Salo T. High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. *Sci Rep*. 2021 Jul 20;11(1):14755.
- Filippou A, Pehkonen H, Karhemo PR, Väänänen J, Nieminen AI, Klefström J, Grénman R, Mäkitie AA, Joensuu H, Monni O. ANO1 Expression Orchestrates p27kip1/MCL1-Mediated Signaling in Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)*. 2021 Mar 9;13(5):1170. doi: 10.3390/cancers13051170.
- Ilmarinen T, Hammarstedt-Nordenvall L, Bäck L, Mäkitie A. Enteral tube feeding of head and neck cancer patients undergoing definitive chemoradiotherapy in the Nordic Countries: Survey of the Scandinavian Society for Head and Neck Oncology. *Eur Arch Otorhinolaryngol*. 2021 Jan 2.
- Koivuholma A, Aro K, Mäkitie A, Salmi M, Mirtti T, Hagström J, Atula T. Three-Dimensional Presentation of Tumor Histopathology: A Model Using Tongue Squamous Cell Carcinoma. *Diagnostics (Basel)*. 2021 Jan 12;11(1):109
- Almangush A, Mäkitie AA, Hagström J, Haglund C, Kowalski LP, Nieminen P, Coletta RD, Salo T, Leivo I. Cell-in-cell phenomenon associates with aggressive characteristics and cancer-related mortality in early oral tongue cancer. *BMC Cancer*. 2020 Sep 3;20(1):843.
- Boëthius H, Saarto T, Laurell G, Farnebo L, Mäkitie AA. A Nordic survey of the management of palliative care in patients with head and neck cancer. *Eur Arch Otorhinolaryngol*. 2020 Sep 1.
- Mohamed H, Haglund C, Jouhi L, Atula T, Hagström J, Mäkitie A. Expression and Role of E-Cadherin, β-Catenin, and Vimentin in Human Papillomavirus-Positive and Human Papillomavirus-Negative Oropharyngeal Squamous Cell Carcinoma. *J Histochem Cytochem*. 2020 Sep;68(9):595-606.
- Mroueh R, Nevala A, Haapaniemi A, Pitkäniemi J, Salo T, Mäkitie AA. Risk of second primary cancer in oral squamous cell carcinoma. *Head Neck*. 2020 Feb 14.
- Almangush A, Leivo I, Mäkitie AA. Overall Assessment of Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: Time to Take Notice. *Acta Otolaryngol*. 2020;140(3):246-248.
- Mäkitie A, Kamali A, Mroueh R, Lindford A, Koivunen P, Autio T, Lassus P, Halle M, Bäck L, Palmgren B, Hammarstedt-Nordenvall L. A descriptive study highlighting the differences in the treatment protocol for oral tongue cancer in Sweden and Finland. *Acta Otolaryngol*. 2020 Feb;140(2):188-194.



**Riitta Möller**  
Senior consultant/Lecturer  
+46 73 3261296  
riitta.moller@ki.se

## **Undergraduate students' clinical learning environment and lifelong learning**

Undergraduate students' clinical learning environment (CLE).

It is widely acknowledged that CLE impacts students' professional development and their ability to achieve the learning outcomes. This project aims to identify and provide an in-depth understanding of students' perception of the clinical learning environment and the relationship to self-reported health-related quality of life across four different undergraduate programs. The first study assessed the CLE by the Undergraduate Clinical Education Environment Measure (UCEEM) and showed significant differences between the programs with physiotherapy students rating highest and medical students lowest their CLE. The project has been progressed with two new qualitative studies.

The other research path concerns undergraduate students' scientific development and attitudes to lifelong learning. Ethical application is to be submitted in the beginning of this year and two new studies are to be started in 2022.

### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>
Malin Sellberg	

### **Ethical permit No.**

2017/38-31/4	2013/2212-31/4	2010/1100-31/1	2010/1606-31/5	2010/1100-31/1	2011/493-32	
--------------	----------------	----------------	----------------	----------------	-------------	--

### **Publications 2019, 2020, 2021**

1. Möller R, Wallberg A, Shoshan M. Faculty perceptions of factors that indicate successful educational outcomes of medical students' research projects: a focus group study. *BMC Med Educ.* 2021 Oct 3;21(1):519. doi: 10.1186/s12909-021-02954-8. PMID: 34600506; PMCID: PMC8487494.
2. Sellberg M, Palmgren PJ, Möller R. A cross-sectional study of clinical learning environments across four undergraduate programs using the undergraduate clinical education environment measure. *BMC Medical Education* (2021) 21:258 <https://doi.org/10.1186/s12909-021-02687-8>
3. Möller R, Ringsted C, Danielsen N. Portföljen synliggör lärandet och kompetensutvecklingen [Portfolio - a tool for making learning and competence development visible]. *Läkartidningen.* 2021 Sep 20;118:21099. Swedish. PMID: 34542895.
4. Möller R. Reformeringen av läkarutbildningen i Sverige. *Finska Läkaresällskapets Handlingar* 2020; 180:2; 52-57.
5. Rosengren B, Möller R, Hellman J, Jood K, Ekstedt M, Särnblad S, Alm S, Gummesson C. EPA (Entrustable professional activities)- an international approach to define key tasks that a doctor should be able to perform. *Läkartidningen.* 2019 May 7;116.
6. Möller R. It's time to define the Swedish Doctor? Lessons learnt from the evaluation of the Finnish undergraduate medical education. *Läkartidningen.* 2019 May 7;116.
7. Hultin M, Möller R. En grundutbildning i förändring. *Läkartidningen.* 2019 May 7;116
8. Möller R, Shoshan M. Does reality meet expectations? An analysis of medical students' expectations and perceived learning during mandatory research projects. *BMC Med Ed* 2019 19;1 93-
9. Möller R, Hultin M. [Examination of future colleagues: We need an assessment culture]. *Läkartidningen* 2019 116;
10. Bexelius T, Lachmann H, Järnbert-Pettersson H, Kalén S, Möller R, Ponzer S. Stress among medical students during clinical courses: a longitudinal study using contextual activity sampling system. *IJME* 2019 10; 68-74
11. Möller R, Safa S, Östberg P. A prospective study for evaluation of structural and clinical validity of the Eating Assessment Tool. *BMC Geriatr* 20, 269 (2020). <https://doi.org/10.1186/s12877-020-01654-0>

**Lina Nygren**

MD., PhD.

+46 73 9810116

[lina.nygren@ki.se](mailto:lina.nygren@ki.se)



## **Hearing in cholesteatoma surgery and evaluation of preceding myringoplasty in cholesteatoma patients.**

Post doctoral studies as part of the project SweChole regarding cholesteatoma in Sweden.

I) Prospective study regarding hearing in patients undergoing cholesteatoma surgery. Hearing is tested before surgery as well as six months, one year and five years post surgery. The hearing test methods are pure tone audiometry (PTA), horizontal sound localization and speech in competing speech. PTA is used in clinical practice to measure the hearing of the cholesteatoma patients. We want to evaluate if the other two methods are better to represent the useful hearing in the patients, compare the data to normal hearing subjects and describe eventual auditory plasticity in spatial hearing over time.

II) Retrospective study of cholesteatoma patients in Sweden using the Swedish Patient Registry and the Swedish Quality Registry for Ear Surgery. We will combine these registries to evaluate the risk of developing cholesteatoma after myringoplasty. We will analyze parameters such as time from myringoplasty to cholesteatoma surgery and also parameters regarding surgical procedure of the myringoplasty and complications during the healing period.

### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>

### **Ethical permit No.**

2022-04517-02	2020-05935			
---------------	------------	--	--	--

### **Publications 2020, 2021, 2022**

1.



**Petter Olsson**  
M.D., Ph.D.  
+46 70 4663 252  
petter.olsson@ki.se

## **Upper airway disease; treatments and health economy**

Research interests include the epidemiology of rhinitis and nasal polyposis, the medical and surgical management of nasal polyposis and more recently, immunotherapy and biologic treatments of upper airway disease, including health economy

### **Ethical permit No.**

2016/2158-31/2				
----------------	--	--	--	--

### **Publications 2020, 2021, 2022**

1. Luong AU, Chua A, Alim BM, Olsson P, Javer A. Allergic Fungal Rhinosinusitis: The Role and Expectations of Biologics. *The journal of allergy and clinical immunology. In practice* 2022 10;12 3156-3162
2. Taniguchi M, Heffler E, Olze H, White A, Corte-Real J, Olsson P, Lazarewicz S. The Role of Omalizumab in NSAID-Exacerbated Respiratory Disease: A Narrative Review. *The journal of allergy and clinical immunology. In practice* 2022 10;10 2570-2578
3. Tsabouri S, Ntritsos G, Koskeridis F, Evangelou E, Olsson P, Kostikas K. Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis. *Rhinology* 2021 Oct 29. doi: 10.4193/Rhin21.159
4. Olsson P, Skroder C, Ahlbeck L, Hjalte F, Welin KO, Westin U, Andersson M, Ahlstrom-Emanuelsson C, Cardell LO. Health-SWEDE: costs with sublingual immunotherapy-a Swedish questionnaire study. *Allergy Asthma and Clinical Immunology* 2021 17;1 55-
5. Mackay AJ, Kostikas K, Roche N, Frent SM, Olsson P, Pfister P, Gupta P, Patalano F, Banerji D, Wedzicha JA. Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study. *Respiratory research* 2020 21;1 93-
6. Muro S, Yoshisue H, Kostikas K, Olsson P, Gupta P, Wedzicha JA. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis. *Respirology (Carlton, Vic.)* 2020 25;4 393-400

**Björn Palmgren**

MD, PhD

+46 70 3244125

[bjorn.palmgren@regionstockholm.se](mailto:bjorn.palmgren@regionstockholm.se)



## Laryngeal cancer at the Karolinska University Hospital 2000-2020

In this project, we want to investigate laryngeal cancer treatment strategies and outcome in patients treated at the Karolinska University Hospital 2000-2020. Furthermore, we want to see if we can find good predictors to better select those patients whose tumors should receive radiotherapy (read radiation sensitive) and those where surgery becomes the primary choice. We also want to see if we can streamline care and follow-up without affecting the quality of care.

The research project preliminarily consists of several sub-projects, all with the aim of highlighting the characteristics and treatment outcomes of laryngeal cancer:

1. A descriptive retrospective study with the purpose to acquire data on the management and outcome of laryngeal squamous cell cancer for patients treated at the Karolinska University Hospital 2000-2020.
2. To specifically evaluate treatment and outcome for large cancers of the larynx, i.e. T3 and T4 tumours. We will specifically analyse x-rays and control the tumors for size, extension of growth and destruction of cartilage.
3. To evaluate the treatment of T3, T4 laryngeal cancer with the Bayesian network model based on observation data. We will analyse 18 variables on approximately 300 Swedish and Finnish patients.

In the research group we also have collaboration with Prof. Mäkitie from Helsinki, Finland. Thus, we aim to compare data on the management and outcome for laryngeal cancer patient in Sweden and Finland.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Rasmus Blomkvist

### Ethical permit No.

2019-04829			
------------	--	--	--

### Publications 2020, 2021, 2022

1. A descriptive study highlighting the differences in the treatment protocol for oral tongue cancer in Sweden and Finland. Mäkitie A, Kamali A, Mroueh R, Lindford A, Koivunen P, Autio T, Lassus P, Halle M, Bäck L, Palmgren B, Hammarstedt-Nordenvall L. Mäkitie A, et al. Acta Otolaryngol. 2020 Feb;140(2):188-194. doi: 10.1080/00016489.2019.1699663. Epub 2019 Dec 18. Acta Otolaryngol. 2020. PMID: 31852347
2. Postsurgical pyoderma gangrenosum and flap necrosis in a head and neck cancer patient following neck dissection. Arebro J, Palmgren B. Arebro J, et al. Clin Case Rep. 2020 Apr 8;8(7):1121-1125. doi: 10.1002/ccr3.2828. eCollection 2020 Jul. Clin Case Rep. 2020. PMID: 32695340
3. Blomkvist, R, Marklund, L, Hammarstedt-Nordenvall, L, Gottlieb-Vedi, E, Mäkitie, A, Palmgren, B. Treatment and outcome among patients with laryngeal squamous cell carcinoma in Stockholm—A population-based study. Laryngoscope Investigative Otolaryngology. 2023; 1- 9. doi:10.1002/lio2.1034



**Henrik Smeds**  
MD, PhD  
+46 702 481035  
henrik.smeds@regionstockholm.se

## Cochlear Implantation in Children with Cochlear Malformation

Cochlear implantation makes hearing restoration possible in patients with severe to profound hearing loss. Our research today focus on clinical studies of cochlear implantation in children with cochlear malformations. During the last years we have examined the effects of cochlear implant surgery on children with x-linked (DFNX2) inner ear malformation. We describe surgical techniques necessary for safe cochlear implantation, and further show that implantation permits hearing restoration and the development of spoken language in these children. Further analysis of hearing and language outcomes, cognition and mental health revealed poorer outcome in hearing, language and mental health and lower executive functional level, as compared to a control group. Genetic analysis confirmed mutations in the POU3F4 gene on the X-chromosome. X-linked malformation deafness has been considered non-syndromic. However, we have shown that these children exhibit signs of neuro-developmental problems consistent with attention deficit and hyperactivity, which is likely related to the POU3F4 mutation. Additionally, during the last years the group has focused on refinement of the classification of inner ear malformations on CT and MRI, including the vestibular system.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Kaijsa Edholm	Eleonor Koro (Umeå)
	Jonas Frodlund

### Ethical permit No.

2014/2068-31/2				
----------------	--	--	--	--

### Publications 2020, 2021, 2022

1. X-linked Malformation Deafness: Neurodevelopmental Symptoms Are Common in Children With IP3 Malformation and Mutation in POU3F4. Smeds H, Wales J, Karlsson E, Anderlid BM, Henricson C, Asp F, Anmyr L, Lagerstedt-Robinson K, Löfkvist U. *Ear Hear*. 2021 Jun 15;43(1):53-69.
2. Wideband tympanometry in ears with superior canal dehiscence before and after surgical correction. Velikoselskii A, Papatziamos G, Smeds H, Verrecchia L. *Int J Audiol*. 2021 Aug 21:1-6.

**Pär Stjärne**  
Adjunct Professor, Consultant  
+46 70 725 0749  
par.stjarne@regionstockholm.se



## Clinical studies on upper airway inflammation, skullbase and sinonasal tumors and treatment of facial fractures.

Inflammation in the upper respiratory tract ; mechanistic mapping and evaluation of medical and surgical intervention . The project contains two parts:

1. Studies of mechanisms in pregnancy rhinitis and its effect on the pregnant woman's quality of life.
2. Epidemiologic studies on acute rhinosinusitis in children. The overall objective is to understand the basic epidemiology and mechanisms and but also to improve the treatment of these patient groups.

Studies on olfactory basic mechanisms and effects on quality of life in olfactory dysfunction.

Zygomatic and orbital blow out fractures ; diagnosis and evaluation of treatment The project includes both retrospective studies as prospective randomized trials and aims to improve the management of patients with facial fractures . Some questions that we want to highlight : •To what extent does the change in orbital volume upon an orbital fracture influence patient's symptoms and what other factors are important for the development of sequelae •What is the significance of fixation of facial fractures in relation to adequate fracture reduction

Studies of sinonasal tumors and pituitary adenomas: We have created an interdisciplinary network that aims to study sinonasal tumors and pituitary adenomas . The network, which covers most aspects from "bench to bedside ", has all prerequisites to get powerful synergies both in terms of basic knowledge about the tumor pathophysiology and epidemiology as well as the implementation of new discoveries in clinical work.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Ola Fridman Bengtsson	Samin Rahbin
	Sofie Henecke

### Ethical permit No.

2012/4931	2018/302-31	2019/04287-1	
-----------	-------------	--------------	--

### Publications 2020, 2021, 2022

1. Bengtsson OF, Sunnergren O, Segerhammar I, Förander P, Olsson M, Hulting AL, Stjärne P. Remission, complications, and overall survival in transsphenoidal pituitary surgery-a Swedish single-center experience of 578 patients. *Acta Neurochir (Wien)*. 2023 Mar;165(3):685-692. doi: 10.1007/s00701-022-05456-8. Epub 2023 Jan 20. PMID: 36662287
2. Stjärne P, Nguyen DT, Kuhl HC. Real-Life Effectiveness of MP-AzeFlu (Dymista®) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale. *Pragmat Obs Res*. 2023 Jan 4;14:1-11. doi: 10.2147/POR.S375403. eCollection 2023. PMID: 36628265
3. Hultman Dennison S, Hertting O, Bennet R, Eriksson M, Holmström M, Schollin Ask L, Lindstrand A, Dimitriou P, Stjärne P, Granath A. A Swedish population-based study of complications due to acute rhinosinusitis in children 5-18 years old. *Int J Pediatr Otorhinolaryngol*. 2021 Nov;150:110866. doi: 10.1016/j.ijporl.2021.110866. Epub 2021 Aug 5.

4. Lundström J, Stjärne P. Förlorat luktsinne – möjligt tidigt tecken på covid-19. *Lakartidningen*. 2020 Apr 8;117:F3P9.
5. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Matricardi PM, Meco C, O Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksić A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia T, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, Lal D, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kjeldsen A, Klimek L, Kim SW, Letort JJ, Lopatin A, Mahdjoubi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raptopoulos M, Rombaux P, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Snidvongs K, Soklic Kosak T, Stjärne P. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology*. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600. PubMed PMID: 32077450.
6. Elliot A, Nasman A, Westman M, Hammarstedt-Nordenvall L, Stjärne P, Marklund L. Stathmin and EGFR correlates to HPV status and clinical outcome in sinonasal inverted papilloma. *Rhinology*. 2020 Feb 1;58(1):74-79. doi: 10.4193/Rhin19.078. PubMed PMID: 31710049.
7. Cardell LO, Stjärne P, Jonstam K, Bachert C. Endotypes of chronic rhinosinusitis: impact on management. *J Allergy Clin Immunol*. 2020 Jan 27. pii: S0091-6749(20)30108-1. doi: 10.1016/j.jaci.2020.01.019. [Epub ahead of print] PubMed PMID: 32001254.

**Joar Sundman**

MD, PhD.

+46 73 6004878

joar.sundman@regionstockholm.se



## **Long-term follow-up of RCT Uvulopalatopharyngoplasty vs Tonsillectomy**

The TEAMUP randomized clinical trial demonstrated that modified uvulopalatopharyngoplasty (UPPP) was not more effective than tonsillectomy (TE) alone in treating patients with tonsillar hypertrophy and moderate to severe obstructive sleep apnea (OSA). Because TE alone is less extensive, it could be considered as an alternative to mUPPP in this selected group of patients with OSA. The longterm effect is still unknown, but could be evaluated by performing an additional polysomnography 5-7 years after surgery. The present study aims to do this.

### **Supervision of PhD-students:**

Main Supervisor	Co-supervisor

### **Ethical permit No.**

2015/755-31/2				
---------------	--	--	--	--

### **Publications 2020, 2021, 2022**

1. Identification of resident memory CD8+ T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. Niessl J, Sekine T, Lange J, Konya V, Forkel M, Maric J, Rao A, Mazurana L, Kokkinou E, Weigel W, Llewellyn-Lacey S, Hodcroft EB, Karlsson AC, Fehrm J, Sundman J, Price DA, Mjösberg J, Friberg D, Buggert M. *Sci Immunol*. 2021 Oct 22;6(64)
2. Long-term evaluation of satisfaction and side effects after modified uvulopalatopharyngoplasty. Friberg D, Sundman J, Browaldh N. *Laryngoscope*. 2020 Jan
3. Eight-Year Follow-up of Modified Uvulopalatopharyngoplasty in Patients With Obstructive Sleep Apnea. Sundman J, Browaldh N, Fehrm J, Friberg D. *Laryngoscope*. 2021 Jan
4. Effectiveness of Tonsillectomy vs Modified Uvulopalatopharyngoplasty in Patients With Tonsillar Hypertrophy and Obstructive Sleep Apnea The TEAMUP Randomized Clinical Trial Sundman, J, MD, PhD; Pia Nerfeldt, MD, PhD; Johan Fehrm, MD, PhD; Johan Bring, PhD; Nanna Browaldh, MD, PhD; Danielle Friberg, MD, PhD *JAMA Otolaryngol Head Neck Surg*. 2022 (2022 Nov, online)



**Bo Tideholm**  
MD, PhD.  
+46 769 480 400  
bo.tideholm@ki.se

## Hearing and speech with bilateral implants

The research focus on language development in children who have undergone surgery with hearing implants, on the development of both language and other development in these subjects. There is new material, non-analyzed subgroups and other aspects to use to deepen the research field and knowledge. The research will elucidate the language development in subjects operated with cochlear implants and bone anchored hearing aids. Language understanding and development, localization of sound is focus

### Supervision of PhD-students:


<i>Main Supervisor</i>	<i>Co-supervisor</i>
	Fatima Moumén Denanto

### Ethical permit No.

2013/104-31/	2013/1127-31/2	2013/104-31/4	
--------------	----------------	---------------	--

### Publications 2020, 2021, 2022

1. Denanto FM, Wales J, Tideholm B, Asp F. Differing Bilateral Benefits for Spatial Release From Masking and Sound Localization Accuracy Using Bone Conduction Devices. *Ear Hear.* 2022 Nov-Dec;43(6):1708-1720.
2. Karlstrom E, Eklöf M, Östlund E, Asp F, Tideholm B, Löfkvist U. Cochlear implants before 9 months of age led to more natural spoken language development without increased surgical risks. *Acta Paediatr.* 2020 Feb;109(2):332-341.



## **Treatment with monoclonal antibodies in patients with chronic rhinosinusitis with nasal polyps**

A randomized, double-blind, head to head comparison of dupilumab versus omalizumab in severe chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma patients.

This is a multicenter study and the aim of the study is to evaluate the efficacy profile of dupilumab is superior compared to omalizumab in treating patients with severe CRSwNP and comorbid asthma.

A randomized, double-blind, parallel group Phase III study to assess the efficacy and safety of 100mg Desmepemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.

This is a multicenter study. The aim of the study is to evaluate the efficacy and safety of desmepemokimab which is a new monoclonal antibody administered every 6 months in a period of 52 weeks in patients with CRSwNP.

### **Supervision of PhD-students:**

<i>Main Supervisor</i>	<i>Co-supervisor</i>

### **Ethical permit No.**

--	--	--	--	--

### **Publications 2020, 2021, 2022**



**Inger Uhlén**

Associate Professor  
+46 73 9661649  
inger.uhlen@ki.se

## Pre-/retrospective, genetic studies and habilitation of hearing loss in children.

The goal is to better understand the etiopathology and evolution of sensorineural hearing loss (SHL) in children. It will help build up better interventional methods and habilitation models for children with SHL. In Sweden children undergo a newborn hearing screening as well as childhood hearing tests to detect SHL for early intervention important for the development of normal speech and language. All children diagnosed are enrolled in our Hearing and habilitation centre for children and youth, registered in a database called Audiohab, where they are followed until adulthood by a multiprofessional team covering their medical, behavioral, psychological and social needs. All children in Stockholm are gathered in a single medical unit which gives us a unique opportunity to assess and follow-up hearing loss in childhood.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Andra Lazar

### Ethical permit No.

2020-07203			
------------	--	--	--

### Publications 2020, 2021, 2021

1. Hoeve HLJ, Goedegebure A, Carr G, Davis A, Mackey AR, Bussé AML, Uhlén IM, Qirjazi B, Kik J, Simonsz HJ, Heijnsdijk EAM. Modelling the cost-effectiveness of a newborn hearing screening programme; usability and pitfalls. International journal of audiology 2023 ; 1-7View in Medline
2. Edvall NK, Mehraei G, Claeson M, Lazar A, Bulla J, Leineweber C, Uhlén I, Canlon B, Cederroth CR. Alterations in auditory brain stem response distinguish occasional and constant tinnitus. The Journal of clinical investigation 2022 132;5 View in Medline View in Web of Science
3. Kik J, Heijnsdijk EAM, Mackey AR, Carr G, Horwood AM, Fronius M, Carlton J, Griffiths HJ, Uhlen IM, Simonsz HJ, Consortium CCJPOTES. Availability of data for cost-effectiveness comparison of child vision and hearing screening programmes. JOURNAL OF MEDICAL SCREENING 2022 ; 9691413221126677- View in Medline View in Web of Science
4. Flynn T, Uhlén I, Miniscalco C. Hearing aid use in 11-year-old children with mild bilateral hearing loss: Associations between parent and child ratings and datalogging. International journal of pediatric otorhinolaryngology 2022 156; 111120- View in Medline View in Web of Science
5. Duan ML, Xie W, Persson L, Hellstrom S, Uhlen I. Postnatal hearing loss: a study of children who passed neonatal TEOAE hearing screening bilaterally. ACTA OTO-LARYNGOLOGICA 2022 142;1 61-66 View in Medline View in Web of Science
6. Mackey AR, Bussé AML, Del Vecchio V, Mäki-Torkko E, Uhlén IM. Protocol and programme factors associated with referral and loss to follow-up from newborn hearing screening: a systematic review. BMC pediatrics 2022 22;1 473- View in Medline View in Web of Science
7. Mackey AR, Bussé AML, Hoeve HLJ, Goedegebure A, Carr G, Simonsz HJ, Uhlén IM, EUSCREEN Foundation. Assessment of hearing screening programmes across 47 countries or regions II: coverage, referral, follow-up and detection rates from newborn hearing screening. International journal of audiology 2021 60;11 831-840 View in Medline View in Web of Science
8. Bussé AML, Mackey AR, Carr G, Hoeve HLJ, Uhlén IM, Goedegebure A, Simonsz HJ, EUSCREEN Foundation. Assessment of hearing screening programmes across 47 countries or regions III: provision of childhood hearing screening after the newborn period. International journal of audiology 2021 60;11 841-848 View in Medline View in Web of Science

9. Bussé AML, Mackey AR, Hoeve HLJ, Goedegebure A, Carr G, Uhlén IM, Simonsz HJ, EUSCREEN Foundation. Assessment of hearing screening programmes across 47 countries or regions I: provision of newborn hearing screening. *International journal of audiology* 2021;60;11 821-830 View in Medline View in Web of Science
10. Engström E, Kallioinen P, Nakeva von Mentzer C, Lindgren M, Sahlén B, Lyxell B, Ors M, Uhlén I. Auditory event-related potentials and mismatch negativity in children with hearing loss using hearing aids or cochlear implants - A three-year follow-up study. *International journal of pediatric otorhinolaryngology* 2021;140; 110519- View in Medline View in Web of Science
11. Verkleij ML, Heijnsdijk EAM, Bussé AML, Carr G, Goedegebure A, Mackey AR, Qirjazi B, Uhlén IM, Sloot F, Hoeve HLJ, de Koning HJ, Country-Committees Joint-Partnership of EUSCREEN Study Consortium. Cost-Effectiveness of Neonatal Hearing Screening Programs: A Micro-Simulation Modeling Analysis. *Ear and hearing* 2021;42;4 909-916 View in Medline View in Web of Science
12. Cederroth CR, Lugo A, Edvall NK, Lazar A, Lopez-Escamez JA, Bulla J, Uhlen I, Hoare DJ, Baguley DM, Canlon B, Gallus S. Association between Hyperacusis and Tinnitus. *JOURNAL OF CLINICAL MEDICINE* 2020;9;8 View in Medline View in Web of Science
13. Engström E, Kallioinen P, Lindgren M, Nakeva von Mentzer C, Sahlén B, Lyxell B, Uhlén I. Computer-assisted reading intervention for children with hearing impairment using cochlear implants: Effects on auditory event-related potentials and mismatch negativity. *International journal of pediatric otorhinolaryngology* 2020;137; 110229- View in Medline View in Web of Science
14. Uhlén I, Kovacsics B, Möller C. [Possibilities to diagnose hearing impairment in children]. *Lakartidningen* 2020;117; View in Medline
15. Uhlen I, Mackey A, Rosenhall U. Prevalence of childhood hearing impairment in the County of Stockholm - a 40-year perspective from Sweden and other high-income countries. *INTERNATIONAL JOURNAL OF AUDIOLOGY* 2020;59;11 866-873 View in Medline View in Web of Science
16. Lugo A, Edvall NK, Lazar A, Mehraei G, Lopez-Escamez JA, Bulla J, Uhlen I, Canlon B, Gallus S, Cederroth CR. Relationship between headaches and tinnitus in a Swedish study. *SCIENTIFIC REPORTS* 2020;10;1 8494- View in Medline View in Web of Science
17. Niu K, Brandström A, Skenbäck S, Duan M, Uhlén I. Risk factors and etiology of childhood hearing loss: a cohort review of 296 subjects. *Acta oto-laryngologica* 2020;140;8 668-674. View in Medline View in Web of Science
18. Trpchevska N, Bulla J, Prada Hellberg M, Edvall NK, Lazar A, Mehraei G, Uhlen I, Schlee W, Canlon B, Gallus S, Lopez-Escamez JA, Cederroth CR. Sex-Dependent Aggregation of Tinnitus in Swedish Families. *Journal of clinical medicine* 2020;9;12 View in Medline View in Web of Science



**Luca Verrecchia**  
Consultant, PhD.  
+46 8 12387401  
luca.verrecchia@ki.se

## Objective balance testing in children

This project, linked to the doctoral eduction of MD Niki Karpeta, of PT Susanne Gripenberg and post doctoral studies of M.Sc.EE., PhD Martin Eklöf aims to validate a modern pediatric objective balance testing in clinical practice. An ongoing validation study is about the balance screening of newborns with vestibular evoked miogenic potentials (VEMP), along with the universal hearing screening program. An observational study deals with the testining of vestibular function and motor proficiency in CI recipients grown up to teenage with the help also of inertial sensors for an automatized analysis by machine learing. A third study is a retrospective analysis of the vestibular function in a cohort of deaf children with eight nerve aplasia/hypoplasia. This project is supported by SCAPA (<https://ki.se/clintec/om-scapa>), a research organisation at CLINTEC for advanced clinical research in pediatric audiology and neu-rotology, which I lead togheter with assoc. professor Erik Berninger and M. Sc. CS, PhD Filip Asp.

## New methods for a better diagnosis of dizziness by bone conducted stimulation

The project represents my post-doctoral studies, as guest researcher at the Department of Electrical Engineering, Chalmers University of Technology. Supervised by full professor Bo Håkansson and assoc professor Sabine Reinfeldt, I'm testing the clinical use of a new bone transducer prototype, the Ortofon B250. In a recently published study we presented a new hearing test based on bone conducted stimulation at malleolus by B250 as a screening test for superior canal dehiscence syndrome (SCDS). We are also investigating the role of B250 in easing and promoting the clinical balance testing by VEMP. Finally we will introduce this device in VEMP testing for children and in testing the so called vibration induced nystagmus.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Susanne Gripenberg	Niki Karpeta
	Andra Lazar

### Ethical permit No.

2013/1177-31	2019-05214	2019-02019	2022-00863-02	
--------------	------------	------------	---------------	--

## Publications 2020, 2021, 2022

- Verrecchia L, Fredén Jansson KJ, Westin M, Velikoselskii A, Reinfeldt S, Håkansson B. Ankle Audiometry: A Clinical Test for the Enhanced HearingSensitivity for Body Sounds in Superior Canal Dehiscence Syndrome. *Audiol Neurotol*. 2023 Jan;12:1-11. PMID:36634643.
- Verrecchia L, Edholm K, Pekkari M. Asymptomatic superior semicircular canal dehiscence. *J Laryngol Otol*. 2022 Jan;136(1):87-90. PMID: 34702381.
- Velikoselskii A, Papatziamos G, Smeds H, Verrecchia L. Wideband tympanometry in ears with superior canal dehiscence before and after surgical correction. *Int J Audiol*. 2022 Aug;61(8):692-697. PMID: 34420430.
- Lazar A, Löfkvist U, Verrecchia L, Karlsson E. Identical twins affected bycongenital cytomegalovirus infections showed different audio-vestibularprofiles. *Acta Paediatr*. 2021 Jan;110(1):30-35. PMID: 32956548.
- Verrecchia L, Galle Barrett K, Karlsson E. The feasibility, validity and reliability of a child friendly vestibular assessment in infants and children candidates to cochlear implant. *Int J Pediatr Otorhinolaryngol*. 2020 Aug;135:110093. PMID: 32422368.
- Wibble T, Engström J, Verrecchia L, Pansell T. The effects of meclizine on motion sickness revisited. *Br J Clin Pharmacol*. 2020 Aug;86(8):1510-1518. PMID: 32077140.

**Mathias von Beckerath**

M.D., Ph.D.

+46 704 223314

[mathias.vonbeckerath@regionstockholm.se](mailto:mathias.vonbeckerath@regionstockholm.se)



## New methods in Head and Neck Surgery

I am involved in the following projects as a supervisor:

- DI- a new swedish questionaire to determine high airway stenosis. The project evaluates the questionaire and validates it. With E Ntouniadakis
- Kort-SGS an evaluation of the technique to treat tracheal stenosis with corticosteroid injections in the stenosis after surgery. With E Ntouniadakis
- Ultrasound guided resections of tounge cancers and evaluation of ultrasound as method of determining tumour thickness in oral cancers compared with MR/CT and palpation. NBI-guided tounge resections to determine dysplasia/cancer in situ around tumors excised. Outcome of different resections in mandibular cancers. With O Nilsson
- A post treatment study of how HPV status affected the outcome of radiation therapy of oropharyngeal cancer. With Anna Oldaeus
- A prospective study of the realtionship between relapse and circulating HPV-virus after treatment of orofaryngeal HPV-positive cancer. With Anna Oldaeus
- Outcome after tracheostomies during the Covid-19 pandemic. With Clara Svenberg Lind.
- Apart from this i am focusing on the Sentinel Node technique in oral and salivary gland cancers and also in cutaneus malignancies.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
	Eleftherios Ntouniadakis
	Olof Nilsson
	Anna Oldaeus Almeren
	Clara Svenberg Lind

### Ethical permit No.

2019-0323	2018-104	2015-548	2016-275	2016-193
-----------	----------	----------	----------	----------

### Publications 2020, 2021, 2022

1. Axelsson L, Holmberg E, Nyman J, Hogmo A, Sjodin H, Gebre-Medhin M, et al. Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival. *Int Arch Otorhinolaryngol.* 2021 Jul;25(3):e433-e42. PubMed PMID: 34377181. Pubmed Central PMCID: PMC8321641. Epub 2021/08/12. eng.
2. Ntouniadakis E, Brus O, von Beckerath M. Dyspnea Index: An upper airway obstruction instrument; translation and validation in Swedish. *Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.* 2021 Mar;46(2):380-7. PubMed PMID: 33277799. Pubmed Central PMCID: PMC7986702. Epub 2020/12/06.
3. von Beckerath M, Svensson J, Landstrom F. Feasibility of an inexperienced examiner using trans-cervical ultrasound in the diagnosis of peritonsillar abscesses. *Acta Otolaryngol.* 2021 Sep;141(9):847-50. PubMed PMID: 34392793. Epub 2021/08/17.
4. Hammarstedt Nordenvall L, Jortso E, von Beckerath M, Tani E, Nordemar S, Bark R. Prevalence of cystic metastases in a consecutive cohort of surgically removed branchial cleft cysts. *Acta Otolaryngol.* 2022 Jan;142(1):100-5. PubMed PMID: 34962438. Epub 2021/12/29.

5. Nilsson O, Knutsson J, Landstrom FJ, Magnuson A, von Beckerath M. Ultrasound accurately assesses depth of invasion in T1-T2 oral tongue cancer. *Laryngoscope Investig Otolaryngol*. 2022 Oct;7(5):1448-55. PubMed PMID: 36258857. Pubmed Central PMCID: PMC9575113. Epub 2022/10/20.
6. Nilsson O, Knutsson J, Landstrom FJ, Magnuson A, von Beckerath M. Ultrasound-assisted resection of oral tongue cancer. *Acta Otolaryngol*. 2022 Sep-Dec;142(9-12):743-8. PubMed PMID: 36537851. Epub 2022/12/21.
7. Ntouniadakis E, Sundh J, von Beckerath M. Monitoring Adult Subglottic Stenosis With Spirometry and Dyspnea Index: A Novel Approach. *Otolaryngol Head Neck Surg*. 2022 Sep;167(3):517-23. PubMed PMID: 34813409. Pubmed Central PMCID: PMC9442627. Epub 2021/11/24.

Jeremy Wales

MD, PhD

+46 8 585 76616

jeremy.wales@regionstockholm.se



## 1. Temporal bone malformation.

Children with temporal bone malformations often present with a significant progressive hearing loss. Cochlea implantation is often needed to improve speech understanding and for the patient to develop the ability to communicate. We are investigating large vestibular aqueduct, and incomplete partition types 2 and 3 malformations. We are assessing new methods in radiological diagnosis, implantation technique, hearing and related neurological factors.

## 2. Intraoperative assessment of the ossicular chain.

Ossicular fixation in the middle ear is one cause of conductive hearing loss where there is no reliable objective system to assess this. We are developing a system (MIVIB) utilising laser vibrometry to assess the movement of the ossicular chain to determine which operation and which prosthesis will give the best hearing result.

## 3. Bilateral bone anchored hearing solutions.

Bone-anchored hearing solutions are often implanted unilaterally. We are assessing whether patients have an improved ability to localise sound and hear when background noise is present if they are provided with bilateral BAHS.

## 4. Tracheostomy in the era of Covid-19.

The pandemic led to an unprecedented amount of patients requiring tracheostomy. We analyse the immediate, short- and long-term complications of this technique when performed by otolaryngologists or intensivists.

### Supervision of PhD-students:

Main Supervisor	Co-supervisor
Clara Svenberg Lind	Fatima Moumen Denanto

### Ethical permit No.

2020-02779	2018/1032-31	2014/2068-31/2		
------------	--------------	----------------	--	--

### Publications 2020, 2021, 2022

1. Denanto, F.M., Wales, J., Tideholm, B., Asp, F. Differing bilateral benefits for spatial release from masking and sound localization accuracy using bone conduction devices. *Ear and Hearing* 2022
2. Wales, J., Smeds, H., Karltorp, E., Anderlid, B.M., Henricson, C., Asp, F., Anmyr, L., Lagerstedt-Robinson, K., Löfkvist, U. X-linked Malformation Deafness: Neurodevelopmental Symptoms Are Common in Children With IP3 Malformation and Mutation in POU3F4. *Ear and hearing* 2021;():-
3. Globalsurg Collaborative, CovidSurg Collaborative. Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. *Anaesthesia* 2021;76(11):1454-1464.
4. Globalsurg Collaborative, CovidSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. *Anaesthesia* 2021;():-
5. CovidSurg Collaborative Globalsurg Collaborative. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. *The British journal of surgery* 2021;108(9):1056-1063
6. Globalsurg Collaborative, CovidSurg Collaborative. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. *Anaesthesia* 2021;76(6):748-758
7. Wales, J., Alinasab, B., Fridman Bengtsson, O. A superficial nasal dermoid cyst excised through a novel horizontal zig-zag incision in a 49-year old man. *Acta Otolaryngologica Case reports*. 2020; 5:28-32.
8. Wales, J., Gladine, K., Silvoli, J., Muyshondt, P., Topsakal, V., Van De Heyning, P., Dirckx, J., von Unge, M. Evaluation of artificial fixation of the incus and malleus with minimally invasive intraoperative laser vibrometry (MIVIB) in a temporal bone model. *Otol. Neurotol.* 2020; 41:45-51.



Malin Wendt  
MD, PhD  
+46 70 4582574  
malin.a.wendt@regionstockholm.se

## Studies on laryngotracheal airway diseases

Long-term outcome of reconstructive airway surgery in pediatric and adult patients

- Pediatric tracheostomy - mortality, morbidity and long-term outcome
- Psychosomatic development and quality of life in pediatric patients with tracheostomy
- Supraglottoplasty for laryngomalacia in pediatric patients with comorbidities

### Supervision of PhD-students:

Main Supervisor	Co-supervisor

### Ethical permit No.

--	--	--	--

### Publicatiions 2020, 2021, 2022

1. Wendt M, Hammarstedt L, Dalianis T, Landin D, Munck-Wikland E, Näsmann A, Marklund L. Long-term survival and recurrence in oropharyngeal squamous cell carcinoma, in relation to HPV and p16-status. Cancers 2021 May 23;13(11):2553.
2. Wendt M, Papatziamos G, Munck-Wikland E and Marklund L. Sclerotherapy with OK 432 on ranula – a prospective, randomised, double-blinded placebo-controlled study. ACTA Otolaryngol. 2021; 27:1-6

Arnason, Sigurdur	.....	86.
Blomkvist, Rasmus	.....	87.
Dahlby Skoog, Malin	.....	88.
Danielsson, Daniel	.....	89.
Eriksson, Björn	.....	90.
Fridman Bengtsson, Ola	.....	91.
Gille, Evelina	.....	92.
Gripenberg, Susanne	.....	93.
Häggström, Jenny	.....	94.
Jafari, Maryam	.....	95.
Johansson, Marlin	.....	96.
Josefsson, Hanna	.....	97.
Jörtsö, Evelina	.....	98.
Karlsson, Sofia	.....	99.
Karpeta, Niki	.....	100.
Kolev, Aeneas	.....	101.
Lagebro, Vilma	.....	102.
Lansing, Lovisa	.....	103.
Lazar, Andra	.....	104.
Malmström, Emma	.....	105.
Modée, Agnes	.....	106.
Moumen Denanto, Fatima	.....	107.
Ohm, Rebecka	.....	108.
Paziou, Eirini (not registered yet)	.....	109.
Piersiala, Krzysztof	.....	110.
Rahbin, Samin	.....	112.
Sepehri, Elnaz	.....	113.
Siegbahn, Malin	.....	114.
Skröder, Carl	.....	115.
Smelik, Martin	.....	116.
Starkhammar, Magnus	.....	117.
Svenberg Lind, Clara	.....	118.
Zhao, Yelin	.....	119.
Åberg, Karin	.....	120.

**Sigurdur Arnason**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

sigurdur.arnason@ki.se

Barbro Hedin Skogman

Åsa Laestadius, Elin Marsk, Malou Hultcrantz,

2019-09-27

2022-12-02

**Facial nerve palsy in children; treatment and clinical outcome**

I. Peripheral facial nerve palsy in children in a Borrelia high endemic area: epidemiology and evaluation of clinical recovery. A retrospective follow-up. To identify the incidence, etiology and prognosis of acute peripheral facial nerve palsy (FNP) in children in the Stockholm area. A retrospective study identifying children from 0-17 years of age visiting a pediatric emergency department for acute FNP during a one-year period from 2014-2015 (77 patients).

II. Efficacy of cortisone vs. placebo in children with idiopathic facial nerve palsy and Lyme neuroborreliosis facial nerve palsy. Participation in the FACE study (Facial nerve palsy And Cortisone Evaluation in children), a multicenter randomized placebo-controlled study on the efficacy of cortisone treatment in children with acute facial nerve palsy. For inclusion the cause of FNP will be either Lyme neuroborreliosis (LNB) or idiopathic facial palsy. Children with LNB will be treated with antibiotics according to present guidelines in combination with the treatment provided in the study (cortisone vs. placebo). Follow-up will take place via telephone and with follow-up visits at 1 and 12 months. Subjects will be graded according to the House-Brackmann and the Sunnybrook facial grading scales and specific standardized facial palsy questionnaires.

III. Long term outcome and neurophysiologic findings in idiopathic facial nerve palsy in a pediatric population. This study will aim to highlight the long-term prognosis of 50 children affected by idiopathic facial nerve palsy. The aim is to follow-up the children with idiopathic facial palsy and record subjective, objective and neurophysiological findings.

IV. Detection of brain damage markers S-100B and NSE in serum in children with Lyme neuroborreliosis for evaluation as prognostic marker for clinical outcome. The brain damage markers S-100 B and NSE (Neuron-specific enolase) will be analyzed in serum in children with LNB and in a non-neuroinflammatory group.

**Ethical permit No.**

2016/1937-31/4	2017/554	2010/106	2021-01926	2022-03295-02
----------------	----------	----------	------------	---------------

**Publications/manuscripts 2020, 2021, 2022**

1. Arnason S, Hultcrantz M, Nilsson A, Laestadius Å. Peripheral facial nerve palsy in children in a Borrelia high-endemic area, a retrospective follow-up study. *Acta paediatrica*. 2020;109(6):1229-35.
2. Karlsson S, Arnason S, Hadziosmanovic N, Laestadius Å, Hultcrantz M, Marsk E, et al. The facial nerve palsy and cortisone evaluation (FACE) study in children: protocol for a randomized, placebo-controlled, multicenter trial, in a Borrelia burgdorferi endemic area. *BMC pediatrics*. 2021;21(1):220.
3. Arnason S, Skogman BH. Effectiveness of antibiotic treatment in children with Lyme neuroborreliosis - a retrospective study. *BMC Pediatr*. 2022 Jun 9;22(1):332.
4. Arnason S, Molewijk K, Henningsson AJ, Tjernbeg I, Skogman BH. Brain damage markers neuron-specific enolase (NSE) and S100B in serum in children with Lyme neuroborreliosis – detection and evaluation as prognostic biomarkers for clinical outcome. *Eur J Clin Microbiol Infect Dis*. 2022 Jul;41(7):1051-1057.

**Rasmus Blomkvist**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

rasmus.blomkvist@ki.se

Linda Marklund

Björn Palmgren, Lalle Hammarstedt-Nordenvall,

Antti Mäkitie

2021-02-16

**Predictive markers for laryngeal cancer**

Cancer of the vocal cords, laryngeal cancer, is one of the most common tumor types in the head and neck region with approximately 180 new cases each year in Sweden. Whereas the survival rate for small tumors (T1) is relatively good, more advanced disease (T2-T4) is associated with poor outcome and has not improved significantly in recent decades. In Sweden and in Stockholm according to national guidelines, patients with T2 and T3 laryngeal cancer are treated with radiotherapy (RT) or chemoradiotherapy (CRT) to preserve the patient's larynx, while patients with T4-tumors are treated surgically with laryngectomy, i.e. resection of the entire larynx and upper trachea often in combination with adjuvant RT/CRT. Our own data and other studies show that there is poorer survival for patients with T3 compared with T4 laryngeal cancer. It is clear that many patients with tumors classified as T3 are undertreated. The question is how to identify which laryngeal tumors that are in need of extended treatment to avoid recurrence and death from laryngeal cancer.

All our sub-studies in this research project aim to identify clinically useful markers and methods that can help us to optimize the choice of treatment strategy for patients with advanced laryngeal cancer.

**Ethical permit No.**

2019-04829

**Publications/manuscripts 2020, 2021, 2022**

1. Blomkvist, R, Marklund, L, Hammarstedt-Nordenvall, L, Gottlieb-Vedi, E, Mäkitie, A, Palmgren, B. Treatment and outcome among patients with laryngeal squamous cell carcinoma in Stockholm—A population-based study. *Laryngoscope Investigative Otolaryngology*. 2023; 1- 9.

**Malin Dahlby Skoos**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

malin.dahlby.skoog@ki.se

Ulrika Löfkvist

Eva Karlsson, Björn Lyxell, Tamara Kalandadze

2021-09-06

**Long term effects of early age at cochlear implantation on metaphor comprehension and executive functions in Swedish teenagers**

Early age at cochlear implantation has positive effects on early spoken language for congenitally deaf children, but there is need for more research on the long-term effects of early implantation to explain the large variability in outcomes seen in this group. The research regarding long term effects of cochlear implantation on higher linguistic skills, such as metaphor comprehension, is scarce. Executive functions are higher cognitive functions including working memory, attention shifting and inhibitory control. Executive functions develop in close relationship with linguistic skills.

The aim of this project, as part of a multidisciplinary follow up program, is to investigate long term effects of early cochlear implantation on the development of executive functions and metaphor comprehension. We are also interested in the possible relationship between executive functions and the higher linguistic skill of metaphor comprehension. The cohort is estimated to be around 100 individuals between 13 and 18 years old, fitted with CI before 30 months of age at the Hearing Implantation Center at Karolinska university hospital. There will also be a normal hearing control group matched for age, sex and socioeconomic status. Children from multilingual as well as monolingual homes will be included.

Metaphor comprehension will be measured using a multiple-choice task. Linguistic skills (vocabulary and reading) will be assessed with standardized tests. Executive functions will be assessed by task performance and the BRIEF questionnaire.


Data collection is planned to start in january 2022

**Ethical permit No.**

2021-04345				
------------	--	--	--	--

**Publications/manuscripts 2020, 2021, 2022**

1. Löfkvist, U., Bäckström, K., Dahly-Skoog, M., Gunnarsson, S., Persson, M., Lohmander, A. (2019). Babbling and consonant production in children with hearing impairment who use hearing aids or cochlear implants – a pilot study. Logopedics Phoniatrics Vocology, Nov 29:1-9. doi: 10.1080/14015439.2019.1695929

**Daniel Danielsson**

Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

daniel.danielsson@ki.se

Eva Munck-Wikland  
Siamak Haghdoost  
2008-10-08  
2020-06-17

## Osteoradionecrosis - Riskfactors and reconstructive outcome

Irradiation, surgery and chemotherapy are the three main treatment modalities for head and neck cancer patients. Irradiation, especially in combination with chemotherapy, is associated with considerable side effects.

Osteoradionecrosis, ORN, is a late and often severe side effect to irradiation. It is defined as necrotic bone exposed through a mucosal and/or skin defect without tumor recurrence and with a duration of more than three months.

There is no exact definition of the pathophysiology of ORN but the current thesis include:

1. Direct damage to local micro vessels causing vascular necrosis in the irradiated area.
2. Production of ROS(reactive oxygen species) that gives an irreversible damage to osteoblasts, -cytes, -clasts.
3. Cytokine mediated dysregulation of fibroblasts and collagen metabolism leading to fibrotic tissue. ORN is for the individual patient a severe condition affecting daily life. Symptoms include trismus, pain, impaired nutritional capacity and infection not seldom associated with oro-cutaneous fistula. ORN is seldom reversible and will progress over time leading to pathological fractures and need for extensive reconstructive surgical intervention including free tissue transfer. This treatment is costly to both patient and society.

Radiation therapy is dose dependant but individual differences exists. The incidence of ORN in the head and neck area is reported to 3-8%.

Aim of our studies:

1. Possible markers for individual radiosensitivity; oxidative stress response, genetic and protein level
2. Osteoradionecrosis impact on indications for extensive maxillomandibular reconstruction
3. Quality of life comparative study for ORN patients before and after extensive reconstructive surgery with free tissue transfer.
4. Impact of Brachy therapy in onset of ORN in patients treated for cancer of the tongue

### Ethical permit No.

2006/1413-32	2016/1578-32	2016/277-32	2016/506-31	
--------------	--------------	-------------	-------------	--

### Publications/manuscripts 2020, 2021, 2022

5.

**Björn Eriksson**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

bjorn.eriksson@ki.se

Caroline Gahm

Martin Halle, Liv Eidsmo, Lalle Hammarsted Nordenvall

2018-01-29

2022-12-09

**Inflammatory changes of soft tissue after radiotherapy**

Reconstruction with free tissue transfer is a well established treatment modality for patients with advanced head and neck cancer. A majority of these patients also receive pre- or postoperative radiotherapy. Radiation-induced injury to surrounding healthy tissue is an important limitation of radiotherapy. Epidemiologic studies have shown an increased risk for cardiovascular events, e.g. stroke and myocardial infarction, in patients that have been irradiated. Biopsies from arteries and veins in this patient group have demonstrated acute and chronic inflammatory changes, believed to contribute to post-treatment complications and a decreased quality of life. Preoperative radiotherapy affects tissue healing properties and increased the risk of postoperative infections and fistulas in our material. Through investigations with immunohistochemistry and gene expression analysis of skin biopsies from patients as well as from a murine model we aim to contribute to the understanding of post-therapeutic inflammation and tissue fibrosis in skin after radiotherapy.

**Ethical permit No.**

2006/834-31	2012/1663-32	2016/1578-32	2008-484-31/2	2008/114-31
-------------	--------------	--------------	---------------	-------------

**Publications/manuscripts 2020, 2021, 2022**

1. Eriksson, B.O, Gahm C., Halle, M; Gene expression analysis and long-term presence of macrophages in irradiated skin in head and neck cancer patients compared to irradiated mice (manuscript, 2023)

**Ola Fridman Bengtsson**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

ola.bengtsson@ki.se

Pär Stjärne

Anna-Lena Hulting, Charlotte Höybye,

Ola Sunnergren

2011-12-22

2021-01-22

**Pituitary tumors; clinical aspects of treatment and expression of Galanin,- and pattern recognition receptors**

Pituitary adenomas are classified into hormone secreting or clinically inactive. Symptoms arise either due to hormononal effects or local compression, usually the optic chiasm.

Treatment for these adenomas are either medical or surgical dependent on characteristics of the tumor. Sometimes radiation can be used for surgically unaccessible locations.

My thesis aims to evaluate treatment in Karolinska University Hospital during the time period 2005-17, focusing on cure rates in ACTH and GH producing adenomas and complications within the group as a whole. This manuscript is recently published.

We have also evaluated different treatment strategies in perioperative cortisol substitution and published on this topic 2019.

Since 2012 we have collected tissue from pituitary adenomas and pituitaries from 11 organ donors as a base for our receptor studies.

Our aim is that these 2 studies are to be completed during 2022. One study will evaluate prevalence of Galaninreceptors, especially type 3, which in previous materials have been indicated as a marker for pituitary adenomas as opposed to normal pituitary tissue.

The fourth study will investigate inflammatory markers, such as TGF Beta and Interleukin 6 among others in pituitary adenomas, compared to normal pituitary tissue

**Ethical permit No.**

2012/1689-31/4 (2019-01941)	2012/891-31/2			
--------------------------------	---------------	--	--	--

**Publications/manuscripts 2020, 2021, 2022**

1. Remission, complications, and overall survival in transsphenoidal pituitary surgery-a Swedish single-center experience of 578 patients, Acta Neurochirurgica (2023) Jan 20. doi: 10.1007/s00701-022-05456-8. Online ahead of print



**Evelina Gille**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

evelina.gille@ki.se

Lalle Hammarstedt Nordenvall

Antti Mäkitie, Elin Marsk

2020-05-25

2023-05-17

## Studies on Nasopharyngeal Cancer – a characterization of a rare disease

I: To describe the pattern of recurrence in patients treated for nasopharyngeal cancer in Stockholm. Hypothesis: Local recurrences occur outside target volume. Retrospective single institution study. Data from medical records and target volume, will be correlated to recurrence and place of recurrence, ie outside or inside target volume. Pattern of failure will teach us more on how to design treatment models in this disease. If recurrences occur outside treatment volume that might be an indication to improve treatment planning. Also to describe the distribution of different histopathological subgroups to assess the viral correlation.

II: A register-based cohort study of Nasopharyngeal Carcinoma in Sweden, using SweHNCR: outcome, failure rate and site of failure Hypothesis: Local regional failure is more common than distant failure Data from Swedish Head and Neck Cancer Registry (SweHNCR). All patients in Sweden diagnosed with Nasopharyngeal carcinoma, histology codes for Squamous cell carcinoma, Lymfoepithelioma or undifferentiated carcinoma will be included. This study will describe the pattern of failure in Sweden and thus indirectly characterize the disease as resembling either the endemic type or the non-endemic type.

III: To explore the risk of NPC among migrants and their children in Sweden. The possible improvement in outcome over time is to be compared with outcome of non-migrants. Hypothesis: Several studies indicates that there is a strong familial risk of NPC.

IV: To identify occupations and work-related exposure agents linked to NPC in the Nordic countries. The study is based on a large cohort of almost 15 million persons from the Nordic countries diagnosed with NPC in 1961-2005. The study suggests that NPC may be associated with exposure agents that are work-related such as smoking, kitchen air pollution and solvents.

### Ethical permit No.

2019-01933					
------------	--	--	--	--	--

### Publications/manuscripts 2020, 2021, 2022

1. Carpén T, Gille E, Hammarstedt-Nordenvall L, Hansen J, Heikkinen S, Lyngé E, et al. Occupational risk variation of nasopharyngeal cancer in the Nordic countries. BMC cancer. 2022;22(1):1130.

**Susanne Gripenberg**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

susanne.gripenberg@ki.se

Luca Verrecchia

Cecilia Lidbeck, Sten Hellström

2022-08-24

**Vestibular function and motor activities in children with hearing loss, balance disorders and motor delays**

The vestibular function i.e the balance function in the inner ear, is crucial for typical motor development in children and it is known that vestibular impairment can cause delays in motor development, unprotected falls and affect orientation. Up to 70% children affected by severe hearing loss show vestibular dysfunction.

My project aims to explore how a vestibular loss affects motor functioning in children and it also aims to explore the effect of an early intervention in children with difficulties with motor functioning related to vestibular dysfunction.

In a first study we explore how motor functioning relate to vestibular function in a group children and young adults with hearing loss who received CI in early childhood. The participants are assessed for vestibular function by a medical doctor and a parallel blinded assessment of motor function using motor tests, is conducted by a physiotherapist. Self-reported physical activity, and experience of balance are measured with questionnaires.

In a second study we collect data from children in study I, with inertial sensors applied on different body parts. We analyze with the help of machine learning. The principal question of this study is whether a computerized system based on inertial sensors may implement the clinical evaluation of motor patterns in children with or without vestibular impairment in comparison with age matched peers. These two studies are part of a long-time follow-up and the collection of data is ongoing.

In a third study we are planning to assess if clinical motor assessments can detect vestibular impairment in infants with hearing loss or motor delay. The infants will be tested in a similar way as the young adults with motor tests. This study is planned to start this fall.

The last study will be a pilot study, where we will evaluate a vestibular rehab intervention designed for infants and children with vestibular impairment and motor delay. This study is under planning.

**Ethical permit No.**

2021-04345	2021-00165	2021-04345	2022-00863-02		
------------	------------	------------	---------------	--	--

**Publications/manuscripts 2020, 2021, 2022**

**Jenny Häggström**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

jenny.haggstrom@ki.se

Christina Hederstierna Forshell

Esma Idrizbegovic, Per Östberg, Nenad Bogdanovic

2016-11-14

2019-05-20

## Hearing, cognition and aging

Huvudsyfte är att belysa central hörsel funktion, hur vi kan mäta den, och dess relation till kognitiv svikt. Mer specifikt att öka förståelsen hur hjärnförändringar vid demens och kognitiv svikt påverkar central hörsel funktion. Antalet äldre ökar stadigt i befolkningen tack vare att vi lever allt längre. Med stigande ålder ökar också risken av att drabbas av kognitiv svikt, demens och hörselnedsättning. En form av hörselnedsättning hos främst äldre är s.k. central auditory processing dysfunction, (CAPD). Dessa personer har svårigheter att uppfatta vad som sägs i störande ljudmiljöer med bakgrundsbuller eller när flera personer talar samtidigt, och de har inte optimal nytta av hörapparatanvändning. Den centrala hörselstörningen beror på försämrat funktion i de delar av centrala nervsystemet som ansvarar för bearbetningen av ljudstimuli. CAPD har påvisats hos patienter med lindrig kognitiv störning och Alzheimers sjukdom genom dikotiska lyssningstest. I delarbete 1 följdes tre grupper av individer med varierande kognitiv funktion med perifera och centrala hörseltestunder efter fem år. I delarbete 2 tittade vi på kognitiv utveckling hos en grupp individer med mild kognitiv störning (MCI) och jämförde kognitivt utfall under 5 år med resultat på dikotiska tester med siffror (DDT) vid baseline. I delarbete 3 korreleras resultat på DDT till deltagarnas biomarkörer i cerebrospinalvätska. I delarbete 4 kommer vi att undersöka hur förändringar i corpus callosum, som förbindar de båda hjärnhalvorna, korrelerar till resultat på DDT hos personer med Alzheimers sjukdom (AD), MCI och subjektiv minnesstörning (SMC). DDT förutsätter en intakt förbindelse mellan hjärnhalvorna via corpus callosum.

**Ethical permit No.**

2005/914-31	2014/2087-31/2	2018/1291-32	
-------------	----------------	--------------	--

**Publications/manuscripts 2020, 2021, 2022**

1. Häggström J, Hederstierna C, Rosenhall U, Östberg P, Idrizbegovic E. Prognostic Value of a Test of Central Auditory Function in Conversion from Mild Cognitive Impairment to Dementia. *Audiology & Neurotology* 2020

**Maryam Jafari**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

maryam.jafar@ki.se

Lars Olaf Cardell

Susanna Kumlien Georén, Laila Hellkvist

2022-09-30

**Studying the effects of allergen specific immunotherapy and tolerance development in allergic rhinitis**

Allergic rhinitis (AR) is a chronic condition with a 30% prevalence in Sweden. Despite widespread availability and frequent use of standard of care medication including antihistamine and nasal steroids, the majority of patients are unsatisfied and report a marked impairment in their quality of life. The high prevalence of AR and lack of satisfactory treatment leads to a loss in productivity (presenteeism) resulting in high costs for the society. Allergen-specific immunotherapy (AIT) is currently the only treatment of AR resulting in long-lasting relief of symptoms. Unfortunately, only 5% of AR patients receive this therapy, due to the extended duration of treatment required for effect (3-5 years) and the risk of severe side effects. Hence, a shorter treatment duration and an improved safety profile are stated as important unmet needs in AIT.

Pharmacotherapy is offered for patients with mild to severe nasal allergy symptoms, while allergen-specific immunotherapy (ASIT) is the main treatment for inducing long-term immunological and clinical tolerance in patient with IgE-mediated allergic disease, and is the only curative treatment. Subcutaneous immunotherapy (SCIT) is a form of ASIT. Though efficacious, SCIT prevents the progression of AR to asthma, but is time-consuming and involves numerous injections. A new form of ASIT is intra lymphatic immunotherapy (ILIT). The treatment duration for ILIT is much shorter and has comparably mild side effects.

At present little is known about how a given injected allergen during SCIT and ILIT affects immune cells in lymph nodes and how it induces immunological tolerance. The overall aim of this doctoral project is to study the immunological changes that induce tolerance to allergen in patients undergoing SCIT and ILIT in combination with vitamin D. We will focus the different projects on memory type allergen-specific T and B cell responses.

**Ethical permit No.**

2021-03633	2021-00325	2021-06514-02	
------------	------------	---------------	--

**Publications/manuscripts 2020, 2021, 2022**

1.

**Marlin Johansson**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

marlin.johansson@ki.se

Erik Berninger

Filip Asp, Sten Hellström, Kamilla Angelo

2016-11-03

2020-09-11

2023-03-31

## Children with Congenital Unilateral Sensorineural Hearing Loss: The effect of Auditory Stimulation in the Impaired Ear During Development

The overall aim is to study the causes and mechanisms underlying congenital unilateral sensorineural hearing loss (uSNHL) and the effects of intervention.

The first publication was a pilot study of hearing aid outcomes in school-aged children with congenital uNSHL. The children demonstrated both hearing aid benefit and dis-benefit. The statistically significant benefit was found in one-to-one communication, based on child and parent questionnaires. Hearing aid dis-benefit was found for sound localization measured with eye-tracking in sound field. Neither significant hearing aid benefit nor dis-benefit existed for speech understanding in background noise/speech (sound field and questionnaires) or reverberation (questionnaires). A close relationship between neural maturation and aided sound localization was also found, indicating that hearing aids may be more efficient if fitted earlier in development, before the brain adapts to asymmetrical hearing.

In the second publication we studied heredity of transient evoked otoacoustic emissions (TEOAEs), that are recorded as part of the universal neonatal hearing-screening program. We found that the TEOAEs at birth are largely inherited, perhaps more than for young adult twins. Additionally, we found that sex and ear differences existed at birth, and that the twin testosterone transfer hypothesis, that female twins with male co-twins would have masculinized TEOAEs, was not supported for neonatal twins.

We have invited 20 neonates with congenital uSNHL born in Region Stockholm to study etiology, early hearing, speech-language and communication development, and the outcomes of very early hearing aid intervention longitudinally. The manuscript with focus on etiology has been finalized and sent for review.

**Ethical permit No.**

2015/1878-31/2	2018/1500-31	2019–03826	
----------------	--------------	------------	--

**Publications/manuscripts 2020, 2021, 2022**

1. Johansson, M., Asp, F., & Berninger, E. (2020a). Children With Congenital Unilateral Sensorineural Hearing Loss: Effects of Late Hearing Aid Amplification-A Pilot Study. *Ear and Hearing*, 41(1), 55-66.
2. Johansson, M., Olofsson, Å., & Berninger, E. (2020b). Twin study of neonatal transient-evoked otoacoustic emissions. *Hearing Research*, 398, 108108.
3. Johansson, M., Karlsson, E., Edholm, K., Drott, M., & Berninger, E. (2022). A Prospective Study of Etiology and Auditory Profiles in Infants with Congenital Unilateral Sensorineural Hearing Loss. *Journal of Clinical Medicine*, 11(14), 3966.
4. Johansson, M., Karlsson, E., Asp, F., & Berninger, E. (2023). A Prospective Study of Genetic Variants in Infants with Congenital Unilateral Sensorineural Hearing Loss. *Journal of Clinical Medicine*, 12(2), 495



**Hanna Josefsson Dahlgren** hanna.josefsson@ki.se  
Main supervisor Cecilia Engmér Berglin  
Co-supervisor Filip Asp  
Registered 2017-04-07  
Halftime seminar 2022-09-02  
Planned dissertation

## Bone Conduction Devices and Active Middle Ear Implants in Children with Unilateral Aural Atresia- Functional and Qualitative Assessments

Individuals with unilateral hearing loss are known to have difficulties in situations requiring binaural processing of sounds, such as listening in noisy environments and localizing sound. This project focuses on children born with unilateral aural atresia causing a conductive hearing loss on the affected side. We aim to study the effect of habilitation with bone conduction devices (BCD) on audiological outcomes such as sound localisation ability (SLA) and speech recognition (SCS), surgical outcomes and the degree of patient satisfaction.

**Study 1:** Horizontal Sound Localization Ability and Speech Perception in Competing Speech in Children with Unilateral Aural Atresia Using Percutaneous BCD.

Children age 5-10 years with BCD is recruited for testing of PTA, SCS and SLA using corneal eye tracking.

**Study 2:** Evaluation of Bone Anchored Hearing Systems, Audiology and Fixture Mechanics.

Children with congenital conductive hearing loss suited for implantation with percutaneous BCD using a titanium fixture are included in this study that evaluates a new type of titanium screw, BHX. In collaboration with Oticon Medical.

**Study 3:** A Retrospective Chart Study of BCD Usage in Children with Aural Atresia at Karolinska University Hospital.

A retrospective chart review of children with aural atresia treated with percutaneous BCD at Karolinska University Hospital.

**Study 4:** Patient Satisfaction and Long-Term Usage of Percutaneous BCD

Subjects aged 0-18 operated with percutaneous BCD at Karolinska University Hospital 2010-2020 are asked to fill out a questionnaire regarding usage of their implant, and reasons for possible non-usage.

**Study 5:** BHAMBI, Binaural Hearing in children with unilateral Atresia using active Middle ear or Bone conduction Implants

Subjects aged 5-18 eligible for implantation with an aMEI or an active transcutaneous BCD. Per- and postoperative surgical complications are registered. Subjects will participate in standard clinical audiology, SLA and SCS.

### Ethical permit No.

2012/1661-313	2018/864-31	2021-02984	
---------------	-------------	------------	--

### Publications/manuscripts 2020, 2021, 2022

**Evelina Jörtsö**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

evelina.jortso@ki.se  
Linda Marklund  
Rusana Bark, Anders Näsmann  
2022-08-24

## Predictive markers for head- and neck tumors

### Branchial cleft cysts

\* Investigate the prevalence of cystic metastases in patients whom had a supposed branchial cleft cyst surgically removed. 13 pat out of 436 had cystic metastases (4 papillary thyroid, 3 base of tongue, 1 tonsilar, 5 CUP). HPV positivity was found in 3 out of the 9 oropharyngeal cancers and CUP.

(Paper 1, published in Acta Otolaryngologica Jan 2022)

\* Investigate if the non-presence of HPV in the cytology report from the branchial cleft cysts can be used as a predictive marker for a cystic mass on the neck to truly be a branchial cleft cyst? Is it possible to rule out tonsillectomy and biopsies in the work-up diagnostics for these patients >40 y?

(Paper 2, collecting data)

### Tonsilar and base of tongue cancer

\* Investigate if EBV, alone or in combination with HPV, p16, CD8, HLA-class is a useful prognostic marker for HPV-neg and HPV-pos tonsilar and base of tongue cancer, and see if it is possible to optimize and individualize the treatment

\* 300 patients with HPV/p16-positive tonsilar- and base of tongue cancer and 150 patients with HPV/p16-negative tonsilar and base of tongue cancer (collected 2006-2016). EBV-RNA will be detected with EBER stain.

\* Overall and disease free survival in relation to EBV presence and presence of HPV, p16, CD8, HLA-class alone or in combination will be analyzed with Kaplan-Meier analysis and COX-regression.

(Paper 3, data is collected but EBV needs to be analyzed)

### Anchored extirpation of lymph node

or other cystic mass on the neck

\* Prospective randomized study, until now:

16 included patients

9 with anchor-technique

\* Evaluation of a surgical method/aiding tool when performing extirpation on difficult to palpate/non-palpable masses

(Paper 4, collecting data)

### Ethical permit No.

2015/0157-32	2009/1278-31/4	2005/431-31/4	2020-00448	2021-00697
--------------	----------------	---------------	------------	------------

### Publications/manuscripts 2020, 2021, 2022

1. Prevalence of cystic metastases in a consecutive cohort of surgically removed branchial cleft cysts. Acta Otolaryngol. 2022 Jan;142(1):100-105. doi: 10.1080/00016489.2021.2016951. Epub 2021 Dec 28. PMID: 34962438



**Sofia Karlsson**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

sofia.karlsson.1@ki.se  
Barbro Hedin Skogman  
Elin Marsk, Malou Hultcrantz  
208-10-08

## Corticosteroid treatment in children with acute facial nerve palsy

My project is based on the Facial nerve palsy And Cortisone Evaluation (FACE) study in children. It is a randomized, placebo-controlled, double-blind, multicentre trial aiming to determine the efficacy of prednisolone treatment in children with acute facial nerve palsy.

Twenty percent of children acquiring an acute facial nerve palsy will not regain full facial function. Symptoms that these children report are, for example, pronunciation problems, drooling and tearing eye in addition to social and psychological consequences of having facial asymmetry. The aim of our study is to determine if prednisolone treatment will improve the outcome for children with acute facial nerve palsy as previously have been shown in adults.

The FACE study includes children with idiopathic facial nerve palsy as well as children with facial nerve palsy associated with Lyme neuroborreliosis. Enrolment takes place at 12 paediatric departments in Sweden and a total of 500 children will be randomized to either prednisolone 1mg/kg/day (maximum 50 mg/day) or placebo per orally for 10 days. The treatment procedure is double-blinded.

Our primary outcome is complete recovery (defined as House-Barackmann grade 1) at 12-months follow-up. In addition to determining the efficacy of prednisolone in children's acute facial nerve palsy, we will also evaluate the agreement between physician-assessed facial grading and self-/proxy-reported disability and quality of life. Furthermore, we will investigate factors of importance for predicting complete recovery in an early phase of the disease.

Inclusion in the FACE study is ongoing since May 2019 and is expected to continue throughout 2022.

### Ethical permit No.

2017/554	2019-01546		
----------	------------	--	--

### Publications/manuscripts 2019, 2020, 2021



**Niki Karpeta**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

niki.karpeta@ki.se  
Maoli Duan  
Luca Verrecchia, Sten Hellström  
2019-09-10

## Developing of objective balance tests in newborns and young children

Balance and vestibular disorders in adults are well studied, but in children are not well determined. Although motor and balance function is still under development throughout childhood, the vestibular function is present at birth and becomes fully integrated in puberty. A vestibular assessment in infants and children is increasingly required in clinical practice especially in those undergoing cochlear implantation as well as in children with neurological diagnoses with delayed motor skills. This knowledge will play a significant role in early rehabilitation and motor development of these children.

Video Impulse test (vHIT) and Vestibular Evoked Myogenic Potentials (VEMP) have been identified as two potential methods of high feasibility in children. The methods are harmless, quick and easy to perform. A test protocol of both has been adopted in the Audiological Department of Karolinska University Hospital in order to access the vestibular function in these underrepresented patient groups.

### Ethical permit No.

2015/1296-31/2			
----------------	--	--	--

### Publications/manuscripts 2020, 2021, 2022

1. Methodological aspects of testing vestibular evoked myogenic potentials in infants at universal hearing screening program. Verrecchia L, Karpeta N, Westin M, Johansson A, Aldenklink S, Brantberg K, Duan M. Sci Rep. 2019 Nov 21;9(1):17225. doi: 10.1038/s41598-019-53143-z. PMID: 31754248
2. The relationship between clinical characteristics and magnetic resonance imaging results of Ménière disease: a prospective study. Xie W, Shu T, Liu J, Peng H, Karpeta N, Marques P, Liu Y, Duan M. Sci Rep. 2021 Mar 30;11(1):7212. doi: 10.1038/s41598-021-86589-1. PMID: 33785791
3. Effects of lesions of the organ of corti on hearing. Yao W, Gao L, Su J, Karpeta N, Xie W, Duan M. Acta Otolaryngol. 2022 Feb;142(2):118-126. doi: 10.1080/00016489.2022.2027517. Epub 2022 Jan 29. PMID: 35098870



**Aeneas Kolev**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

aeneas.kolev@ki.se  
Lars Olaf Cardell  
Gregori Margolin, Linda Marklund  
2020-05-14

## Sentinel node in oral- and oropharyngeal cancer

Sentinel node biopsy is a technique used to investigate if a cancer that spread through the lymphatic system has metastasized. By injecting a radioactive and fluorescent tracer near the tumor, the sentinel nodes, which are the first lymph nodes to receive drainage from the tumor site, can be identified and removed. The sentinel nodes are the first locations where metastases typically occur. This research project focuses on the application of the sentinel node technique in oral and oropharyngeal cancer and its potential for further development.

One area of interest is the topography of the sentinel node, which can sometimes deviate from established lymphatic drainage pathways. In the first sub-study, the topographic placement of sentinel nodes and occult metastases in 40 patients with N0 tongue cancer is being investigated, along with the sensitivity of the technology as used at the clinic.

In the second sub-study, the use of the sentinel node technique in already metastatic (N+) oral cancer is being explored. The technique can be used as a guide to a more radical neck dissection.

In the third study, the application of the sentinel node technique in radiation planning for oral cancer treatment is being investigated. Although traditionally used as a diagnostic technique by surgeons, the sentinel node could also be used to individualize radiation plans by reflecting the true lymphatic pathways.

The fourth study will explore the applicability of the sentinel node technique in tonsil cancer. Specifically, we will investigate the best injection technique and the topography of sentinel nodes. As tonsil cancer is primarily treated with radiation therapy to the primary tumor and neck lymph nodes, the sentinel node technique could eventually be of interest to oncologists in radiation planning.

### Ethical permit No.

2019-03518	2021-01265		
------------	------------	--	--

### Publications/manuscripts 2020, 2021, 2022

**Vilma Lagebro**

Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

vilma.lagebro@ki.se

Lars Olaf Cardell

Susanna Kumlien Georén, Eva Munck-Wikland

2021-01-25

## **Sentinel node B-cells and their interaction with host's immune system in head and neck cancer**

Many patients with head and neck squamous cell cancer (HNSCC) present regional spread to the cervical lymph nodes (LN), while distant metastases are rare. Nodal involvement is the most important factor adversely affecting both the treatment and outcome. The treatment involves surgical removal of primary tumour, and removal of LN from one or more anatomical regions of the neck. However, extensive neck dissection is not without risks for severe complications. We want to provide an improved perioperative staging, so that only patients diagnosed with metastasis or unfavorable immunological features in sentinel node will receive a full neck dissection. Our preliminary results, clearly indicate that patients with low T-cells activation in LN have significantly higher risk of recurrence and death. Moreover, the development of new cancer treatments, especially immune checkpoint inhibitors (CPI), have changed the field of oncology. However, less than 20% of patients with HNSCC treated with CPI responds to this treatment. This is why, in order to fully benefit from this paradigm shift we have to improve the way we select patients for various treatment alternatives.

The overall goal is to provide a better outcome prognostic marker as well as introduce an improved selection of patients who need more rigorous follow-up and those who would benefit from CPI. The overall aims are firstly to provide a detailed characterization of different B cellular components of a lymph node. Secondly, to comprehensively investigate the humoral immune response against various tumour-associated antigens (TAAs) and lastly, to explore the mechanism of B cell cellular interactions and B cell mediated immune suppression in patients with oral cancer.

**Ethical permit No.**

2019-03518	2021-01265		
------------	------------	--	--

**Publications/manuscripts 2020, 2021, 2022**

1. Piersiala K, da Silva PFN, Lagebro V, Kolev A, Starkhammar M, Elliot A, Marklund L, Munck-Wikland E, Margolin G, Georén SK, Cardell LO. Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. *Transl Oncol.* 2022 Jun 14;23:101469. doi: 10.1016/j.tranon.2022.101469. Epub ahead of print. PMID: 35714487; PMCID: PMC9207719.



**Lovisa Lansing**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

lovisa.lansing@ki.se  
Elin Marsk  
Sophia Brismar Wendel  
2017-06-01  
2023-03-30

## Bell's palsy in pregnancy and puerperium

T

o examine the incidence of Bell's palsy among pregnant women in Stockholm during a 10-years period, to find risk factors for developing Bell's palsy during pregnancy and the puerperium (first 6 weeks post partum), to see how these women heal compared to non pregnant women with Bells palsy and how the disease affects the patient's quality of life.

### Ethical permit No.

2015/2349-31/1			
----------------	--	--	--

### Publications/manuscripts 2020, 2021, 2022

1. Lansing, L., Wendel, S.B., Hultcrantz, M. and Marsk, E. (2023), Bell's Palsy in Pregnancy and Postpartum: A Retrospective Case-Control Study of 182 Patients. Otolaryngol Head Neck Surg. <https://doi.org/10.1002/ohn.188>



**Andra Lazar**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

andra.lazar@ki.se  
Maoli Duan  
Luca Verrecchia, Inger Uhlén  
2022-06-15

## Pre/retrospective, genetics study and habilitation of hearing loss in children

In this study, we focus on a group of older children with hearing loss requiring hearing aids who are enrolled in the Hearing Rehabilitation for Children and Youngsters. Among other things, we look at the cause and the natural course of their hearing loss as well as various factors that may have affected their habilitation.

### Ethical permit No.

--	--	--	--	--

### Publications/manuscripts 2020, 2021, 2022



**Emma Malmström**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation


emma.malmstrom@ki.se

Stellan Hertegård

Elin Marsk, Gregory Margolin

2012-05-24

## A new aid for better visibility during laryngoscopy: The cricoid depressor A new improved laryngoscope stand



Transoral surgery of the larynx with a microscope under anesthesia (microlaryngoscopy) often requires external pressure over the larynx for good visualization of the vocal folds, especially when the pathology is located anteriorly. This requires the surgeon to use one hand to apply pressure at the larynx or have an assistant doing that during all or part of the surgery. Aids such as using tape from one side of the operating table to the other side over the patient's larynx can be used, but rarely generate the pressure needed in more challenging patients.

The new aid "cricoid depressor", can be used in microlaryngoscopic surgery to improve visibility. The cricoid depressor is a metal arm that is attached to the support arm of the laryngoscope stand (see picture) and generates a stable pressure over the larynx during surgery. The pressure of the depressor can be varied as needed by adjusting it laterally and vertically. The cricoid depressor has been tested at Karolinska University Hospital for about two years (2020-2022) and has been shown to improve visibility and facilitate surgery in both microlaryngoscopy and major endoscopic tumor surgery. We therefore initially wish to examine how often external pressure is necessary during microlaryngoscopies (MLS). This is to evaluate whether there is a need for a cricoid depressor in vocal fold surgery. If so, we wish to investigate the cricoid depressor's pros and cons further.

**Ethical permit No.**

--	--	--	--

**Publications/manuscripts 2020, 2021, 2022**



**Agnes Modée**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

agnes.modee@ki.se  
Åsa Bonnard  
Cecilia Engström Berglin, Johan Knutsson  
2021-11-02

## **Adverse events in cholesteatoma surgery - risk, contributing factors and quality of life**

Cholesteatoma, the growth of squamous cell epithelium into the middle ear may cause complications such as hearing loss, infections, bone destruction and facial palsy. The treatment is surgical, and surgery is performed in an area defined by the facial nerve, the sigmoid dura, the middle fossa dura plate, the labyrinth, the temporomandibular joint and the posterior wall of the ear canal. Sensitive structures that may be affected during surgery.

The aim of the thesis is analyzing different aspects of adverse events and effects on quality of life after cholesteatoma surgery as well as risk factors for the disease. This will be studied both nationally in a registry based study and locally in retrospective as well as prospective studies.

### **Ethical permit No.**

2020-05935	2019-05190	2020-00245		
------------	------------	------------	--	--

### **Publications/manuscripts 2020, 2021, 2022**

**Fatima Moumèn Denanto**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

fatima.moumen.denanto@ki.se

Filip Asp

Jeremy Wales, Bo Tideholm, Sten Hellström

2020-04-20

2022-06-02

**Bilateral bone anchored hearing devices**

Binaural hearing is important for everyday listening tasks. The ability to localize sound and understanding speech in a noisy environment is dependent on the difference in time and level at which the sound reaches the two ears. In bone conducted sound this ability is affected due to the properties of the skull and surrounding tissue. In my doctoral project we study whether a bilateral fitting of bone conduction hearing devices (BCD) gives a better hearing compared to one device in terms of horizontal sound localization accuracy and speech understanding in spatially separated competing speech. In addition, self-perceived benefit and quality of life will be assessed. Normal hearing subjects as well as patients with bilateral conductive/mixed hearing loss that are using one BCD will be assessed and tested with bilateral fitting compared to unilateral BCD.

**Ethical permit No.**

2019-04696

**Publications/manuscripts 2020, 2021, 2022**

1. Differing Bilateral Benefits for Spatial Release From Masking and Sound Localization Accuracy Using Bone Conduction Devices, Ear and Hearing 43(6):p 1708-1720, November/December 2022.  
| DOI:10.1097/AUD.0000000000001234



**Rebecka Ohm**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

rebecka.ohm@ki.se  
Birgit Stark  
Elin Marsk, Filip Farnebo  
2017-11-30

## **Surgical interventions in peripheral facial palsy; assessment of regained function and quality of life**

Persistent sequelae of peripheral facial palsy imposes a great reduction in quality of life. This thesis aims to evaluate sequelae from different perspectives; - Investigate incidence of long term sequelae and treatment needs after peripheral facial palsy

- Identify patients at risk for eye complications in a prospective study in collaboration with S:t Eriks Eye Hospital
- Evaluation of two surgical methods to target severe sequelae following peripheral facial palsy; early cross facial nerve transpositions, the Babsitter procedure, in Bell's palsy and highly selective neurectomies to treat synkinesis, i.e. mass muscle movements.

### **Ethical permit No.**

2011/598-32	2019-00421	2021-00246	2023-00761-01	
-------------	------------	------------	---------------	--

### **Publications/manuscripts 2020, 2021, 2022**

1. Incidence and management of sequelae from peripheral facial palsy: retrospective analysis of 525 patients - submitted for publication

**Eirini Paziou**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

eirini.paziou@regionstockholm.se  
Lars Olaf Cardell  
Laila Hellkvist

## **Intralymphatic immunotherapy (ILIT) empowered by vitamin D, a double-blind, randomized, placebo-controlled study and comparison with SLIT**

Allergic rhinitis (AR) is a chronic condition with a 30% prevalence in Sweden. Despite widespread availability and frequent use of standard of care medication most patients are unsatisfied and report a marked impairment in their quality of life.

AIT is currently the only treatment that includes long-lasting relief of symptoms. It can be administered either traditionally as subcutaneous injections (SCIT) every 6–8 weeks or as a sublingual alternative (SLIT). Both routes involve treatment during at least three years.

Ten years ago, intralymphatic injections (ILIT) were proposed as a new route for AIT. ILIT delivers allergen directly to the lymph nodes (in the groin) and as tolerance induction primarily is centred to the lymph nodes this method provides the maximal chance for tolerance induction.

Three injections with the same allergen-based vaccine as in SCIT but 100 times lower concentration injected with an interval of four weeks results in a comparable clinical effect as three years of traditional AIT (reduction of symptoms, skin prick sensitivity and serum Ig E levels) with fewer side effects and better compliance.

VitD is a hormone that after intake gets activated by UV-radiation. There is convincing evidence for a positive influence of vitD in treatment of allergic inflammation. The time of initiation of AIT (off pollen season) overlaps the time of the year when the level of naturally produced vitamin D (vitD) might be at its lowest. The hypothesis is that the addition of vitD during the ILIT markedly improves the outcome, potentially making all patients good responders, and ultimately resulting also in a curative effect. And further more a 'head to head' comparison

with SLIT will take place.

A successful outcome will promote the establishment of ILIT as an accessible alternative to the more difficult implement traditional forms of AIT.

### **Ethical permit No.**

2022-02039-01			
---------------	--	--	--

### **Publications/manuscripts 2020, 2021, 2022**

**Krzysztof Piersiala**

Main supervisor

krzysztof.piersiala@ki.se

Co-supervisor

Lars Olaf Cardell

Registered

Eva Munck af Rosenskiöld Wikland, Susanna Kumlien Georén

Halftime seminar

2019-08-29

Planned dissertation

2022-06-16

**Sentinel node B-cells and their role in tumour specific immune suppression in head and neck cancer**

For decades, cancer research was focused on finding external pharmaceutical agents bearing the ability to recognize and destroy cancer cells in cases of metastatic disease. A very recent clinical discovery of immune checkpoint inhibitors (CPI) proved that the human immune system in appropriate conditions has the capability to eradicate on its own even metastatic cancer disease. However, still only a small fraction of patients shows a positive durable response to CPI treatment. The contribution of different immune cell subsets, especially T cells, in CPI mediated regained anti-tumour immune response is well established. In contrast to T cells, the anti-tumour contribution of B cells has been scarcely investigated. B-cells are often overlooked even though they are important players in a fully integrated immune response and constitute a substantial fraction of lymphocytes draining tumour tissue. We hypothesise that by a better understanding of B-cell mediated anti-tumour response, we can identify new biomarkers predicting survival, response to standard anti-cancer treatment, CPI therapy or even develop new immune therapy targets. At the same time, giving the foundation to personalized immunotherapy the approach in advanced HNSCC, we intend to test drug sensitivity, including CPI agents, and primary tumour cell culture in the presence of lymphocytes derived from neck lymphatic system of affected patients.

**Ethical permit No.**

2019-03518

**Publications/manuscripts 2020, 2021, 2022**

1. Piersiala K, Kakabas L, Bruckova A, Starkhammar M, Cardell LO. Acute odynophagia: A new symptom of COVID-19 during the SARS-CoV-2 Omicron variant wave in Sweden. *Journal of internal medicine* 2022;292;1 154-161
2. Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO. A prolonged innate systemic immune response in COVID-19. *Scientific reports* 2022;12;1 9915-
3. Weinreb SF, Piersiala K, Dhar SI, Hillel AT, Akst L, Best SRA. Impact of human immunodeficiency virus status on laryngeal cancer survival and locoregional control. *LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY* 2022;7;1 153-160
4. Cardenas EI, Ekstedt S, Piersiala K, Petro M, Karlsson A, Kågedal Å, Kumlien Georén S, Cardell LO, Lindén A. Increased IL-26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID-19. *Frontiers in immunology* 2022;13; 1016991-
5. Piersiala K, Weinreb SF, Akst LM, Hillel AT, Best SR. Laryngeal disorders in people living with HIV. *American journal of otolaryngology* 2022;43;1 103234-
6. Kałużny J, Klimza H, Tokarski M, Piersiala K, Witkiewicz J, Katulska K, Wierzbicka M. The holmium:YAG laser lithotripsy-a non-invasive tool for removal of midsize stones of major salivary glands. *Lasers in medical science* 2022;37;1 163-169
7. Saibene AM, Allevi F, Ayad T, Lechien JR, Mayo-Yáñez M, Piersiala K, Chiesa-Estomba CM. Treatment for parotid abscess: a systematic review. *Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale* 2022;42;2 106-115
8. Piersiala K, da Silva PFN, Lagebro V, Kolev A, Starkhammar M, Elliot A, Marklund L, Munck-Wikland E, Margolin G, Georen SK, Cardell LO. Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. *TRANSLATIONAL ONCOLOGY* 2022;23; 101469-
9. Piersiala K, Loroch A, Jackowska J, Wierzbicka M. An Incidental Finding of a Double-Lumen Trachea. *ACTA MEDICA PORTUGUESA* 2021;34;3 229-231

10. Saibene AM, (...), Piersiala K, Plzak J, Remacle M, Rommel N, Saleh H, Szpecht D, Tedla M, Tincati C, Tucciarone M, Zelenik K, Lechien JR. Appropriateness for SARS-CoV-2 vaccination for otolaryngologist and head and neck surgeons in case of pregnancy, breastfeeding, or childbearing potential: Yo-IFOS and CEORL-HNS joint clinical consensus statement. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2021;278:10 4091-4099
11. Lechien JR, Hans S, Simon F, Horoi M, Calvo-Henriquez C, Chiesa-Estomba CM, Mayo-Yáñez M, Bartel R, Piersiala K, Nguyen Y, Saussez S. Association Between Laryngopharyngeal Reflux and Media Otitis: A Systematic Review. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2021;42:7 e801-e814
12. Piersiala K, Farrajota Neves da Silva P, Hjalmarsson E, Kolev A, Kågedal Å, Starkhammar M, Elliot A, Marklund L, Margolin G, Munck-Wikland E, Kumlien Georén S, Cardell LO. CD4+ and CD8+ T cells in sentinel nodes exhibit distinct pattern of PD-1, CD69, and HLA-DR expression compared to tumor tissue in oral squamous cell carcinoma. Cancer science 2021;112:3 1048-1059
13. Che KF, Paulsson M, Piersiala K, Sax J, Mboob I, Rahman M, Rekha RS, Säfholm J, Adner M, Bergman P, Cardell LO, Riesbeck K, Lindén A. Complex Involvement of Interleukin-26 in Bacterial Lung Infection. Frontiers in immunology 2021;12: 761317-
14. Weinreb SF, Piersiala K, Hillel AT, Akst LM, Best SR. Dysphonia and dysphagia as early manifestations of autoimmune inflammatory myopathy. American journal of otolaryngology 2021;42:1 102747-
15. Westerberg J, Tideholm E, Piersiala K, Drakskog C, Kumlien Georén S, Mäki-Torkko E, Cardell LO. JAK/STAT Dysregulation With SOCS1 Overexpression in Acquired Cholesteatoma-Adjacent Mucosa. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2021;42:1 e94-e100
16. Piersiala K, Akst LM, Hillel AT, Best SR. Laryngeal Pathologies and Their Associations With Mental Health Disorders. LARYNGOSCOPE 2021;131:1 E231-E239
17. Sidell DR, (...), Piersiala K, Prager JD, Pransky SM, Preciado D, Raynor T, Rinkel RNPM, Rodriguez H, Rodríguez VP, Russell J, Scatolini ML, Scheffler P, Smith DF, Smith LP, Smith ME, Smith RJH, Sorom A, Steinberg A, Stith JA, Thompson D, Thompson JW, Varela P, White DR, Wineland AM, Yang CJ, Zdanski CJ, Derkay CS. Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. The Laryngoscope 2021;131:6 E1941-E1949
18. Kagedal A, Hjalmarsson E, da Silva PFN, Piersiala K, Georen SK, Margolin G, Munck-Wikland E, Winqvist O, Häyry V, Cardell LO. Activation of T helper cells in sentinel node predicts poor prognosis in oral squamous cell carcinoma. SCIENTIFIC REPORTS 2020;10:1 22352-
19. Kågedal Å, Margolin G, Held C, da Silva PFN, Piersiala K, Munck-Wikland E, Jacobsson H, Häyry V, Cardell LO. A Novel Sentinel Lymph Node Approach in Oral Squamous Cell Carcinoma. Current pharmaceutical design 2020;26:31 3834-3839
20. Klimza H, Pietruszewska W, Jackowska J, Piersiala K, Wierzbicka M. Author Correction: Evaluation of narrow band imaging in the assessment of laryngeal granuloma. Scientific reports 2020;10:1 4385-
21. Piersiala K, Akst LM, Hillel AT, Best SR. Chronic Pain Syndromes and Their Laryngeal Manifestations. JAMA otolaryngology--head & neck surgery 2020;146:6 543-549
22. Piersiala K, Krajewski J, Dadej D, Loroń A, Czerniak W, Rozpłochowski B, Kierepa A, Mozer-Lisewska I. Correlates of inconsistent condom use and drug use among men having sex with men in Poland: a cross-sectional study. International journal of STD & AIDS 2020;31:9 894-902
23. Piersiala K, Akst LM, Hillel AT, Best SR. CT Lung Screening in Patients with Laryngeal Cancer. Scientific reports 2020;10:1 4676-
24. Witkiewicz J, Klimza H, Piersiala K, Jackowska J, Wierzbicka M. The usefulness of the narrow band imaging (NBI) in decision-making process regarding second look procedure (SL) in laryngeal cancer follow-up after transoral laser microsurgery. PloS one 2020;15:8 e0236623-



**Samin Rahbin**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

samin.rahbin@ki.se  
Babak Alinasab  
Ola Sunnergren, Hatef Darabi, Pär Stjärne  
2020-08-18  
2021-10-22

## Zygomaticomaxillary Complex Fractures: Aspects of Diagnostic Methods, Treatments and Complications

Zygomaticomaxillary Complex (ZMC) fractures are one of the most common types of facial fractures and frequently managed at Karolinska University Hospital (KUH). Functional complications (e.g. trismus, double vision or impaired sensation) and cosmetic complications (e.g. ocular dystopia or a sunken/broadened cheek) are common and managed either by conservative or surgical treatment. Although the body of literature offers a wide range of suggestions and algorithms for managing ZMC fractures, it is still largely the surgeons' individual training, experience and preference that influence the choice of treatment instead of systematic evidence.

Overall aim of the project:

- To describe a new complication following orbital floor reconstructions.
- To evaluate long-term results of patients with ZMC fractures managed at KUH and to gain an overview of the most common functional and cosmetic complications.
- To introduce the volume difference along the external surface (VDAES) as a novel method of assessing zygomatic bone asymmetry.

### Ethical permit No.

2017/960-31/1	2018-302/31		
---------------	-------------	--	--

### Publications/manuscripts 2020, 2021, 2022

1. Rahbin S, Toufani T, Al-Khabbaz AM, Lindblom J, Sunnergren O, Darabi H, Qureshi A R, Alinasab B: The Volume Difference Along the External Surface of the Zygomatic Bone: A Novel Method of Measuring Zygomatic Bone Asymmetry. *J Craniofac Surg.* 2022 Mar/Apr 01;33(2):463-468. DOI: 10.1097/SCS.0000000000008186 (2022).
2. SRahbin, MKjellberg, M Söderlind & AEkborn: Well-planned rather than rushed extraction of airway foreign body in 532 g preterm neonate. *Acta Oto-Laryngologica Case Reports.* 6:1, 85-87. DOI: 10.1080/23772484.2021.2002153 (2021).
3. Rahbin, S; Liakos, A; Alinasab, B: Loss of Malar Bags in Lower Eyelid in Orbital Blow Out Fracture Reconstruction Following Pre- or Retro-Sepal Transconjunctival Incision. *J Craniofac Surg.* May/Jun 2020;31(3):769-771. DOI: 10.1097/SCS.0000000000006103 (2020).

**Elnaz Sepehri**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

elnaz.sepehri@ki.se  
Cecilia Engmér Berglin  
Magnus von Unge, Per Olof Eriksson  
2019-03-18

## **Assessment and activation of tympanic membrane progenitor/stem cells- clinical and laboratory studies**

This PhD-project aims to map the occurrence and activation of regenerative zones in the human ear drum.

In laboratory studies we try to identify stem cells and proliferative zones in normal human tympanic membranes as well as in tympanic membranes that has been mechanically and chemically injured. The goal is to better understand the healing mechanism.

Plasminogen is an endogenous protein and has a role in cell migration and wound healing and has been identified as a possible drug for medical treatment of chronic tympanic membrane perforation. In a clinical trial different doses of plasminogen are injected close to the tympanic membrane in the ear canal in patients with chronic perforations and the effect on healing of the ear drum is evaluated.

With this project we aim to increase knowledge about the normal healing process and to improve the treatment of tympanic membrane perforations with the ultimate goal to design a simple, out-patient procedure without the need for advanced surgery.

### **Ethical permit No.**

2018/364	2017/2011-31		
----------	--------------	--	--

### **Publications/manuscripts 2020, 2021, 2022**

**Malin Siegbahn**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

malin.siegbahn@ki.se

Cecilia Engmér Berglin

Filip Asp, Rodrigo Moreno

2014-10-27

2019-10-11

2023-11-24

**Central auditory structure and function in unilateral hearing loss**

Central auditory system of participants with unilateral hearing loss in congenital atresia is examined with functional hearing tests and MRI scans. An animal model, Sprague Dawley rats with unilateral induced conductive hearing loss through removal of the left ear canal was also created and examined with MRI. Further, a study was added with participants with unilateral sensorineural deafness and a localization test. So far, two studies are published. One shows findings of deteriorated localization capacity in unilateral atresia, dependent on level of hearing loss of the atretic ear. The other is a method description of defining the white matter pathway between the medial geniculate body and the auditory cortex in clinical MRI scans, but also show no evident differences of this pathway in atresia. Further studies will be presented during the year.

**Ethical permit No.**

113/15	191/4	2012/3:9	2017/4:3	
--------	-------	----------	----------	--

**Publications/manuscripts 2020, 2021, 2022**

1. Siegbahn M, Engmér-Berglin C, Moreno R. Automated segmentation of the core of the acoustic radiation in humans. *Front Neurolog*. 2022 sept 23. doi: 10.3389/fneur.2022.934650
2. Siegbahn M, Engmér-Berglin C, Hultcrantz M, Asp F. Adults with unilateral congenital ear canal atresia -sound localization and recognition of speech in competing speech in unaided condition. *Acta Otolaryngol*. 2021 Juli;141(7):689-694. doi:10.1080/00016489.2021.1921843.
3. Submitted manuscript: "No signs of atrophy -The primary auditory cortex is preserved in congenital unilateral conductive hearing impairment." Siegbahn M, Jörgens D, Asp F, Hultcrantz M, Moreno R, Engmér-Berglin C.



**Carl Skröder**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

carl.skroder@ki.se  
Lars Olaf Cardell  
Ulla Westin  
2020-05-14

## Treatment of allergic rhinitis with systemic steroids and health economic aspects

Allergic rhinitis (AR) is a chronic condition with a 30% prevalence in Sweden. Despite widespread availability and frequent use of standard of care medication the majority of patients are unsatisfied and report a marked impairment in their quality of life. When standard of care treatment fails, like in the middle of a severe pollen season, short-term systemic corticosteroids are often prescribed, especially in private practice. However, injected corticosteroids is not recommended in modern guidelines, due to risk for side effects and lack of documented efficacy. Despite this, the longstanding praxis of giving a pre-seasonal intramuscular injection methylprednisolone remains at several places around the world.

Primary hypothesis: 80 mg (2 ml) intramuscular injected methylprednisolone reduce symptoms more efficiently compared to placebo (2 ml intramuscular injected NaCl).

20 mg Prednisolone results in a significant symptom reduction compared to 20 mg Kestine.

Secondary hypothesis: A short-term systemic corticosteroids treatment improve quality-of-life (SNOT-22 and Juniper RQLQ) during the study period. Levels of bone turn over marker (CTX) will not change significantly.

In the methylprednisolone study there was a significant difference in daily symptom score (dSS), daily medical score (dMS) and daily combined symptom- and medical score (dCSMS) between the groups throughout the birch pollen season 2019. The slightly improved dCSMS in the patients treated with a single intramuscular injection of 80 mg methylprednisolone conjure no strong evidence for the beneficial effects of using systemic steroids in addition to standard of care for treatment of seasonal allergic rhinitis during the peak of the pollen season.

In the prednisolone study, no significant difference was seen in dSS, dMS, dCSMS or QoL (SNOT-22 and Juniper RQLQ) between the groups, throughout the birch pollen season 2018.

### Ethical permit No.

2016/2158	2017/947	2018/11	
-----------	----------	---------	--

### Publications/manuscripts 2020, 2021, 2022

1. HealthSWED: Costs with sublingual immunotherapy - a questionnaire study. Petter Olsson, Carl Skröder, Lars Ahlbeck, Frida Hjalte, Karl-Olof Welin, Ulla Westin, Morgan Andersson, Cecilia Ahlström-Emanuelsson & Lars-Olaf Cardell. Allergy, Asthma & Clinical Immunology volume 17, Article number: 55 (2021) Manuscript:
2. It is advisable to be hesitant in the use of prednisolone tablets as treatment of pollen induced allergic rhinitis - Databearbetning. Carl Skröder, Laila Hellkvist, Ulla Westin, Pernilla Sahlstrand-Johnsson, Åslög Dahl, Leif Bjermer, Lars Olaf Cardell
3. Is the effect of methylprednisolone treating pollen induced allergic rhinitis mainly due to a placebo effect? - manus klart för inskick . Carl Skröder, Laila Hellkvist, Åslög Dahl, Leif Bjermer, Ulla Westin, Lars Olaf Cardell

**Martin Smelik**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

martin.smelik@ki.se

Mikael Benson

Oleg Sysoev, Claudio Cantu, Lars Olaf Cardell

2022-11-09

## Learning Disease Models for personalised medicine

In "Multi-Organ Single Cell Analysis Reveals an On/Off Switch System with Potential for Personalized Treatment of Immunological Diseases" project we use a large cohort of Lupus patients to identify patient subgroups having similar disease severity indicators and influential variables that define these subgroups.

This project was a part of larger, multidisciplinary effort to identify systems with potential for personalized treatment in Immunological diseases. We constructed a machine learning model that jointly analysed the protein levels as well as the clinical data like age, gender, smoking history, recently prescribed drugs and many others. This model was tested for several subgroups of patients to compare the effects of influential variables on the disease severity indicators.

**Ethical permit No.**

--	--	--	--	--

**Publications/manuscripts 2020, 2021, 2022**

1. A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets, Multi-Organ Single Cell Analysis Reveals an On/Off Switch System with Potential for Personalized Treatment of Immunological Diseases

**Magnus Starkhammar**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

magnus.starkhammar@ki.se

Lars Olaf Cardell

S-E Dahlén, M Adner, S Kumlien Georén

2008-02-18

2014-05-19

2024-06-09

**Airway hyperresponsiveness in conjunction with stimulation of viral recognizing Toll-like receptors.**

Viral respiratory tract infections are a common cause of acute exacerbations of asthma and rhinitis. During an airway infection, individuals with asthma suffer from longer-lasting illness and more severe respiratory symptoms, such as airway hyperresponsiveness, compared to healthy persons. The mechanisms behind these phenomena are not fully understood and new ways of treatment are required. Toll-like receptors (TLRs) are pattern recognition receptors that can identify viruses in the airway and by that evoke an inflammatory response. TLRs are found located in different cell types implicated in the pathogenesis of asthma, such as in airway epithelial cells, smooth muscle cells, or in leukocytes. TLRs may be an important link between viral infections and asthma exacerbations. This project aims to study the effects on airway reactivity and inflammatory patterns in connection with the stimulation of viral recognizing TLRs.

**Ethical permit No.**

N152/06	N152/11	N348/11	N44/12	N41/14	N143/14
---------	---------	---------	--------	--------	---------

**Publications/manuscripts 2020, 2021, 2022**

1.

**Clara Svenberg Lind**

Main supervisor

Co-supervisor

Registered

Halftime seminar

Planned dissertation

clara.svenberg-lind@ki.se

Jeremy Wales

Mathias von Beckerath, Jessica Kåhlin,  
Lalle Hammarstedt Nordenvall

2023-01-01

2023-06-01

**Tracheostomy in the era of Covid-19**

The Covid-19 pandemic led to an unprecedented amount of patients requiring tracheostomy. We analyse the immediate, short- and long-term complications of this technique when performed by otolaryngologists or intensivists.

**Ethical permit No.**

2020-2779	2022-05241-01			
-----------	---------------	--	--	--

**Publications/manuscripts 2020, 2021, 2022**

1. Globalsurg Collaborative, Covidsurg Collaborative. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. *Anaesthesia* 2021;76(6):748-75
2. Covidsurg Collaborative Globalsurg Collaborative. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. *The British journal of surgery* 2021;108(9):1056-1063
3. Globalsurg Collaborative, Covidsurg Collaborative. Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. *Anaesthesia* 2021;76(11):1454-1464.
4. Globalsurg Collaborative, Covidsurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. *Anaesthesia* 2022 Jan;77(1):28-39.
5. Submittad artikel (nov 2022): Breathing, voice and swallowing difficulties one-year after tracheostomy in COVID-19-patients.



**Yelin Zhao**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

yelin.zhao@ki.se  
Mikael Benson  
Oleg Sysoev, Claudio Cantu, Lars-Olaf Cardell  
2022-11-23

## A single cell-based strategy to identify mechanisms and biomarkers for early diagnosis, prevention and treatment of common diseases

This project contains several sub-project. In one sub-project, I studied single-cell RNA sequencing of five different solid tumors, and constructed a shared multi-cellular model that could be used to prioritize possible pan-cancer diagnostic marker. By testing these candidate markers in both RNA and protein data of 20 differernt cancers samples, I found a combination of some of these biomarkers can be used as pan-cancer diagnostic marker. This manuscript is currently under review by Genome Medicine.

### Ethical permit No.

--	--	--	--	--

### Publications/manuscripts 2020, 2021, 2022

1. Yelin Zhao, Xinxiu Li, Berghtor Björnsson, Joseph Loscalzo, Martin Smelik, Oleg Sysoev, Dina Mansour Aly, Mikael Benson. A Scalable, Single Cell-Based Strategy for Prioritization of Multi-omics Pan-cancer Biomarkers. (Under review)
2. Xinxiu Li, Eun Jung Lee, Sandra Lilja, Joseph Loscalzo, Samuel Schäfer, Martin Smelik, Maria Regina Strobl, Oleg Sysoev, Hui Wang, Huan Zhang, Yelin Zhao, Danuta R. Gawel, Barbara Bohle & Mikael Benson. A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets . (Published) Genome Medicine. 2022.
- 3.



**Karin Åberg**  
Main supervisor  
Co-supervisor  
Registered  
Halftime seminar  
Planned dissertation

karin.aberg.1@ki.se  
Marit Westman  
Marianne van Hage, Mats Holmström, Anna Asarnoj  
2017-12-21

## Predictors of upper airway symptoms in the BAMSE birth cohort

**Background:** Rhinitis and rhinosinusitis are inflammatory diseases in the upper airways, often associated with asthma. Allergic rhinitis (AR) is an IgE-mediated disease. It is one of the most costly diseases to the society. Sensitization is a strong risk factor for later development of AR and, in some cases, asthma. During the last decade, there has been a rapid increase in knowledge about specific allergen proteins (allergen components). This has primarily been used within food allergy to be able to separate life threatening allergies from cross reactions (component resolved diagnostics).

Chronic rhinosinusitis (CRS) is a multifactorial inflammatory disease in the upper airways, with several different endotypes. The prevalence is somewhat uncertain since the diagnosis is difficult to ensure via questionnaires.

To be able to estimate prognosis and decide on treatment for these diseases, there is a need for prognostic biomarkers.

**Aim:** The overall aim of this project is to identify early prognostic factors for upper airway disease and to increase the understanding of the relationship between symptoms from the upper and lower airways.

**Methods:** We use data from the population based birth cohort BAMSE (Barn Allergi Miljö Stockholm Epidemiologi) consisting of 4089 children. The children have been followed repeatedly by questionnaires. At 4, 8, 16 and 24 years of age clinical examinations were performed, including blood samples for specific IgE. We have also performed a subgroup study of the 24-year-olds with CRS symptoms. The data from this study has been analysed and the article is soon to be submitted.

### Ethical permit No.

93:189	98:175	2007/1634-31	2010/1474-31/3	2016/1380-31/2
--------	--------	--------------	----------------	----------------

### Publications/manuscripts 2020, 2021, 2022

1. Westman M, Åberg K, Apostolovic D, Lupinek C, Gattinger P, Mitterman I, Andersson N, Melèn E, Bergström A, Antò J M, Bousquet J, Valenta R, Wickman M, van Hage M. Longitudinal assessment of sensitization to grass pollen allergen molecules in a birth cohort – the importance of Phl p 4 for diagnosis and prediction of grass pollen allergy. JACI April 2020

## Appendix 1

## Checklista för ansvarig forskare/prövare: Uppstart av klinisk studie

Datum: 2021-11-04

Denna checklista är ett internt dokument som kan användas som stöd inför uppstart av forskningsprojekt på patienter och forskningspersoner som bedrivs vid Karolinska Universitetssjukhuset.

Det är en övergripande checklista med syfte att underlätta planeringen av olika typer av studier, såväl kliniska läkemedelsprövningar som mindre omfattande analyser av patientmaterial.

Dokumentet är tänkt att användas som en mall och kan anpassas utifrån specifika studier och verksamhetens interna rutiner. Alla delar av checklistan är därför inte applicerbar på alla studier. Checklistan upprättas för varje studie och förvaras hos ansvarig forskare. En kopia lämnas till verksamhetschefen där studiens huvudsakligen bedrivs i samband med att studien påbörjas.

Titel på forskningsprojektet/studien	Karolinska diarie nr
Tema/Funktion/Medicinsk enhet	Ansvarig verksamhetschef
Ansvarig forskare/prövare	Ansvarig Forskningssjukskötarska/forskningskoordinator
Sponsor för studien	



2 (16)

Id.	Kommentar	Utfört
1.1	Alla studier som bedrivs inom Karolinska Universitetssjukhusets verksamhetsområde och där Karolinska Universitetssjukhuset står med på etikprövningsansökan ska registreras i databasen.  <u>Databas för kliniska studier (karolinska.se)</u>	
2.1	<b>Ansökningar och godkännanden</b>  DIARIENUMMER  K Diarienummer: _____  Ansök om diarienummer för studien via <a href="mailto:Registrar.karolinska@regionstockholm.se">Registrar.karolinska@regionstockholm.se</a>  Karolinska Universitetssjukhuset är en myndighet och omfattas därför av de regler och lagar som rör offentlighetsprincipen. Detta innebär bland annat att vi ska diarieföra eller registrera de flesta av våra handlingar. Alla avtal som Karolinska Universitetssjukhuset ingår med extern part ska enligt lag diarieföras.	
2.2	ANSVARSINTYG  Ansvarsintygen utgör sjukhusinterna dokument och ska aldrig hanteras av extern part. Tillämpligt ansvarsintyg ska alltid vara upprättat innan uppstart av studien.  <b>Ansvarsintyg K/KI</b> är avsett att användas för studier som kräver ett etikgodkännande och ska genomföras i samverkan mellan Karolinska Universitetssjukhuset och Karolinska Institutet. Samverkan avses när ansvarig forskare är knuten till både Karolinska Universitetssjukhuset och Karolinska Institutet <a href="#"><u>Intyg om ansvarsfördelning K/KI (2018-06-25)</u></a>  <b>Ansvarsintyg K</b> är avsett att användas för studier som kräver ett etikgodkännande och som ska genomföras på fler än en Medicinsk enhet (ME) på Karolinska Universitetssjukhuset. <a href="#"><u>Ansvarsintyg inom Karolinska Universitetssjukhuset (21-02-12)</u></a>	

2.3	<p>ETIKPRÖVNINGSMYNDIGHETEN (EPM) inkl. strålskydd, ansökan och godkämnande</p> <p>Diarinummer: _____        Ansökt datum: _____        Godkänt datum: _____        Ändringsansökan datum: _____</p> <p>Viktig information och instruktion om hur och vad som ska inkluderas i etikprövningsansökan finns på <a href="https://etikprövningssmyndigheten.se/">https://etikprövningssmyndigheten.se/</a></p> <p>Om studien godkänts med villkor måste dessa uppfyllas innan studien startar.        För kliniska läkemedelsprövningar:        Väsentliga ändringar till EPM (ändringsansökan) behöver även skickas till Läkemedelsverket.        Undantag: Byte av ansvarig forskare (PI) vid ett center eller tillägg av center skall skickas till EPM, men behöver inte skickas in till LV om amendment inte omfattar något utöver detta. Informationen om byte av PI skickas då till LV vid nästa väsentliga amendment.</p> <p>Notera: Om studien inkluderar humana pröver kan ett rådgivande möte bokas med Stockholms medicinska biobank (SMB) för diskussion innan inskick till EPM (se nedan under sektion 1.5 BIOBANK).</p> <p><b>Om kompenstation till forskningspersonerna</b> förekommer ska detta vara godkänt av Etikprövningssmyndigheten        Notera: För medicintekniska kliniska prövningar används ett samlat förfarande där alla ansökningshandlingar skickas till LV som fördelar delar av dokumentationen till EPM. Specifica blanketter skall dock laddas ner från EPM på följande länk: <a href="https://etikprövningssmyndigheten.se/medicintekniska-produkter/">https://etikprövningssmyndigheten.se/medicintekniska-produkter/</a></p>	
2.4	<p>LÄKEMEDELSVERKET, anmälan/ansökan och godkännande</p>	

	Viktig information och instruktion om hur och vad som ska inkluderas i annmälän/ansökan om medicinteknisk klinisk prövning finns på: <a href="https://www.lakemedelsverket.se/sv/tillstand-godkannande-och-kontroll/klinisk-prövning-medicinteknik/ansökan-eller-annmälän">https://www.lakemedelsverket.se/sv/tillstand-godkannande-och-kontroll/klinisk-prövning-medicinteknik/ansökan-eller-annmälän</a>	
2.5	<p>BIOBANK, ansökan och godkännande</p> <p>Diarinummer: _____            Ansökt datum: _____            Godkänt datum: _____            MTA Godkänt datum: _____</p> <p>Biobanksavtal upprättas där extra forskningsprover tas inom studien. I Biobankslagen finns undantagsregel för prover som analyseras <b>inom 6 månader</b> efter provtagningsdatum <b>och destrueras</b> i direkt anslutning till analys. OBS! <b>Båda</b> villkoren måste vara uppfyllda.</p> <p>Är det aktuellt med undantagsregeln så skall detta beskrivas i ansökan till EPM under punkten 14.1.5.            Multicenterbiobanksavtal (N1) upprättas vanligen för alla nya prover om det är fler center som medverkar i Sverige och kompletteras samtidigt med lokal biobank för varje site (L1 och L1a) om uttag från befintligt prov behövs.            Kontakta SMB <a href="http://biobankstockholm.se">biobankstockholm.se</a> vid frågor om hur biobanksansökan ska skrivas.</p> <p>Ett MTA (Material Transfer Agreement) behöver upprättas då biobanksprov med tillhörande provkod överförs från en huvudman till en annan. <a href="http://www.biobanksverige.se/information/biobanksverige.se">MTA information (biobanksverige.se)</a></p> <p>Ansökningsblanketter finns på <a href="http://www.biobanksverige.se/forskning">www.biobanksverige.se/forskning</a> och skickas elektroniskt till <a href="mailto:biobankstockholm.karolinska@regionstockholm.se">biobankstockholm.karolinska@regionstockholm.se</a> samt i pappersform. Se Biobankens hemsida för information om hur många exemplar dokumenten skall upprättas i.</p>	



5 (16)

2.6	GDPR
	<p><b>Anmälan av personuppgiftsbehandling vid Karolinska Universitetssjukhuset</b></p> <p>Karolinska Universitetssjukhuset är skyldig att föra ett register över de personuppgiftsbehandlingar som utförs under sjukhusets ansvar. Varje personuppgiftsbehandling (t.ex. forskningsstudier, kvalitetsregister mm.) måste anmälas till detta register.</p> <p>Från och med 2021-10-01 ska samtliga personuppgiftsbehandlingar anmälas i Privacy Records (Draftit). Information om hur man registrerar i Privacy Records finns på inuti: <a href="#">Personuppgiftsbehandling (GDPR) – För dig som är forskare (karolinska.se)</a></p> <p>Inför vissa personuppgiftsbehandlingar behöver det upprättas en konsekvensbedömning/DPIA gällande personuppgiftsbehandlingen. Så är fallet när det rör sig om behandling av känsliga personuppgifter, när man behandlar personuppgifter i stor omfattning, när man använder ny teknik eller nya organisatoriska lösningar.</p> <p>Mall för DPIA finns här: <a href="#">Sjukhusgemensamma dokument (sll.se)</a></p> <p><b>PUB-avtal (Personuppgiftsbiträdesavtal)</b></p> <p>Enligt dataskyddsförordningen ska personuppgiftsansvariga och personuppgiftsbiträden reglera sina relationer genom ett skriftligt avtal. När sjukhuset läter en extern part hantera personuppgifter för sjukhusets räkning skall därför ett PUB-avtal upprättas.</p> <p>Information finns på <a href="https://www.datainspektionen.se/lagar-regler/dataskyddsforordningen/personuppgiftsansvariga-och-personuppgiftsbitraden/personuppgiftsbitradesavtal/">https://www.datainspektionen.se/lagar-regler/dataskyddsforordningen/personuppgiftsansvariga-och-personuppgiftsbitraden/personuppgiftsbitradesavtal/</a></p> <p>Mall för PUB-avtal finns på: <a href="https://inuti.karolinska.se/verksamheter/sjukhusovergripande/rattskansli/sjukhus-och-myndighetsjuridik/personuppgiftsbehandling-gdpr/personuppgiftsbehandling-gdpr-for-dig-som-ar-forskare/">https://inuti.karolinska.se/verksamheter/sjukhusovergripande/rattskansli/sjukhus-och-myndighetsjuridik/personuppgiftsbehandling-gdpr/personuppgiftsbehandling-gdpr-for-dig-som-ar-forskare/</a></p> <p><b>Utlämnande av patientdata för forskningsändamål:</b></p> <p>Om data utlämnas till en annan part för egna forskningsändamål skall en Begäran om utlämnande av patientdata upprättas. På inuti finns en beskrivning och kontaktuppgifter</p>

	<p><u>Utlämnande av patientdata för forskningsändamål (karolinska.se)</u></p>													
2.7	<p>Om sponsor finns i ett land utanför EU kan man på <u>Integritetsmyndighetens hemsida</u> hitta information om landet är godkänt för utlämning av uppgifter. Om landet inte finns med så behöver FoU-juristerna kontakta innan studieavtal signeras</p> <p><b>REGISTRERING I OFFENTLIG DATABASES.</b></p> <p>Varie forskningsstudie som omfattar mänskor ska enligt Helsingforsdeklarationen registreras i en offentlig tillgänglig databas innan den första forskningspersonen rekryteras. (Ref. <i>Helsingforsdeklarationen</i>, 35).</p> <p>Registering kan göras i t.ex. <u>ClinicalTrials.gov</u>. Kontakta Katarina Risbecker Sektionschef section forskningsstöd (katarina.risbeckeregionstockholm.se) för att få inlogg i clinicaltrials.gov</p> <p>På WHO:s hemsida finns exempel på andra offentliga databaser. <a href="https://www.who.int/clinical-trials-registry-platform/network/primary-registries">https://www.who.int/clinical-trials-registry-platform/network/primary-registries</a></p> <p>OBS! Finansiärer och/eller tidskrifter kan ha särskilda krav på var registreringen ska ske.</p>													
3.1	<table border="1"> <thead> <tr> <th>Id</th> <th>Avtal och Ekonomi</th> <th>Kommentar</th> <th>Utfört</th> </tr> </thead> <tbody> <tr> <td>AVTAL</td> <td>Alla avtal som skrivs med extern part behöver inför avtalssignering granskas av jurist på Karolinska Universitetssjukhuset. Kontakta FoU jurist via email: <a href="mailto:forskningsavtal.karolinska@regionstockholm.se">forskningsavtal.karolinska@regionstockholm.se</a></td> <td></td> <td></td> </tr> <tr> <td></td> <td>Kliniska studieavtal signeras enligt gällande arbets-och delegationsordning (<u>Stukhusgemensamma dokument</u> <a href="http://sll.se">sll.se</a>) med nedan förtilligande:</td> <td></td> <td></td> </tr> </tbody> </table> <p><b>PI &amp; Verksamhetschef (VC):</b> Det är viktigt att PI och VC är införstådda i vad avtalet omfattar. PI och VC signeras som indikator på ”läst och förstått” / ”read and understood”, vilket bekräftar att de ansvarar för genomförande av projektet / studien i enlighet med avtalet.</p>	Id	Avtal och Ekonomi	Kommentar	Utfört	AVTAL	Alla avtal som skrivs med extern part behöver inför avtalssignering granskas av jurist på Karolinska Universitetssjukhuset. Kontakta FoU jurist via email: <a href="mailto:forskningsavtal.karolinska@regionstockholm.se">forskningsavtal.karolinska@regionstockholm.se</a>				Kliniska studieavtal signeras enligt gällande arbets-och delegationsordning ( <u>Stukhusgemensamma dokument</u> <a href="http://sll.se">sll.se</a> ) med nedan förtilligande:			
Id	Avtal och Ekonomi	Kommentar	Utfört											
AVTAL	Alla avtal som skrivs med extern part behöver inför avtalssignering granskas av jurist på Karolinska Universitetssjukhuset. Kontakta FoU jurist via email: <a href="mailto:forskningsavtal.karolinska@regionstockholm.se">forskningsavtal.karolinska@regionstockholm.se</a>													
	Kliniska studieavtal signeras enligt gällande arbets-och delegationsordning ( <u>Stukhusgemensamma dokument</u> <a href="http://sll.se">sll.se</a> ) med nedan förtilligande:													

	<p><b>Temachef (TC/Funktionschef (FC)) signerar forskningsavtal upp till 5 MSEK</b> under förutsättning att avtalet är granskat juridiskt, säkerställt att det är ekonomiskt kostnadstäckande och att PI/ VC läst och förstått, dvs vetenskapligt granskat avtalet. Även CDA/NDA avtal innefattas i denna punkt.</p> <p><b>Sjukhusdirektören signerar forskningsavtal värda 5 MSEK och över</b> under förutsättning att avtalet är signerat av TC/FC, vilket då innebär att avtalet är:</p> <p>Juridiskt granskat av avtalsjurist eller i vissa fall av erfaren personal på kliniska studieverksamheten på temat/funktionen.</p> <p>Ekonominst granskat av PI och VC och/eller personal på kliniska studieverksamheten. Stöd för detta finns också centralt på sektion forskningsstöd (Se rubrik Ekonomiskt avtal).</p> <p>Vetenskapligt granskat av PI som ska efterleva avtalet och av VC som stöttar projektet.</p> <p>Sjukhusdirektören signerar alla EU-finansierade projekt eftersom dessa bedöms vara av särskild risk.</p>	
3.2	<p><b>EKONOMISKT AVTAL</b></p> <p>Studiens kostnader och tidsåtgång beräknas av enhet/sektionschef eller av VC utsedd person.  Därefter upprättas ett ekonomiskt avtal mellan Karolinska Universitetssjukhuset och sponsor.  Detta avtal ska vara underskrivet och <b>klart innan</b> start av studie. Karolinska Universitetssjukhusets original skickas till registrator på Karolinska Universitetssjukhuset.</p> <p>Kopior på alla ekonomiska avtal för studien förvaras i prövarpärmen eller på annan avsedd plats (se punkt prövarpärn).</p> <p>För hjälp med underlagsmall för avtal och stöd för kostnadsberäkning och avtalsprocess kontakta sektionschef för sektion forskningsstöd: <a href="mailto:katarina.risbecker@regionstockholm.se">katarina.risbecker@regionstockholm.se</a></p> <p>Forskningsprislista gällande timpriser samt slutenvårdpriser finns att ladda ner från inuti <a href="http://inuti.karolinska.se/lnuti/Verksamheter/Centrala-staber/FoU/Kliniska-studier/">http://inuti.karolinska.se/lnuti/Verksamheter/Centrala-staber/FoU/Kliniska-studier/</a></p>	
3.3	<p><b>INTERNA AVTAL</b></p> <p>Interna avtal mellan Karolinska Universitetssjukhusets verksamheter signeras av VC alternativt chef för klinisk studieverksamhet om budgetansvar för verksamheten åligger denne.  Interna avtal / överenskommelser är inte juridiskt bindande i samma bemärkelse som externa avtal.  Det kan vara av stort värde för ansvariga inom verksamheten och forskningsprojekten att ha en process på plats där ansvariga chefer i verksamheten är informerade om och tar ansvar för genomförande av kliniska studier.</p>	

3.4	APOTEKET	<p>Ett avtal ska upprättas med apoteket när prövningssläkemedel ska användas. Avtal upprättas i de flesta fall direkt mellan sponsor och apoteket. Kopia av apoteksavtalet tillhandahålls av sponsor och förvaras i prövarärmen.</p> <p>I de all Karolinska Universitetssjukhuset är sponsor/tecknar avtal med apoteksfunktion skall ApoEx anlitas. Email adress: klinprov.stockholm@apoex.se</p>
3.5	BILD OCH FUNKTION (BoF)	<p>Ett internavtal kan behöva upprättas med BoF för studiespecifika undersökningar tex CT/MR/PET, ultrajud mfl.</p> <p>Kontakta till BoF Enheten för kliniska studier (EKS) <a href="mailto:rtg.klimprov.karolinska@regionstockholm.se">rtg.klimprov.karolinska@regionstockholm.se</a> För barnstudier kontaktas <a href="mailto:FOBarndiagnostikliniskastudier.karolinska@regionstockholm.se">FOBarndiagnostikliniskastudier.karolinska@regionstockholm.se</a></p> <p>Röntgen återkommer med ett internavtal som signeras enligt gällande arbets-och delegationsordning.</p>
3.6	PATOGEN	<p>I vissa studier behöver ett avtal upprättas med patologen tex. när arkiverat tumörmaterial ska skickas för analys . Det kan då också behövas en ansvarig patolog för studien.</p> <p>Det finns två sorters avtal, biobanksavtal (skickas till <a href="mailto:puc.samordning.karolinska@regionstockholm.se">puc.samordning.karolinska@regionstockholm.se</a>) och kostnadsavtal (skickas till studiecenter på MDK) efter det att Patologen har tagit fram en offert på projektet.</p> <p>Projekt som omfattar humanvävnad insamlad inom Sverige ska ha ett biobanksavtal upprättat innan kostnadsavtal upprättas.</p> <p>I prövarärmen ska det finnas instruktion för hur man beställer, hanterar och vart (lokalt/centralet lab) patologmaterial skickas.</p>

3.7	<p><b>PROVTAGNING/STUDIECENTER lab</b></p> <p>Beroende på studiens upplägg kan avtal behövas, såsom vid provtagning utöver klinisk rutin, prover som ej finns i sortimentet m.m.</p> <p>Kontaktkuppgifter: <a href="mailto:studiecenterlab.karolinska@regionstockholm.se">studiecenterlab.karolinska@regionstockholm.se</a></p> <p>Studiecenter återkommer med internavtal för signing enligt gällande arbets- och delegationsordning.</p>
3.8	<p><b>ÖGON</b></p> <p>Om ögonundersökning ska utföras kan Stockholms ögonklinik användas.</p> <p>Skicka e-post med en kort sammanfattnings om studien, vilka undersökningar som är aktuella och när undersökningarna ska utföras. Bifoga information från forskningsplanen/protokollet som beskriver vad som ska undersökas (flödesschema) till; <a href="mailto:kundcenter@stockholmsgonklinik.se">kundcenter@stockholmsgonklinik.se</a> för upprättande av internavtal</p>
3.9	<p><b>FYSLAB</b></p> <p>Ett avtal ska upprättas om studiespecifika EKG ska utföras.</p> <p>För barnstudier kontaktas barnkardiologen.</p>

## Appendix 2

# Lägga till ett nytt e-postkonto i Outlook

Outlook för Microsoft 365 Outlook för Microsoft 365 för Mac Outlook 2021 [Fler...](#)

## Håll kontakten och schemat

Du kan vara organiserad och hålla tidsplaneringen med Outlook – din livsorganisatör.

### [Prova 1 månad utan kostnad](#)


**Det finns många olika typer av e-postkonton som du kan lägga till i Outlook, bland annat Microsoft 365, Gmail-, Yahoo-, iCloud- och Exchange-konton.**

Vissa tredjepartsleverantörer av e-post, till exempel Gmail, Yahoo och iCloud, kräver att du ändrar vissa inställningar på respektive webbplats innan du kan lägga till dessa konton i Outlook.

### [Outlook för PC](#)[Outlook för Mac](#)[Mobil e-post](#)

De här stegen är desamma oavsett om du lägger till ditt första e-postkonto eller andra e-postkonton i Outlook.

1. Välj **Arkiv > Lägg till konto**.




2. Vad som visas närmast beror på vilken version av Outlook du har.


**För Outlook för Microsoft 365 och Outlook 2016**

**För Outlook 2013 och Outlook 2010**

Källa: <https://support.microsoft.com/sv-se/office/l%C3%A4gga-till-ett-nytt-e-postkonto-i-outlook-6e27792a-9267-4aa4-8bb6-c84ef146101b>



Ange din e-postadress och klicka på **Anslut**.



Ange namn, e-postadress och lösenord och klicka på **Nästa**.

3. Ange lösenordet igen om du uppmanas till det och välj sedan **OK** > **Slutför** för att börja använda ditt e-postkonto i Outlook.

### Outlook accepterar inte mitt lösenord

Om Outlook inte accepterar ditt lösenord och du vet att du använder rätt lösenord för e-postkontot, kanske du har ett e-postkonto som kräver ytterligare säkerhetsfunktioner.

Gmail-, Yahoo-, iCloud-, Outlook.com- och AOL-konton använder alla tvåfaktorautentisering för att verifiera att du är den person som försöker komma åt ditt e-postkonto.

För att lägga till ditt e-postkonto i Outlook behöver du ett applösenord, även kallat ett programlösenord. Det är ett annat lösenord än ditt vanliga lösenord för e-postkontot. Du vet att du behöver ett applösenord om du ser följande meddelande: *Tvåfaktorautentisering har ställts in för ditt konto. Logga in med ditt lösenord för programmet.*

Stegen för att hämta ett applösenord är olika för varje e-postleverantör. Välj din leverantör i listrutan för att få anvisningar.



## **Har du problem med att lägga till ditt e-postkonto? Använd avancerade inställningar.**

Du kan behöva lägga till ditt e-postkonto manuellt. Välj någon av de avancerade metoderna nedan:

### **Använda avancerade inställningar för att lägga till ett POP- eller IMAP-konto i Outlook för Windows**

Du kan använda Outlooks avancerade inställningar om du behöver ange specifika värden för namn på inkommande och utgående server, portnummer eller SSL-inställningar. Du kan använda de här anvisningarna för att lägga till ett POP- eller IMAP-konto i Outlook.

1. Öppna Outlook och välj **Arkiv > Lägg till konto**.
2. På nästa sida anger du din e-postadress och väljer **Avancerade alternativ**. Markera sedan kryssrutan för **Jag vill konfigurera mitt konto manuellt** och välj **Anslut**.
3. Välj din kontotyp. Oftast när du måste använda det här alternativet väljer du **IMAP**.
4. Sidan **Kontoinställningar** bör vara fyllt med de flesta av de kontoinställningarna som du behöver. Men om du måste leta reda på inställningarna läser du avsnittet [Inställningar för POP- och IMAP-konto](#). Ange inställningar för inkommande och utgående server och välj **Nästa**.
5. Ange ditt lösenord och välj sedan **Anslut**.

### **Använda avancerade inställningar för att lägga till ett IMAP-konto från tredje part i Outlook för Windows**

Om du använder en MAPI-tredjepartsleverantör laddar du ned och konfigurerar leverantörens MAPI-e-postprogram som föreslås av leverantörsföretaget.

1. Öppna Outlook och välj **Arkiv > Lägg till konto**.
2. På nästa sida anger du din e-postadress och väljer **Avancerade alternativ**. Markera sedan kryssrutan för **Jag vill konfigurera mitt konto manuellt** och välj **Anslut**.
3. På sidan **Avancerad konfiguration** väljer du **Annan**.
4. Välj vilken typ av server som du vill ansluta till i listan på skärmen **Annan**.  
**Obs!** Alternativet **Annan** och din kontotyp som visas under det visas bara om du har installerat och konfigurerat MAPI-leverantören korrekt.
5. Klicka på **Anslut**.
6. Det MAPI-leverantörsprogram för tredje part som är installerat på datorn bör startas.
7. Slut för kontokonfigurationen genom att följa MAPI-leverantörens instruktioner.

### **Vill du uppdatera inställningar för ett befintligt e-postkonto i Outlook?**

Om du redan har skapat ett e-postkonto och vill uppdatera befintliga inställningar på grund av ett aktuellt problem går du till [Ändra eller uppdatera inställningar för e-postkonto i Outlook för Windows](#).


## **Se även**

[Ändra eller uppdatera inställningar för e-postkonto i Outlook för Windows](#)

[POP- och IMAP-e-postinställningar för Outlook](#)

## Appendix 3

# Admission process at CLINTEC (In Swedish)



## Rekrytering:

Alla doktorandplatser vid KI ska utlyses genom annonsering, förutom i de fall då undantag från kravet på utlysning medges <https://ki.se/medarbetare/antagning-till-forskarutbildning>

Vid inlämnandet av grönt ljus ansökan skall även Appendix 1-3 bifogas och Inrättande av doktorandplats.

Doktorandplatser ska:

- annonseras via KIs rekryteringssystem Varbi med den annonsmall som finns i systemet.
- annonseras under lämplig tidpunkt och ansökningstiden rekommenderas att vara tre veckor eller längre.
- annons ska finnas på svenska och/eller engelska.

## Flödesschema där undantag för annonsering föreligger

Steg 1	Beredningsmöte inför antagning	<p>Blankett: Inrättande av doktorandplats Blankett: Finansieringsplan Blankett: Grönt ljus ansökan, Blankett: Appendix 1-3</p> <p>Lämnas in enligt resp. inlämningsdag med deadline för inlämnandet av ansökan till enhetschef, se schema.</p> <p>Alla dokument lämnas in enkelsidiga!</p> <p>Resp. enhetschef inbjuds som föredragande av ansökan till ett beredningsmöte. Rekommenderar att de sökande går igenom ansökan med sin enhetschef innan mötet.</p> <p>Godkänd/avslagen ansökan meddelas enhetschef för vidarebefordran till den sökande.</p>
Steg 2	Bedömning av behörighet	<p>Efter att steg 1 är avklarad. Får den sökande epost från LADOK-administratören med vidare instruktioner och länk till Varbi, där den blivande doktoranden skall ansöka om behörighet till forskarutbildningen vid KI.</p> <p>Föreligger behörighet skickas ett behörighetsutlåtande via epost till kandidat och handledare, vilket skrivs ut och bifogas "Beslut om antagning"</p>

Steg 3	Beslut om antagning	Efter att steg 1-2 är klara lämnas nedanstående blanketter med bilagor in till LADOK-administratören inför beslut av studierektorn och prefekt.  Blankett: Beslut om antagning till utbildning på forskarnivå
Steg 4	Individuell studieplan	Fr o m 1 februari 2021 lanserades digital individuell studieplan (ISP). Samtliga institutioner ska börja använda digital ISP för doktorander antagna från 1 februari 2021.  Huvudhandledare tilldelas behörighet till den digitala ISP via epost från LADOK-administratören. Huvudhandledare skapar här en ny ISP till sin doktorand.  Mer information om hur du skapar en ny ISP inkl. manualer finns på KIs hemsida "Create, write and submit ISP"
Steg 5	Antagningsseminarium	Doktoranden kommer att bjudas till ett antagningsseminarium vid CLINTEC, tillsammans med sin huvudhandledare, för att呈现出 sitt projekt under 5 minuter.  Presentationen (max 4 bilder utan animeringar (ppt)) skickas till LADOK-administratören senast två dagar innan seminariet. Presentationen skall framföras på engelska.  Kommer presentationen att ske via länk (ZOOM) delar doktoranden sin presentation via länken

Vid eventuella frågor, kontakta LADOK-administratören

Agneta Wittlock  
 forskarutbildning@clintec.ki.se  
 08-585 87353